WO2024020156A1 - Emopamil-binding protein inhibitors and uses thereof - Google Patents
Emopamil-binding protein inhibitors and uses thereof Download PDFInfo
- Publication number
- WO2024020156A1 WO2024020156A1 PCT/US2023/028271 US2023028271W WO2024020156A1 WO 2024020156 A1 WO2024020156 A1 WO 2024020156A1 US 2023028271 W US2023028271 W US 2023028271W WO 2024020156 A1 WO2024020156 A1 WO 2024020156A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azaspiro
- sulfonyl
- methyl
- octan
- trifluoromethyl
- Prior art date
Links
- 102100031765 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Human genes 0.000 title claims description 38
- 101710204697 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 title claims description 38
- 229940121649 protein inhibitor Drugs 0.000 title description 2
- 239000012268 protein inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 178
- 150000003839 salts Chemical class 0.000 claims abstract description 159
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 77
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 40
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- -1 OR5a Chemical group 0.000 claims description 450
- 238000000034 method Methods 0.000 claims description 106
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 90
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 12
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 210000003007 myelin sheath Anatomy 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 2
- 150000003053 piperidines Chemical class 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 150000003235 pyrrolidines Chemical class 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 119
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 114
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 239000000203 mixture Substances 0.000 description 83
- 239000000243 solution Substances 0.000 description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 81
- 238000006243 chemical reaction Methods 0.000 description 74
- 238000005481 NMR spectroscopy Methods 0.000 description 65
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 49
- 235000019439 ethyl acetate Nutrition 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 43
- 238000003786 synthesis reaction Methods 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- 208000035475 disorder Diseases 0.000 description 35
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 101150041968 CDC13 gene Proteins 0.000 description 15
- 239000003607 modifier Substances 0.000 description 15
- 239000003643 water by type Substances 0.000 description 15
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 102000006386 Myelin Proteins Human genes 0.000 description 13
- 108010083674 Myelin Proteins Proteins 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 238000001990 intravenous administration Methods 0.000 description 13
- 210000005012 myelin Anatomy 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000002953 preparative HPLC Methods 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- 239000012455 biphasic mixture Substances 0.000 description 12
- 239000005457 ice water Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- NIMQPUWFSRJDSU-UHFFFAOYSA-N 2-azaspiro[3.4]octan-6-one Chemical compound O=C1CCC2(CNC2)C1 NIMQPUWFSRJDSU-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- MORWFSVOFMNQDO-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride Chemical compound CN1N=C(C(F)(F)F)C=C1S(Cl)(=O)=O MORWFSVOFMNQDO-UHFFFAOYSA-N 0.000 description 6
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 6
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 150000003432 sterols Chemical class 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229910017920 NH3OH Inorganic materials 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000000105 evaporative light scattering detection Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000019256 formaldehyde Nutrition 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000023105 myelination Effects 0.000 description 5
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- LWEPLASGBUWJDR-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-amine Chemical compound C1C(N)CC11CNC1 LWEPLASGBUWJDR-UHFFFAOYSA-N 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- YEWWSDCCCBXWIY-UHFFFAOYSA-N 5-oxa-2-azaspiro[3.4]octan-7-one Chemical compound C1NCC11OCC(C1)=O YEWWSDCCCBXWIY-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 208000008795 neuromyelitis optica Diseases 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BNCNLCKWRCXBQH-UHFFFAOYSA-N 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride Chemical compound CC1=NC(C(F)(F)F)=CC=C1S(Cl)(=O)=O BNCNLCKWRCXBQH-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- KOUVDKDABFOPIG-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane;oxalic acid Chemical compound OC(=O)C(O)=O.C1NCC11COC1 KOUVDKDABFOPIG-UHFFFAOYSA-N 0.000 description 3
- ZQEROTOETXELJU-UHFFFAOYSA-N 3-cyano-5-fluorobenzenesulfonyl chloride Chemical compound FC1=CC(C#N)=CC(S(Cl)(=O)=O)=C1 ZQEROTOETXELJU-UHFFFAOYSA-N 0.000 description 3
- ANZLDHZFNLCQAS-UHFFFAOYSA-N 4-(difluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)OC1=CC=C(S(Cl)(=O)=O)C=C1 ANZLDHZFNLCQAS-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910020889 NaBH3 Inorganic materials 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- NTVVXWBUFPOSBS-UHFFFAOYSA-N tert-butyl 6-oxo-2-azaspiro[3.4]octane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CC(=O)CC2 NTVVXWBUFPOSBS-UHFFFAOYSA-N 0.000 description 3
- KMHUVVBPRISZRL-UHFFFAOYSA-N tert-butyl 7-oxo-5-oxa-2-azaspiro[3.4]octane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21OCC(=O)C2 KMHUVVBPRISZRL-UHFFFAOYSA-N 0.000 description 3
- MNSWITGNWZSAMC-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl prop-2-enoate Chemical compound FC(F)(F)C(C(F)(F)F)OC(=O)C=C MNSWITGNWZSAMC-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PVJZBZSCGJAWNG-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 2
- FYLQOSUXOCPQGB-UHFFFAOYSA-N 2,5-dimethylpyrazole-3-sulfonyl chloride Chemical compound CC=1C=C(S(Cl)(=O)=O)N(C)N=1 FYLQOSUXOCPQGB-UHFFFAOYSA-N 0.000 description 2
- PEDCOKAJSPIIFY-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-one Chemical compound C1C(=O)CC11CNC1 PEDCOKAJSPIIFY-UHFFFAOYSA-N 0.000 description 2
- VJDKMRVIGNGUJS-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-one hydrochloride Chemical class Cl.O=C1CC2(CNC2)C1 VJDKMRVIGNGUJS-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OUFBLTGDJDQVTA-UHFFFAOYSA-N 2-oxaspiro[3.3]heptan-6-amine Chemical compound C1C(N)CC11COC1 OUFBLTGDJDQVTA-UHFFFAOYSA-N 0.000 description 2
- MQOFXVWAFFJFJH-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-amine Chemical compound NC1CCC(F)(F)CC1 MQOFXVWAFFJFJH-UHFFFAOYSA-N 0.000 description 2
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 208000008457 Neurologic Manifestations Diseases 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UJELMAYUQSGICC-UHFFFAOYSA-N Zymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)C=CCC(C)C)CCC21 UJELMAYUQSGICC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012972 dimethylethanolamine Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- WMBCUXKYKVTJRF-UHFFFAOYSA-N n-methyl-1-(oxan-4-yl)methanamine Chemical compound CNCC1CCOCC1 WMBCUXKYKVTJRF-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 2
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- CGSJXLIKVBJVRY-XTGBIJOFSA-N zymosterol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]21 CGSJXLIKVBJVRY-XTGBIJOFSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MCPRXSXYXHMCKF-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanamine Chemical compound NCC1(C)COC1 MCPRXSXYXHMCKF-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-UHFFFAOYSA-N (3alpha, 5alpha)-Cholest-7-en-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 IZVFFXVYBHFIHY-UHFFFAOYSA-N 0.000 description 1
- QYJPFTAKVBDDPD-UHFFFAOYSA-N (4,4-difluorocyclohexyl)azanium;chloride Chemical compound Cl.NC1CCC(F)(F)CC1 QYJPFTAKVBDDPD-UHFFFAOYSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- ZXMGHDIOOHOAAE-UHFFFAOYSA-N 1,1,1-trifluoro-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)NS(=O)(=O)C(F)(F)F ZXMGHDIOOHOAAE-UHFFFAOYSA-N 0.000 description 1
- ZXOFAHRGRROAQR-UHFFFAOYSA-N 1-(isocyanomethylsulfonyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1S(=O)(=O)C[N+]#[C-] ZXOFAHRGRROAQR-UHFFFAOYSA-N 0.000 description 1
- XCBHYDPDIJQQGM-UHFFFAOYSA-N 1-[1-(4-methoxyphenyl)sulfonylpiperidin-4-yl]-4-methylpiperidine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCC(N2CCC(C)CC2)CC1 XCBHYDPDIJQQGM-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- ZPJGOWOMUISLPL-UHFFFAOYSA-N 1-oxa-6-azaspiro[3.3]heptane Chemical compound O1CCC11CNC1 ZPJGOWOMUISLPL-UHFFFAOYSA-N 0.000 description 1
- FJSAJUXIHJIAMD-UHFFFAOYSA-N 2,4-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(F)=C1 FJSAJUXIHJIAMD-UHFFFAOYSA-N 0.000 description 1
- FREOGXBZEAMJQN-UHFFFAOYSA-N 2,4-dimethylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(C)=C1 FREOGXBZEAMJQN-UHFFFAOYSA-N 0.000 description 1
- CIHVMVFZOOKEEB-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1C(F)(F)F CIHVMVFZOOKEEB-UHFFFAOYSA-N 0.000 description 1
- IRINAFUPYRWEKL-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-3-sulfonyl chloride Chemical compound FC(F)(F)C1=NC=CC=C1S(Cl)(=O)=O IRINAFUPYRWEKL-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- MOEVKJDZRZEFCC-UHFFFAOYSA-N 2-methoxy-5-methylpyridine-3-sulfonyl chloride Chemical compound COc1ncc(C)cc1S(Cl)(=O)=O MOEVKJDZRZEFCC-UHFFFAOYSA-N 0.000 description 1
- KOHBEDRJXKOYHL-UHFFFAOYSA-N 2-methoxy-n-methylethanamine Chemical compound CNCCOC KOHBEDRJXKOYHL-UHFFFAOYSA-N 0.000 description 1
- RKATWUBDSJHPEV-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-amine Chemical compound NC1CC(F)(F)C1 RKATWUBDSJHPEV-UHFFFAOYSA-N 0.000 description 1
- UCHKRHGVKYVGTC-UHFFFAOYSA-N 3,6-dibromo-2-methylpyridine Chemical compound CC1=NC(Br)=CC=C1Br UCHKRHGVKYVGTC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KSXGQRBTBLQJEF-UHFFFAOYSA-N 3-methoxyazetidine;hydrochloride Chemical compound Cl.COC1CNC1 KSXGQRBTBLQJEF-UHFFFAOYSA-N 0.000 description 1
- RHLVCLIPMVJYKS-UHFFFAOYSA-N 3-octanone Chemical compound CCCCCC(=O)CC RHLVCLIPMVJYKS-UHFFFAOYSA-N 0.000 description 1
- ZXKBVCUVSLFOSC-UHFFFAOYSA-N 3-oxabicyclo[3.1.0]hexane Chemical compound C1OCC2CC21 ZXKBVCUVSLFOSC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UWZZQKFFJSYPAL-UHFFFAOYSA-N 4-chloro-2,5-dimethylpyrazole-3-sulfonyl chloride Chemical compound CC1=NN(C)C(S(Cl)(=O)=O)=C1Cl UWZZQKFFJSYPAL-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- LPWIDWXNZMPLDJ-UHFFFAOYSA-N 5-bromo-4-methyl-2-(trifluoromethyl)pyrimidine Chemical compound CC1=NC(C(F)(F)F)=NC=C1Br LPWIDWXNZMPLDJ-UHFFFAOYSA-N 0.000 description 1
- XLPGJVFDGAPUIH-UHFFFAOYSA-N 5-cyano-2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(C#N)C=C1S(Cl)(=O)=O XLPGJVFDGAPUIH-UHFFFAOYSA-N 0.000 description 1
- ZQCZKNJMUNAGGK-UHFFFAOYSA-N 5-oxabicyclo[2.1.1]hexane Chemical compound C1CC2CC1O2 ZQCZKNJMUNAGGK-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- QETLKNDKQOXZRP-XTGBIJOFSA-N 5alpha-cholest-8-en-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]21 QETLKNDKQOXZRP-XTGBIJOFSA-N 0.000 description 1
- QETLKNDKQOXZRP-UHFFFAOYSA-N 5alpha-cholest-8-en-3beta-ol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21 QETLKNDKQOXZRP-UHFFFAOYSA-N 0.000 description 1
- LNGCWLNVGKBMEH-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=C(C(F)(F)F)N=C1 LNGCWLNVGKBMEH-UHFFFAOYSA-N 0.000 description 1
- IMKNTDZQBJFGQR-UHFFFAOYSA-N 6-chloro-2-methylpyridine-3-sulfonyl chloride Chemical compound CC1=NC(Cl)=CC=C1S(Cl)(=O)=O IMKNTDZQBJFGQR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000001827 Ataxia with vitamin E deficiency Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 238000011111 UV-scan method Methods 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Substances CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical group C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000003264 familial isolated deficiency of vitamin E Diseases 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGYZZCUTSHNMET-UHFFFAOYSA-N n-methyloxan-4-amine Chemical compound CNC1CCOCC1 WGYZZCUTSHNMET-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- HBXNJMZWGSCKPW-UHFFFAOYSA-N octan-2-amine Chemical compound CCCCCCC(C)N HBXNJMZWGSCKPW-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000252 photodiode array detection Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CTDSKHCAIGOHQU-SECBINFHSA-N tert-butyl (6R)-6-amino-2-azaspiro[3.4]octane-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2(C1)CC[C@@H](N)C2 CTDSKHCAIGOHQU-SECBINFHSA-N 0.000 description 1
- PWCXTAYTSYDZTN-QMMMGPOBSA-N tert-butyl (7S)-7-hydroxy-5-oxa-2-azaspiro[3.4]octane-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC2(C1)C[C@H](O)CO2 PWCXTAYTSYDZTN-QMMMGPOBSA-N 0.000 description 1
- WJDUCDSPGKNBBW-UHFFFAOYSA-N tert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(N)C1 WJDUCDSPGKNBBW-UHFFFAOYSA-N 0.000 description 1
- HQHRAGXKFOTSQE-UHFFFAOYSA-N tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CC(=O)C2 HQHRAGXKFOTSQE-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present disclosure relates to inhibitors of Emopamil-Binding Protein (EBP), and pharmaceutically acceptable salts thereof, compositions of these compounds, processes for their preparation, their use in the treatment of diseases, their use in optional combination with a pharmaceutically acceptable carrier for the manufacture of pharmaceutical preparations, the use of the pharmaceutical preparations in the treatment of diseases, and methods of treating diseases comprising administering the EBP inhibitor to a warm-blooded animal, especially a human.
- EBP Emopamil-Binding Protein
- Emopamil-Binding Protein is a A8-A7 sterol isomerase enzyme which isomerizes the double bond in sterol molecules, moving the double bond from the 8-9 position to the 7-8 position.
- EBP converts either zymostenol to lathosterol, or zymosterol to dehydrolathosterol, during the biosynthesis of cholesterol (Silve et al., 1996, J Biol Chem. 271 (37), 22434-22440). It has been shown that an accumulation of 8-9 unsaturated sterols activates oligodendrocyte formation and remyelination (Hubler et al., 2019, Nature 560 (7718), 372-376).
- Myelin is lipid-based molecule which forms protective layers (myelin sheathes) around nerve cell axons and insulates the axons.
- Demyelinating diseases, or myelin-related diseases are a result of these myelin sheathes being damaged, degraded, or reduced in thickness.
- the loss of the myelin sheathes disrupts the electronic signals from the brain and can lead to nerve damage, vision loss, numbness, muscle weakness, cognitive decline, loss of motor functions, and other similar symptoms.
- myelin-related diseases such as multiple sclerosis, a subject’s immune system targets and breaks down their own myelin sheathes.
- the ability to repair and regenerate the myelin sheathes is key to treating these myelin-related diseases. Due to its function converting 8-9 sterols, inhibition of EBP is a potential target for activating remyelination, as its inhibition leads to an increase of these 8-9 sterol starting materials (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
- EBP has also been shown to be a key enzyme in certain colorectal cancers due to the reduction in essential lipids such as cholesterol (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
- EBP inhibitors as potential therapeutic agents for treating diseases or disorders that are responsive to EBP inhibition.
- the present disclosure provides compounds that are EBP inhibitors.
- the present disclosure relates to compounds having the Formula I: or a pharmaceutically acceptable salt thereof, wherein:
- X is O, CH2, or a bond
- R 1 and R 2 are each independently selected from H, Ci-ealkyl, Ci-shaloalkyl, C3- scycloalkyl, Het, and -Z-Het, wherein the Ci-ealkyl, Cs-xcycloalkyl, and Het are each optionally substituted with one or more R 4 , provided at least one of R 1 and R 2 is not
- R 1 and R 2 together with the N atom from which they are attached form a 4 to 7-membered monocyclic heterocycle or 6 to 10-membered bicyclic heterocycle, each of which is optionally substituted with one or more R 4 ;
- Z is Ci-4alkyl optionally substituted with one or more R 4 ;
- Het is a 4 to 6 membered monocyclic heterocyclyl, or a 6 to 8-membered bicyclic heterocyclyl, each of which is optionally substituted with R 4 ; each R 4 is independently selected from OR 4a , halo, C 1-3 alkyl, Ci-shaloalkyl, and 4 to 7-membered monocyclic heterocycle;
- R 4a is selected from H, C 1-3 alkyl, and Ci-shaloalkyl
- R 3 is phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, or 6 to 10 membered bicyclic heterocycle, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, and 6 to 10 membered bicyclic heterocycle are each optionally substituted with one or more substituent R 5 ; each R 5 is independently selected from C 1-3 alkyl, Ci-shaloalkyl, OR 5a , cyano, and halo;
- R 5a is selected from H, C 1-3 alkyl, and Cs-ecycloalkyl, wherein the C 1-3 alkyl is optionally substituted with one or more halo; provided that R 1 and R 2 together with the N atom from which they are attached do not form an unsubstituted pyrrolidine, unsubstituted piperidine, or 4-methyl piperazine.
- compositions comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutical carrier.
- the present disclosure provides a method of treating a disease or disorder that is responsive to inhibition of EBP in a subject comprising administering to said subject an effective amount of at least one compound described herein or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method for treating multiple sclerosis.
- the present disclosure provides a method for promoting myelination in a subject with a myelin-related disorder.
- Another aspect of the present disclosure relates to the use of at least one compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or disorder responsive to inhibition of EBP. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder responsive to inhibition of EBP.
- the present disclosure provides compounds and pharmaceutical compositions thereof that may be useful in the treatment of diseases or disorders through mediation of EBP function/activity, such as multiple sclerosis or other myelin-related disorders.
- the compounds of present disclosure are EBP inhibitors.
- the present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (I) are as defined in the first aspect above.
- R 3 is phenyl or 5 or 6-membered monocyclic heteroaryl, each of which are each optionally substituted with one to three substituent R 5 ; and the remaining variables are as described in the first embodiment.
- R 3 is phenyl, pyridinyl, pyrimidinyl, or pyrazoyl, each of which are each optionally substituted with one to three substituent R 5 ; and the remaining variables are as described in the second embodiment.
- R 3 is represented by the following formula: ; wherein each of the formula depicted above is optionally substituted with one to three R 5 ; and the remaining variables are as described in the second embodiment.
- R 1 and R 2 together with the N atom from which they are attached form a saturated 4 to 6-membered monocyclic heterocycle or a saturated 7 to 10 membered bicyclic heterocycle, each of which is optionally substituted with one or two R 4 ; and the remaining variables are as described in the first, second, third, or fourth embodiment.
- R 1 and R 2 together with the nitrogen atom from which they are attached form groups represented by the following formula: wherein each of the formula depicted above is optionally substituted with one or two R 4 ; and the remaining variables are as described in the fifth embodiment.
- R 1 is H or C i -sal kyl optionally substituted with one to three R 4 ;
- R 2 is C 1-3 alkyl, Cs-ecycloalkyl, Het, or -Z-Het, wherein the C 1-3 alkyl, Cs-ecycloalkyl; and Het is a saturated 4 to 6 membered monocyclic heterocycle containing 1 to 2 heteroatoms selected from oxygen and nitrogen, at least one of which is oxygen, wherein the saturated 4 to 6 membered monocyclic heterocycle is optionally substituted with one to three R 4 ; and the remaining variables are as described in the first, second, third, or fourth embodiment.
- Het is selected from tetraphydropyran and oxetane, each of which is optionally substituted with one to two R 4 ; and the remaining variables are as described in the seventh embodiment.
- the compound of the present disclosure is represented by Formula (II): or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (II) are as defined in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
- R 3 is represented by the following formula: the remaining variables are as described in the ninth embodiment.
- R 5 for each occurrence, is independently selected from C 1-3 alkyl, Ci- shaloalkyl, and OR 5a ; and the remaining variables are as described in the ninth or tenth embodiment.
- R 5 for each occurrence is independently selected from -CH3, -CF3, -CF2CH3, -CH(CH 3 ) 2 , and -OCHF2; and the remaining variables are as described in the eleventh embodiment.
- R 1 and R 2 together with the nitrogen atom from which they are attached form groups represented by the following formula: the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment.
- R 1 is H and R 2 is represented by the following formula wherein each of the formula depicted above is optionally substituted with one or two R 4 ; and the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment.
- R 1 is H and R 2 is represented by the wherein each of the formula depicted above is optionally substituted with one or two R 4 ; and the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment.
- R 2 is represented by the following formula ; and the remaining variables are as described in the fourteenth embodiment.
- R 2 is represented by the following the remaining variables are as described in the fourteenth embodiment.
- R 4 for each occurrence, is independently selected from Ci-salkyl and 4 to 7-membered monocyclic heterocycle; and the remaining variables are as described in the ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or fifteenth embodiment.
- R 4 for each occurrence, is independently selected from -CFF and tetrahydropyran; and the remaining variables are as described in the sixteenth embodiment.
- the compound of the present disclosure is represented by or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (III) or (IV) are as defined in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
- the compound of the present disclosure is represented by Formula (IIIA), (IIIB), (IVA), or (IVB): or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (IIIA), (IIIB), (IVA), or (IVB) are as defined in the eighteenth embodiment.
- R 3 is represented by the
- R 5 for each occurrence, is independently selected from halo, cyano, Ci.2alkyl, Ci.2haloalkyl and OR 5a ; and R 5a is Ci.2alkyl or Ci-2haloalkyl; and the remaining variables are as described in the eighteenth, nineteenth, or twentieth embodiment.
- R 5 for each occurrence, is independently selected from F, Cl, cyano, -CFF, -CF3, -CHF2, -OCH3, and -OCHF2; and the remaining variables are as described in the twenty-first embodiment.
- R 1 and R 2 together with the nitrogen atom from which they are attached form groups represented by the following formula: variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment.
- R 1 is H or C 1-3 alkyl
- R 2 is C 1-3 alkyl, Cs-ecycloalkyl, -Z-Het, or Het, each of which is optionally substituted with one to three R 4 ; and the remaining variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment.
- R 1 is H or -CH3 and R 2 is C 1-3 alkyl optionally substituted with one R 4 , or is represented by the following formula: wherein each of the formula depicted above is optionally substituted with one or two R 4 ; and the remaining variables are as described in the twenty-fourth embodiment.
- R 1 is H or -CH3 and R 2 is represented by the following formula: remaining variables are as described in the twenty-fifth embodiment.
- R 4 for each occurrence, is independently selected from OR 4a , halo, and C 1-3 alkyl, and wherein R 4a is C 1-3 alkyl; and the remaining variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth embodiment.
- R 4 for each occurrence, is independently selected from halo, -CH3, and -OCH3; and the remaining variables are as described in the twenty-seventh embodiment.
- the present disclosure provides a compound described herein (e.g., a compound of any one of Examples 1 to 83), or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a compound selected from the group consisting of:
- the present disclosure provides a pharmaceutical composition comprising a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.
- the present disclosure provides a method of treating a disease or disorder mediated by EBP comprising administering to a subject an effective amount of a compound according to any one of embodiments one to thirty, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the thirty-first embodiment.
- the present disclosure provides a compound according to any one of embodiments one to thirty, for use in the treatment of a disease or disorder mediated by EBP.
- the present disclosure provides the use of a compound according to any one of embodiments one to thirty in the manufacture of a medicament for the treatment of a disease or disorder mediated by EBP.
- the compounds and intermediates described herein may be isolated and used as the compound per se. Alternatively, when a moiety is present that is capable of forming a salt, the compound or intermediate may be isolated and used as its corresponding salt.
- the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound described herein. “Salts” include in particular “pharmaceutical acceptable salts”.
- pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds described herein and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids or organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandi sulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methyl sulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/ di
- Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
- the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
- Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
- the salts can be synthesized by conventional chemical methods from a compound containing a basic or acidic moiety. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
- the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
- Isotopically-labeled compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically- labeled reagents in place of the non-labeled reagent previously employed.
- the present disclosure provides deuterated compounds described herein or a pharmaceutically acceptable salt thereof.
- solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, de- DMSO.
- the compounds of the present invention may contain chiral centers and as such may exist in different stereoisomeric forms.
- the term “an optical isomer” or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present disclosure. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the disclosure includes enantiomers, diastereomers or racemates of the compound.
- Enantiomers are a pair of stereoisomers that are non-superimposable mirror images of each other.
- a 1 : 1 mixture of a pair of enantiomers is a “racemic” mixture.
- the term “racemic” or “rac” is used to designate a racemic mixture where appropriate.
- a single stereoisomer with known relative and absolute configuration of the two chiral centers is designated using the conventional RS system (e.g., (15,25)).
- “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system.
- stereochemistry at each chiral carbon may be specified by either R or S.
- Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
- the resolved compounds can be defined by the respective retention times for the corresponding enantiomers/diastereomers via chiral HPLC.
- Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- Optically active (R)- and (S)-stereoi somers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., separated on chiral SFC or HPLC chromatography columns, such as CHIRALPAK R TM and CHIRALCEL R TM available from DAICEL Corp, using the appropriate solvent or mixture of solvents to achieve good separation). If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- EBP inhibitory activity refers to the ability of a compound or composition to induce a detectable decrease in EBP activity in vivo or in vitro (e.g., at least 10% decrease in EBP activity as measured by a given assay such as the bioassay described in the examples and known in the art).
- the present disclosure provides a method of treating a disease or disorder responsive to inhibition of EBP activity (referred herein as “EBP mediated disease or disorder” or “disease or disorder mediated by EBP”) in a subject in need of the treatment.
- the method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirty embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
- the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
- the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
- the EBP mediated disorder is colorectal cancer.
- the present disclosure provides a method of treating an autoimmune disease in a subject in need of the treatment.
- the method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
- the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an autoimmune disease in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an autoimmune disease in a subject in need of the treatment.
- the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease in a subject in need of the treatment.
- the autoimmune disease is multiple sclerosis (MS).
- MS multiple sclerosis
- the compounds of the present disclosure can be used for treating all stages of MS, including relapsing multiple sclerosis (or relapsing form(s) of multiple sclerosis), relapsing-remitting multiple sclerosis, primary progress multiple sclerosis, secondary progressive multiple sclerosis and clinically isolated syndrome (hereinafter “CIS”).
- CIS clinically isolated syndrome
- Relapsing multiple sclerosis includes clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
- Relapsing-remitting multiple sclerosis is a stage of MS characterized by unpredictable relapses followed by periods of months to years of relative quiet (remission) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave problems, the latter in about 40% of attacks and being more common the longer a person has had the disease. This describes the initial course of 80% of individuals with multiple sclerosis.
- Secondary progressive multiple sclerosis occurs in around 65% of those with initial relapsing-remitting multiple sclerosis, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission. Occasional relapses and minor remissions may appear. The most common length of time between disease onset and conversion from relapsing-remitting to secondary progressive multiple sclerosis is 19 years.
- Primary progressive multiple sclerosis is characterized by the same symptoms of secondary progressive multiple sclerosis, i.e., progressive neurologic decline between acute attacks without any definite periods of remission, without the prior relapsing-remitting stage.
- CIS is a first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system. The episode, which by definition must last for at least 24 hours, is characteristic of multiple sclerosis but does not yet meet the criteria for a diagnosis of MS because people who experience a CIS may or may not go on to develop MS.
- CIS When CIS is accompanied by lesions on a brain MRI (magnetic resonance imaging) that are similar to those seen in MS, the person has a high likelihood of a second episode of neurologic symptoms and diagnosis of relapsing-remitting MS.
- CIS When CIS is not accompanied by MS-like lesions on a brain MRI, the person has a much lower likelihood of developing MS.
- the present disclosure provides a method of promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
- the method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
- the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
- the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
- the myelin-related disease or disorder is selected from multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), acute disseminated encephalomyelitis (ADEM), central pontine myelolysis (CPM), adrenoleukodystrophy, Alexander's disease, Pelizaeus Merzbacher disease (PMD), Vanishing White Matter Disease, Wallerian Degeneration, transverse myelitis, amylotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post radiation injury, neurologic complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen- Komzweig syndrome, Marchiafava-
- the present disclosure provides a method of treating cancer in a subject in need of the treatment.
- the method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
- the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer in a subject in need of the treatment.
- the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need of the treatment.
- a compound described herein e.g., a compound described in any one of the first to thirtieth embodiments
- a pharmaceutically acceptable salt thereof e.g., a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need of the treatment.
- the cancer is colorectal cancer.
- the present disclosure relates to the aforementioned methods, wherein said subject is a mammal.
- the subject is a primate.
- the subject is a human.
- an “effective amount” and a “therapeutically effective amount” can used interchangeably. It means an amount effective for treating or lessening the severity of one or more of the diseases, disorders or conditions as recited herein. In some embodiments, the effective dose can be between 10 pg and 500 mg.
- the compounds and compositions, according to the methods of the present disclosure may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases, disorders or conditions recited above.
- the present disclosure relates to the aforementioned methods, wherein said compound is administered parenterally.
- the present disclosure relates to the aforementioned methods, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, rectally, intrathecally, topically or intranasally.
- the present disclosure relates to the aforementioned methods, wherein said compound is administered systemically.
- the compounds of the present invention can be used as a pharmaceutical composition (e.g., a compound of the present invention and at least one pharmaceutically acceptable carrier).
- pharmaceutically acceptable carrier includes generally recognized as safe (GRAS) solvents, dispersion media, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, preservatives, drug stabilizers, buffering agents (e.g., maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, and the like), and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed.
- solvates and hydrates are considered pharmaceutical compositions comprising a compound of the present invention and a solvent (i.e., solvate) or water (i.e., hydrate).
- the formulations may be prepared using conventional dissolution and mixing procedures.
- the bulk drug substance i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)
- a suitable solvent in the presence of one or more of the excipients described above.
- the compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product.
- the pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug.
- an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form.
- Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like.
- the container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package.
- the container has deposited thereon a label that describes the contents of the container. The label may also include appropriate warnings.
- composition comprising a compound of the present disclosure is generally formulated for use as a parenteral or oral administration or alternatively suppositories.
- the pharmaceutical oral compositions of the present disclosure can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
- the pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
- the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethylene glycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
- diluents e.g., lactose, dextrose, sucrose,
- Tablets may be either film coated or enteric coated according to methods known in the art.
- compositions for oral administration include a compound of the disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
- the parenteral compositions are aqueous isotonic solutions or suspensions.
- the parenteral compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- the compositions are generally prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
- the compound of the present disclosure or pharmaceutical composition thereof for use in a subject is typically administered orally or parenterally at a therapeutic dose.
- the dosage may depend upon the infusion rate at which an IV formulation is administered.
- the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, pharmacist, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
- the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
- the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
- the dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
- a “patient,” “subject” or “individual” are used interchangeably and refer to either a human or non-human animal.
- the term includes mammals such as humans.
- the animal is a mammal.
- a subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- the subject is a primate.
- the subject is a human.
- the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
- the term “treat”, “treating” or “treatment” of any disease, condition or disorder refers to the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to obtaining desired pharmacological and/or physiological effect.
- the effect can be therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, condition or disorder; ameliorating or improving a clinical symptom, complications or indicator associated with the disease, condition or disorder; or delaying, inhibiting or decreasing the likelihood of the progression of the disease, condition or disorder; or eliminating the disease, condition or disorder.
- the effect can be to prevent the onset of the symptoms or complications of the disease, condition or disorder.
- cancer has the meaning normally accepted in the art.
- the term can broadly refer to abnormal cell growth.
- autoimmune disease has the meaning normally accepted the art.
- the term can broadly refer to a disease where the host’s immune system targets or attacks normal or healthy tissue of the host.
- myelination has the meaning normally accepted in the art.
- the term can broadly mean the process by which myelin is produced.
- myelin-related disease or disorder As used herein, the term “myelin-related disease or disorder”, “demyelinating disorder”, or “demyelation disorder” has the meaning normally accepted in the art. These terms can broadly refer to diseases or disorders which involve damage to myelin.
- a subject is “in need of’ a treatment if such subject would benefit biologically, medically or in quality of life from such treatment (preferably, a human).
- an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
- an optionally substituted group can be substituted with one or more substituents, each of which can the same or different.
- the “one or more” substituents can be 1, 2, 3, 4, 5, 6, etc. substituents, each of which can the same or different. In some embodiment, the “one or more” substituents can be 1 to 6, 1 to 4, 1 to 3 or 1 to 2 substituents, each of which can the same or different.
- alkyl refers to a fully saturated branched or unbranched hydrocarbon moiety.
- the term “Ci-4alkyl” refers to an alkyl having 1 to 4 carbon atoms.
- C 1-3 alkyl and “Ci.2alkyl” are to be construed accordingly.
- Representative examples of “Ci-4alkyl” include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, secbutyl, iso-butyl, and tert-butyl.
- the alkyl portion (i.e., alkyl moiety) of an alkoxy have the same definition as above.
- alkane radical or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally, one to three substituents except in the case of halogen substituents such as perchloro or perfluoroalkyls).
- alkoxy refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (i.e. a — O— Ci-4 alkyl group wherein Ci-4 alkyl is as defined herein).
- Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy and the like.
- alkoxy groups Preferably, alkoxy groups have about 1-4 carbons, more preferably about 1-2 carbons.
- Ci-2 alkoxy is to be construed accordingly.
- Ci-4 alkoxyCi-4 alkyl refers to a Ci.4allkyl group as defined herein, wherein at least of the hydrogen atoms is replaced by an Ci.4alkoxy.
- the Ci.4alkoxyCi. 4 alkyl group is connected through the rest of the molecule described herein through the alkyl group.
- C x -xx The number of carbon atoms in a group is specified herein by the prefix “C x -xx”, wherein x and xx are integers.
- C1.3 alkyl is an alkyl group which has from 1 to 3 carbon atoms.
- Halogen or “halo” may be fluorine, chlorine, bromine or iodine.
- halo-substituted-Ci ⁇ alkyl or “ Ci.4haloalkyl” refers to a Ci- 4alkyl group as defined herein, wherein at least one of the hydrogen atoms is replaced by a halo atom.
- the Ci.4haloalkyl group can be monohalo-Ci-4alkyl, dihalo-Ci.4alkyl or polyhalo-Ci-4 alkyl including perhalo-Ci.4alkyl.
- a monohalo-Ci.4alkyl can have one iodo, bromo, chloro or fluoro within the alkyl group.
- Dihalo-Ci-4alkyl and polyhalo-Ci.4alkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl.
- the polyhalo-Ci.4alkyl group contains up to 9, or 8, or 7, or 6, or 5, or 4, or 3, or 2 halo groups.
- Ci-4haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, di chloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and di chloropropyl.
- a perhalo-Ci.4alkyl group refers to a Ci-4alkyl group having all hydrogen atoms replaced with halo atoms.
- aryl refers to an aromatic carbocyclic single ring or two fused ring system containing 6 to 10 carbon atoms. Examples include phenyl and naphthyl.
- heteroaryl refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S. In some instances, nitrogen atoms in a heteroaryl may be quaternized.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”.
- a heteroaryl group may be mono- or bi-cyclic. Monocyclic heteroaryl includes, for example, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, furanyl, oxadiazolyl, thiophenyl, and the like.
- Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings.
- Non-limiting examples include pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, imidazopyridinyl, and indoyl.
- carbocyclic ring or “carbocyclyl” refers to a 4- to 12-membered saturated or partially unsaturated hydrocarbon ring and may exist as a single ring, bicyclic ring (including fused, spiral or bridged carbocyclic rings) or a spiral ring.
- Bi-cyclic carbocyclyl groups include, e.g., unsaturated carbocyclic radicals fused to another unsaturated carbocyclic radical, cycloalkyl, or aryl, such as, for example, 2,3-dihydroindenyl, decahydronaphthal enyl, and 1,2,3,4-tetrahydronaphthalenyl.
- the carbocyclic ring generally contains 4- to 10- ring members.
- C3-6 cycloalkyl refers to a carbocyclic ring which is fully saturated (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl).
- heterocycle refers to a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S.
- a heterocyclyl group may be mono- or bicyclic (e.g., a bridged, fused, or spiro bicyclic ring).
- monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and piperdinyl.
- Bi-cyclic heterocyclyl groups include, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical, cycloalkyl, aryl, or heteroaryl ring, such as, for example, tetrahydro-3H-[l,2,3]triazolo[4,5-c]pyridinyl, 2-oxa-6-azaspiro[3.3]heptanyl, 5- oxabicyclo[2.1.1]hexanyl and 9-azabicyclo[3.3.1]nonanyl.
- the heterocyclyl group is a 4 to 6 membered monocyclic heterocyclyl group.
- the heterocyclyl group is a 4 to 6 membered monocyclic saturated heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic saturated heterocyclyl group.
- spiral ring means a two-ring system wherein both rings share one common atom.
- spiral rings include, 2-oxa-6-azaspiro[3.3]heptanyl and the like.
- fused ring refers to two ring systems share two adjacent ring atoms.
- Fused heterocycles have at least one the ring systems contain a ring atom that is a heteroatom selected from O, N and S (e.g., 3-oxabicyclo[3.1.0]hexane).
- bridged refers to a 5 to 10 membered cyclic moiety connected at two non-adjacent ring atoms (e.g. 5-oxabicyclo[2.1.1]hexane).
- phrases “pharmaceutically acceptable” indicates that the substance, composition or dosage form must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
- the term “compounds of the present disclosure” refers to compounds of Formula (I), as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, isotopically labeled compounds (including deuterium substitutions).
- salts are included as well, in particular pharmaceutically acceptable salts.
- the term “a,” “an,” “the” and similar terms used in the context of the present invention are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
- the use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. It is also possible that the intermediates and compounds of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.
- the term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier.
- proton tautomers also known as prototropic tautomers
- proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations.
- a specific example of a proton tautomer is the imidazole moiety where the proton may migrate between the two ring nitrogens.
- Valence tautomers include interconversions by reorganization of some of the bonding electrons.
- the present disclosure relates to a compound of the Formula (I) as defined herein, in free form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in salt form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in acid addition salt form. In a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable salt form. In yet a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in free form.
- the present disclosure relates to any one of the compounds of the Examples in salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable salt form. In still another embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable acid addition salt form.
- Compounds of the present disclosure may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein.
- the starting materials are generally available from commercial sources such as Sigma- Aldrich or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
- reaction schemes depicted below provide potential routes for synthesizing the compounds of the present disclosure as well as key intermediates.
- Examples section below For a more detailed description of the individual reaction steps, see the Examples section below.
- specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions.
- PE petroleum ether
- MgSCU magnesium sultate
- DIPEA diisopropylethyl amine
- Na2SO4 sodium sulfate
- K2CO3 potassium carbonate
- NaHCO 3 sodium bicarbonate
- SiCh silicon dioxide or silica
- TosMIC toluenesulfonylmethyl isocyanide
- LiHMDS Lithium bis(trimethylsilyl)amide
- MS mode MS:ESI+ scan range 165-650 daltons
- Modifier Ammonium hydroxide 0.2% (v/v) cone.
- MS mode MS:ESI+ scan range 165-650 daltons
- MS mode MS:ESI+ scan range 165-650 daltons
- Modifier 0.2% Ammonium hydroxide (v/v) cone.
- MS mode MS:ESI+ scan range 165-650 daltons
- MS mode MS:ESI+ scan range 165-650 daltons
- MS mode MS:ESI+ scan range 165-650 daltons
- MS mode MS:ESI+ scan range 165-650 daltons
- MS mode MS:ESI+ scan range 165-650 daltons
- the mixture was purified by prep-HPLC (Welch Xtimate C18 150 x 25mm x 5pm, Condition: water (NH 4 HCO 3 )-MeCN, 28% to 48%, Flow Rate (mL/min): 25) to give 6-(2-((6-(l , 1 - difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-2-oxa-6- azaspiro[3.3]heptane (32 mg, 32%) as white solid.
- LCMS m/z 414.1 [M+H] + .
- the mixture was purified by prep-HPLC (Welch Xtimate Cl 8 150 x 25mm x 5pm, Condition: water (NH 4 HCO 3 )-MeCN, 37% to 52%, Flow Rate (mL/min): 25) to give 2-((6-(l,l- difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N -(tetrahydro-2//-pyran-4-yl)-2- azaspiro[3.3]heptan-6-amine (25 mg, 25%) as white solid.
- LCMS m/z 416.2 [M+H] + .
- step 1 (69 mg, 0.2 mmol) was dissolved in MeOH (1 mL) and DCM (3 mL). (3- Methyloxetan-3-yl)methanamine (25 mg, 0.3 mmol) and AcOH (25 pL, 0.4 mmol) were added and the solution stirred for 15 mins. NaBH(OAc)3 (220 mg, 1.0 mmol) was added and the reaction stirred at rt for 24 h. The reaction was diluted with EtOAc and quenched with aq. NaHCO 3 solution. The solution was extracted with EtOAc (3x), the combined organic extracts were washed with water and concentrated in vacuo.
- the reaction was maintained at ⁇ 5 °C and stirred for 2 h.
- the reaction was quenched by slow addition of aqueous saturated NaHCO 3 solution, the mixture was stirred at 23 °C for 30 mins, then extracted with DCM (3x).
- the combined organic extracts were dried over anhydrous MgSCU, filtered and concentrated under reduced pressure.
- NaBH(OAc)3 (307 mg, 1.5 mmol) was added to a mixture of 4-methylpiperidine (79 mg, 0.8 mmol), tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (153 mg, 0.7 mmol) and AcOH (50 pL, 0.8 mmol) in DCM (5 mL) and the reaction was stirred for 3 days at rt.
- reaction mixture was washed with 10% aqueous solution of KOH and water, dried over Na2SO4 and the solvent was evaporated to give tert-butyl 6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane- 2-carboxylate, that was used in the next step without purification.
- N -(4,4-Difluorocyclohexyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine was obtained as a white solid (42 mg, 19%), from 2-((2-methoxy- 5-methylpyri din-3 -yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 4,4-difluorocyclohexan-l -amine hydrochloride, following a similar procedure to that described in Example 21, step 4, except the crude product was purified by prep-HPLC (Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NEEElCOs ⁇ MeCN, 32% to 62%, Flow Rate (mL/min): 25).
- N -(3,3-Difluorocyclobutyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine was obtained as a white solid(78 mg, 31% yield), from 2-((2- methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 3,3-difluorocyclobutylamine, following a similar procedure to that described in Example 21, step 4, except the crude product was purified by prep-HPLC (Column: Boston Prime C18 150 x 30mm x 5 pm, Condition: water (NH4HCO3)-MeCN, 28% to 58%, Flow Rate (mL/min): 25).
- the crude product was purified by prep-HPLC ((Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NHvHzO+NH-tHCOsj-MeCN, 41% to 71%, Flow Rate (mL/min): 25)) to give 3-((7-((4,4-difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile (56 mg, 31%) as a white solid.
- LCMS m/z 430.1 [M+H] + .
- the product was further purified by prep-HPLC using a Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 55% B (0.2% NH4OH final v/v % modifier) with flow rate at 80 mL/min.
- LCMS m/z 373.2 [M+H] + .
- the combined organic extracts were dried over magnesium sulfate, the mixture filtered and concentrated under reduced pressure.
- the crude product was purified by silica gel column chromatography with (25-80% 3 : 1 EtOAc:EtOH in heptane.)
- the product was further purified by HPLC using a Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 55% B (0.2% NH4OH final v/v % modifier) with flow rate at 60 mL/min to give 4-(2-((l-methyl-3 -(trifluoromethyl)- ⁇ H- pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine as a colorless film (57 mg, 30%).
- the combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo.
- the crude was purified by prep-HPLC ((Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NH 3 H 2 O+NH 4 HCO 3 )-MeCN, 45% to 75%, Flow Rate (mL/min): 25)) to give 3 -((7- ((4,4-difluorocyclohexyl)(methyl)amino)-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)-4- fluorobenzonitrile (40 mg, 43%) as a white solid.
- Example 40 4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine (Example 40) was further purified by SFC using a Chiralpak IG 30x 250 mm, 5 pm column using 20%
- Peak 1 (A)-4-(2-((2-methyl-6-(trifhioromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (ri)-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid, (13 mg, 24%).
- LCMS m/z 420.2 [M+H] + .
- Examples 62 and 63 (R )-4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine and (S)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine
- Peak 1 (A)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (5)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid (21 mg, 26%).
- LCMS m/z 420.2 [M+H] + .
- Peak 2 (8)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3 ,4]octan-6- yl)morpholine and (A > )-4-(2-((4-methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid (22 mg, 28%).
- Peak 1 (A)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (5)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as an off-white solid (51 mg, 28%).
- LCMS m/z 386.1 [M+H] + .
- Peak 1 (R )-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (8)-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as a tan oil (95 mg, 34%).
- LCMS m/z 355.2 [M+H] + .
- Peak 2 (8)-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (R )-4-(2-((l,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as a tan oil (68 mg, 24%).
- LCMS m/z 355.2 [M+H] + .
- N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine 35 mg, 67.6% was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2-azaspiro[3.3]heptan-6-amine (50 mg, 127.4 pmol) and (CH2O) n (764 mg, 637 pmol) following the procedure described in Example 59.
- LCMS m/z 407.1 [M+H] + .
- N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine (20 mg. 24%) was obtained from 2- ((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-2- azaspiro[3.3]heptan-6-amine (80 mg, 185 pmol) and (CH2O) n (63 mg, 1.85 mmol) following the procedure described in Example 59.
- the EBP immunoaffinity (IA) LC-MS assay measures the potency of small molecule inhibitors of EBP by quantifying their concentration-dependent changes in the enzyme’s substrate and product using liquid chromatography atmospheric pressure chemical ionization multiple reaction monitoring mass spectrometry (LC-APCI MRM MS).
- LC-APCI MRM MS liquid chromatography atmospheric pressure chemical ionization multiple reaction monitoring mass spectrometry
- HEK293T cells were utilized as the source of EBP enzyme.
- the enzyme was incubated with the small molecule inhibitors at variable concentrations for 30 min.
- Deuterated form of EBP substrate, zymosterol-d5 (Avanti Polar Lipids, Cat# 700068P-lmg) was then added and the plate was incubated at 37 °C for 4 h.
- sterol isomers were extracted and injected to LC-APCI MRM MS.
- MRM transition used for the quantification for both zymosterol and dihydrolathosterol is 372.3-203.2, CE 30 and DP 80 in positive ion mode.
- Percent conversion of the zymosterol-d5 to dehydrolathosterol-d5 was used to derive IC50 curves.
- Tasin-1 (l'-[(4-Methoxyphenyl)sulfonyl]-4-methyl-1,4’-bipiperidine, CAS 792927-06-1) was used as the reference small molecule inhibitor.
- Percent conversion versus the compound concentration data were fit to the following 4- parameter logistic model to generate IC50 curves: DATA FOR EXAMPLES *N/Ameans>3 ⁇ M ; + means 3 ⁇ M to>0.5 ⁇ M ; ++ means 0.1 -0.5 ⁇ M ; +++ means ⁇ 0.1 ⁇ M ;
Abstract
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.
Description
EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF
RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application No. 63/391,578 filed on July 22, 2022. The entire contents of the foregoing application are expressly incorporated herein by reference.
FIELD OF THE INVENTION
The present disclosure relates to inhibitors of Emopamil-Binding Protein (EBP), and pharmaceutically acceptable salts thereof, compositions of these compounds, processes for their preparation, their use in the treatment of diseases, their use in optional combination with a pharmaceutically acceptable carrier for the manufacture of pharmaceutical preparations, the use of the pharmaceutical preparations in the treatment of diseases, and methods of treating diseases comprising administering the EBP inhibitor to a warm-blooded animal, especially a human.
BACKGROUND OF THE INVENTION
Emopamil-Binding Protein (EBP) is a A8-A7 sterol isomerase enzyme which isomerizes the double bond in sterol molecules, moving the double bond from the 8-9 position to the 7-8 position. Specifically, EBP converts either zymostenol to lathosterol, or zymosterol to dehydrolathosterol, during the biosynthesis of cholesterol (Silve et al., 1996, J Biol Chem. 271 (37), 22434-22440). It has been shown that an accumulation of 8-9 unsaturated sterols activates oligodendrocyte formation and remyelination (Hubler et al., 2019, Nature 560 (7718), 372-376).
Myelin is lipid-based molecule which forms protective layers (myelin sheathes) around nerve cell axons and insulates the axons. Demyelinating diseases, or myelin-related diseases, are a result of these myelin sheathes being damaged, degraded, or reduced in thickness. The loss of the myelin sheathes disrupts the electronic signals from the brain and can lead to nerve damage, vision loss, numbness, muscle weakness, cognitive decline, loss of motor functions, and other similar symptoms. In some myelin-related diseases, such as multiple sclerosis, a subject’s immune system targets and breaks down their own myelin sheathes. The ability to repair and regenerate the myelin sheathes is key to treating these myelin-related diseases. Due to its function converting 8-9 sterols, inhibition of EBP is a potential target for activating
remyelination, as its inhibition leads to an increase of these 8-9 sterol starting materials (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
In addition to its role in remyeliniation, EBP has also been shown to be a key enzyme in certain colorectal cancers due to the reduction in essential lipids such as cholesterol (Theodoropoulous et al, 2020, J. Am. Chem. Soc., 142, (13), 6128-6138).
Thus, there is a need for EBP inhibitors as potential therapeutic agents for treating diseases or disorders that are responsive to EBP inhibition.
SUMMARY OF THE INVENTION
The present disclosure provides compounds that are EBP inhibitors. In a first aspect, the present disclosure relates to compounds having the Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X is O, CH2, or a bond;
R1 and R2 are each independently selected from H, Ci-ealkyl, Ci-shaloalkyl, C3- scycloalkyl, Het, and -Z-Het, wherein the Ci-ealkyl, Cs-xcycloalkyl, and Het are each optionally substituted with one or more R4, provided at least one of R1 and R2 is not
H; or R1 and R2 together with the N atom from which they are attached form a 4 to 7-membered monocyclic heterocycle or 6 to 10-membered bicyclic heterocycle, each of which is optionally substituted with one or more R4;
Z is Ci-4alkyl optionally substituted with one or more R4;
Het is a 4 to 6 membered monocyclic heterocyclyl, or a 6 to 8-membered bicyclic heterocyclyl, each of which is optionally substituted with R4; each R4 is independently selected from OR4a, halo, C1-3alkyl, Ci-shaloalkyl, and 4 to 7-membered monocyclic heterocycle;
R4a is selected from H, C1-3alkyl, and Ci-shaloalkyl;
R3 is phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, or 6 to 10 membered bicyclic heterocycle, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, and 6
to 10 membered bicyclic heterocycle are each optionally substituted with one or more substituent R5; each R5 is independently selected from C1-3alkyl, Ci-shaloalkyl, OR5a, cyano, and halo;
R5a is selected from H, C1-3alkyl, and Cs-ecycloalkyl, wherein the C1-3alkyl is optionally substituted with one or more halo; provided that R1 and R2 together with the N atom from which they are attached do not form an unsubstituted pyrrolidine, unsubstituted piperidine, or 4-methyl piperazine.
Another aspect of the disclosure relates to pharmaceutical compositions comprising compounds of Formula (I) or pharmaceutically acceptable salts thereof, and a pharmaceutical carrier.
In yet another aspect, the present disclosure provides a method of treating a disease or disorder that is responsive to inhibition of EBP in a subject comprising administering to said subject an effective amount of at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a method for treating multiple sclerosis. In some embodiments, the present disclosure provides a method for promoting myelination in a subject with a myelin-related disorder.
Another aspect of the present disclosure relates to the use of at least one compound described herein or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease or disorder responsive to inhibition of EBP. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder responsive to inhibition of EBP.
DETAILED DESCRIPTION OF THE INVENTION
The present disclosure provides compounds and pharmaceutical compositions thereof that may be useful in the treatment of diseases or disorders through mediation of EBP function/activity, such as multiple sclerosis or other myelin-related disorders. In some embodiments, the compounds of present disclosure are EBP inhibitors.
COMPOUNDSAND COMPOSITIONS
In a first embodiment, the present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (I) are as defined in the first aspect above.
In a second embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R3 is phenyl or 5 or 6-membered monocyclic heteroaryl, each of which are each optionally substituted with one to three substituent R5; and the remaining variables are as described in the first embodiment.
In a third embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R3 is phenyl, pyridinyl, pyrimidinyl, or pyrazoyl, each of which are each optionally substituted with one to three substituent R5; and the remaining variables are as described in the second embodiment.
In a fourth embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
; wherein each of the formula depicted above is optionally substituted with one to three R5; and the remaining variables are as described in the second embodiment.
In a fifth embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the N atom from which they are attached form a saturated 4 to 6-membered monocyclic heterocycle or a saturated 7 to 10 membered bicyclic heterocycle, each of which is optionally substituted with one or two R4; and the remaining variables are as described in the first, second, third, or fourth embodiment.
In a sixth embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
wherein each of the formula depicted above is optionally substituted with one or two R4; and the remaining variables are as described in the fifth embodiment.
In a seventh embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, R1 is H or C i -sal kyl optionally substituted with one to three R4; R2 is C1-3alkyl, Cs-ecycloalkyl, Het, or -Z-Het, wherein the C1-3alkyl, Cs-ecycloalkyl; and Het is a saturated 4 to 6 membered monocyclic heterocycle containing 1 to 2 heteroatoms selected from oxygen and nitrogen, at least one of which is oxygen, wherein the saturated 4 to 6 membered monocyclic heterocycle is optionally substituted with one to three R4; and the remaining variables are as described in the first, second, third, or fourth embodiment.
In an eighth embodiment, for the compounds of Formula (I), or a pharmaceutically acceptable salt thereof, Het is selected from tetraphydropyran and oxetane, each of which is optionally substituted with one to two R4; and the remaining variables are as described in the seventh embodiment.
In a ninth embodiment, the compound of the present disclosure is represented by Formula (II):
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (II) are as defined in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
In a tenth embodiment, for the compounds of Formula (I) or (II), or a pharmaceutically acceptable salt thereof, R3 is represented by the following formula:
the remaining variables are as described in the ninth embodiment.
In an eleventh embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R5, for each occurrence, is independently selected from C1-3alkyl, Ci- shaloalkyl, and OR5a; and the remaining variables are as described in the ninth or tenth embodiment.
In a twelfth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R5, for each occurrence is independently selected from -CH3, -CF3,
-CF2CH3, -CH(CH3)2, and -OCHF2; and the remaining variables are as described in the eleventh embodiment.
In a thirteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment.
In a fourteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R1 is H and R2 is represented by the following formula
wherein each of the formula depicted above is optionally substituted with one or two R4; and the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment. In an alternative fourteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R1 is H and R2 is represented by the
wherein each of the formula depicted above is optionally substituted with one or two R4; and the remaining variables are as described in the ninth, tenth, eleventh, or twelfth embodiment.
In a fifteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R2 is represented by the following formula
; and the remaining variables are as described in the fourteenth embodiment. In an alternative fifteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R2 is represented by the following
the remaining variables are as described in the fourteenth embodiment.
In a sixteenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R4, for each occurrence, is independently selected from Ci-salkyl and 4 to 7-membered monocyclic heterocycle; and the remaining variables are as described in the ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, or fifteenth embodiment.
In a seventeenth embodiment, for the compounds of Formula (II), or a pharmaceutically acceptable salt thereof, R4, for each occurrence, is independently selected from -CFF and tetrahydropyran; and the remaining variables are as described in the sixteenth embodiment.
In an eighteenth embodiment, the compound of the present disclosure is represented by
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (III) or (IV) are as defined in the first, second, third, fourth, fifth, sixth, seventh, or eighth embodiment.
In a nineteenth embodiment, the compound of the present disclosure is represented by Formula (IIIA), (IIIB), (IVA), or (IVB):
or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (IIIA), (IIIB), (IVA), or (IVB) are as defined in the eighteenth embodiment.
In a twentieth embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R3 is represented by the
In a twenty-first embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R5, for each occurrence, is independently selected from halo, cyano, Ci.2alkyl, Ci.2haloalkyl and OR5a; and R5a is Ci.2alkyl or Ci-2haloalkyl; and the remaining variables are as described in the eighteenth, nineteenth, or twentieth embodiment.
In a twenty-second embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R5, for each occurrence, is independently selected from F, Cl, cyano, -CFF, -CF3, -CHF2, -OCH3, and -OCHF2; and the remaining variables are as described in the twenty-first embodiment.
In a twenty-third embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment.
In a twenty-fourth embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R1 is H or C1-3alkyl; and R2 is C1-3alkyl, Cs-ecycloalkyl, -Z-Het, or Het, each of which is optionally substituted with one to three R4; and the remaining variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, or twenty-second embodiment.
In a twenty-fifth embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R1 is H or -CH3 and R2 is C1-3alkyl optionally substituted with one R4, or is represented by the following formula:
wherein each of the formula depicted above is optionally substituted with one or two R4; and the remaining variables are as described in the twenty-fourth embodiment.
In a twenty- sixth embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R1 is H or -CH3 and R2 is represented by the following formula:
remaining variables are as described in the twenty-fifth embodiment.
In a twenty- seventh embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R4, for each occurrence, is independently selected from OR4a, halo, and C1-3alkyl, and wherein R4a is C1-3alkyl; and the remaining variables are as described in the eighteenth, nineteenth, twentieth, twenty-first, twenty-second, twenty-third, twenty-fourth, twenty-fifth, or twenty-sixth embodiment.
In a twenty-eighth embodiment, for the compounds of Formula (III), (IIIA), (IIIB), (IV), (IVA), or (IVB), or a pharmaceutically acceptable salt thereof, R4, for each occurrence, is independently selected from halo, -CH3, and -OCH3; and the remaining variables are as described in the twenty-seventh embodiment.
In a twenty-ninth embodiment, the present disclosure provides a compound described herein (e.g., a compound of any one of Examples 1 to 83), or a pharmaceutically acceptable salt thereof.
In a thirtieth embodiment, the present disclosure provides a compound selected from the group consisting of:
6-(2-((6-( 1,1 -Difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
2-((6-( 1,1 -Difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(tetrahy dro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)morpholine;
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
2-((2-Methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-N-( l-(tetrahy dro-2H- pyran-4-yl)cyclopropyl)-2-azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-N-((3 -methyl ox etan-3 - yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)morpholine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-(oxetan-3- ylmethyl)-2-azaspiro[3.3]heptan-6-amine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-((3- m ethyl ox etan-3 -yl)methyl)-2-azaspiro[3.3 ]heptan-6-amine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-(oxetan-3-yl)- 2-azaspiro[3.3]heptan-6-amine;
6-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
6-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
2-Methyl-N-(2-(tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-yl)-6- (trifluoromethyl)pyridine-3-sulfonamide;
4-(2-((3-Isopropyl-l-methyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan- 6-yl)morpholine;
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-6-(4-methylpiperidin-l-yl)-2- azaspiro[3.3]heptane;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)- 5-oxa-2-azaspiro[3.4]octan-7-amine;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(2-oxa-6- azaspiro[3.3]heptan-6-yl)-5-oxa-2-azaspiro[3.4]octane;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(3-methoxyazetidin-l-yl)-5- oxa-2-azaspiro[3 ,4]octane;
N-(4,4-Difluorocyclohexyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5- oxa-2-azaspiro[3.4]octan-7-amine;
N-(3,3-Difluorocyclobutyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5- oxa-2-azaspiro[3.4]octan-7-amine;
3-((7-((4,4-Difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile;
4-Fluoro-3 -((7-((tetrahydro-2H-pyran-4-yl)amino)-5 -oxa-2- azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
3-((7-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-5-fluorobenzonitrile;
4-(2-((3,5-Dimethylpyridin-2-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
6-(2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)- 2-oxa-6-azaspiro[3.3]heptane;
N-(4,4-Difluorocyclohexyl)-2-((6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-amine;
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-N-(2-methoxyethyl)-N-methyl- 2-azaspiro[3 ,4]octan-6-amine;
N-(2-Methoxyethyl)-N-methyl-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-
5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-amine;
4-(2-((3-Methoxy-l-methyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((l,3-Dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((4-Chloro-l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-
6-yl)morpholine;
4-(2-((4-(Difluoromethyl)-l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Methoxy-2-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-(Mesitylsulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-(Difluoromethoxy)phenyl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((2,4-Dimethylphenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((2,4-Difluorophenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4,6-Dimethylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
(R)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile;
4-(2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((l-methyl-3 -(trifluoromethyl)- lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
(S)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile;
2-(Mesitylsulfonyl)-7-morpholino-5-oxa-2-azaspiro[3.4]octane;
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3 ,4]octane;
2-((l,3-Dimethyl-lH-pyrazol-5-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa- 2-azaspiro[3 ,4]octane;
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5- oxa-2-azaspiro[3 ,4]octane;
2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-7-morpholino-5- oxa-2-azaspiro[3 ,4]octane;
(R)-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-7- morpholino-5-oxa-2-azaspiro[3.4]octane;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3 ,4]octane;
(R)-2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5- oxa-2-azaspiro[3 ,4]octane;
3-((7-((4,4-Difluorocyclohexyl)(methyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(R)-4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(S)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(R)-4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(S)-4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
6-(2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N- (tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(oxetan- 3 -yl)-2-azaspiro[3.3 ]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-methyl-N- ((tetrahydro-2H-pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl -2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N- (tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N- (oxetan-3-yl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine; and
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-
((tetrahydro-2H-pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine; or a or a pharmaceutically acceptable salt thereof.
In a thirty-first embodiment, the present disclosure provides a pharmaceutical composition comprising a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.
In a thirty-second embodiment, the present disclosure provides a method of treating a disease or disorder mediated by EBP comprising administering to a subject an effective amount of a compound according to any one of embodiments one to thirty, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the thirty-first embodiment.
In a thirty-third embodiment, the present disclosure provides a compound according to any one of embodiments one to thirty, for use in the treatment of a disease or disorder mediated by EBP.
In a thirty-fourth embodiment, the present disclosure provides the use of a compound according to any one of embodiments one to thirty in the manufacture of a medicament for the treatment of a disease or disorder mediated by EBP.
The compounds and intermediates described herein may be isolated and used as the compound per se. Alternatively, when a moiety is present that is capable of forming a salt, the compound or intermediate may be isolated and used as its corresponding salt. As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound described herein. “Salts” include in particular “pharmaceutical acceptable salts”. The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds described herein and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
Pharmaceutically acceptable acid addition salts can be formed with inorganic acids or organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfornate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandi sulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methyl sulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/ dihydrogen
phosphate, polygalacturonate, propionate, stearate, succinate, sulfate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
The salts can be synthesized by conventional chemical methods from a compound containing a basic or acidic moiety. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
Isotopically-labeled compounds of Formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-
labeled reagents in place of the non-labeled reagent previously employed. In one embodiment, the present disclosure provides deuterated compounds described herein or a pharmaceutically acceptable salt thereof.
Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, de- DMSO.
It will be recognized by those skilled in the art that the compounds of the present invention may contain chiral centers and as such may exist in different stereoisomeric forms. As used herein, the term “an optical isomer” or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present disclosure. It is understood that a substituent may be attached at a chiral center of a carbon atom. Therefore, the disclosure includes enantiomers, diastereomers or racemates of the compound.
“Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1 : 1 mixture of a pair of enantiomers is a “racemic” mixture. The term “racemic” or “rac” is used to designate a racemic mixture where appropriate. When designating the stereochemistry for the compounds of the present invention, a single stereoisomer with known relative and absolute configuration of the two chiral centers is designated using the conventional RS system (e.g., (15,25)). “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Alternatively, the resolved compounds can be defined by the respective retention times for the corresponding enantiomers/diastereomers via chiral HPLC.
Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
Unless specified otherwise, the compounds of the present disclosure are meant to include all such possible stereoisomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)-stereoi somers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques (e.g., separated on chiral SFC or HPLC chromatography columns, such as CHIRALPAKR™ and
CHIRALCELR™ available from DAICEL Corp, using the appropriate solvent or mixture of solvents to achieve good separation). If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
METHODS OF USE
The compounds disclosed herein have EBP inhibitory activity. As used herein, “EBP inhibitory activity” refers to the ability of a compound or composition to induce a detectable decrease in EBP activity in vivo or in vitro (e.g., at least 10% decrease in EBP activity as measured by a given assay such as the bioassay described in the examples and known in the art).
In certain embodiments, the present disclosure provides a method of treating a disease or disorder responsive to inhibition of EBP activity (referred herein as “EBP mediated disease or disorder” or “disease or disorder mediated by EBP”) in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirty embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of a EBP mediated disorder or disease in a subject in need of the treatment.
In certain embodiments, the EBP mediated disorder is colorectal cancer.
In certain embodiments, the present disclosure provides a method of treating an autoimmune disease in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first
to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an autoimmune disease in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in the treatment of an autoimmune disease in a subject in need of the treatment.
In certain embodiments, the autoimmune disease is multiple sclerosis (MS). The compounds of the present disclosure can be used for treating all stages of MS, including relapsing multiple sclerosis (or relapsing form(s) of multiple sclerosis), relapsing-remitting multiple sclerosis, primary progress multiple sclerosis, secondary progressive multiple sclerosis and clinically isolated syndrome (hereinafter “CIS”).
Relapsing multiple sclerosis (or relapsing form(s) of multiple sclerosis) includes clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis.
Relapsing-remitting multiple sclerosis is a stage of MS characterized by unpredictable relapses followed by periods of months to years of relative quiet (remission) with no new signs of disease activity. Deficits that occur during attacks may either resolve or leave problems, the latter in about 40% of attacks and being more common the longer a person has had the disease. This describes the initial course of 80% of individuals with multiple sclerosis.
Secondary progressive multiple sclerosis occurs in around 65% of those with initial relapsing-remitting multiple sclerosis, who eventually have progressive neurologic decline between acute attacks without any definite periods of remission. Occasional relapses and minor remissions may appear. The most common length of time between disease onset and conversion from relapsing-remitting to secondary progressive multiple sclerosis is 19 years.
Primary progressive multiple sclerosis is characterized by the same symptoms of secondary progressive multiple sclerosis, i.e., progressive neurologic decline between acute attacks without any definite periods of remission, without the prior relapsing-remitting stage.
CIS is a first episode of neurologic symptoms caused by inflammation and demyelination in the central nervous system. The episode, which by definition must last for at least 24 hours, is characteristic of multiple sclerosis but does not yet meet the criteria for a diagnosis of MS because people who experience a CIS may or may not go on to develop MS. When CIS is accompanied by lesions on a brain MRI (magnetic resonance imaging) that are similar to those seen in MS, the person has a high likelihood of a second episode of neurologic symptoms and diagnosis of relapsing-remitting MS. When CIS is not accompanied by MS-like lesions on a brain MRI, the person has a much lower likelihood of developing MS.
In certain embodiments, the present disclosure provides a method of promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in promoting myelination in a subject with a myelin-related disease or disorder in a subject in need of the treatment.
In certain embodiments, the myelin-related disease or disorder is selected from multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), acute disseminated encephalomyelitis (ADEM), central pontine myelolysis (CPM), adrenoleukodystrophy, Alexander's disease, Pelizaeus Merzbacher disease (PMD), Vanishing White Matter Disease, Wallerian Degeneration, transverse myelitis, amylotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post radiation injury, neurologic complications of chemotherapy, stroke, acute ischemic optic
neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen-Komzweig syndrome, Marchiafava-Bignami syndrome, autism, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, chronic inflammatory demyelinating polyneuropathy, Guillian-Barre syndrome, Charcot-Marie-Tooth disease, Bell's palsy and radiation-induced demyelination, for example, neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophies, neonatal white matter injury, age-related dementia, and schizophrenia.
In certain embodiments, the present disclosure provides a method of treating cancer in a subject in need of the treatment. The method comprises administering to the subject a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
In certain embodiments, the present disclosure provides the use of a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer in a subject in need of the treatment.
In certain embodiments, the present disclosure provides a compound described herein (e.g., a compound described in any one of the first to thirtieth embodiments) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need of the treatment.
In certain embodiments, the cancer is colorectal cancer.
In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said subject is a mammal. In certain embodiments, the subject is a primate. In certain embodiments, the subject is a human.
As used herein, an “effective amount” and a “therapeutically effective amount” can used interchangeably. It means an amount effective for treating or lessening the severity of one or more of the diseases, disorders or conditions as recited herein. In some embodiments, the effective dose can be between 10 pg and 500 mg.
The compounds and compositions, according to the methods of the present disclosure, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases, disorders or conditions recited above.
In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered parenterally. In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered intramuscularly, intravenously, subcutaneously, orally, pulmonary, rectally, intrathecally, topically or intranasally. In certain embodiments, the present disclosure relates to the aforementioned methods, wherein said compound is administered systemically.
The compounds of the present invention can be used as a pharmaceutical composition (e.g., a compound of the present invention and at least one pharmaceutically acceptable carrier). As used herein, the term “pharmaceutically acceptable carrier” includes generally recognized as safe (GRAS) solvents, dispersion media, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, preservatives, drug stabilizers, buffering agents (e.g., maleic acid, tartaric acid, lactic acid, citric acid, acetic acid, sodium bicarbonate, sodium phosphate, and the like), and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated. For purposes of this disclosure, solvates and hydrates are considered pharmaceutical compositions comprising a compound of the present invention and a solvent (i.e., solvate) or water (i.e., hydrate).
The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., compound of the present invention or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent)) is dissolved in a suitable solvent in the presence of one or more of the excipients described above. The compound of the present invention is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product.
The pharmaceutical composition (or formulation) for application may be packaged in a variety of ways depending upon the method used for administering the drug. Generally, an article for distribution includes a container having deposited therein the pharmaceutical formulation in an appropriate form. Suitable containers are well-known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, metal cylinders, and the like. The container may also include a tamper-proof assemblage to prevent indiscreet access to the contents of the package. In addition, the container has deposited
thereon a label that describes the contents of the container. The label may also include appropriate warnings.
The pharmaceutical composition comprising a compound of the present disclosure is generally formulated for use as a parenteral or oral administration or alternatively suppositories.
For example, the pharmaceutical oral compositions of the present disclosure can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers, etc.
Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethylene glycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
Tablets may be either film coated or enteric coated according to methods known in the art.
Suitable compositions for oral administration include a compound of the disclosure in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate;
granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
The parenteral compositions (e.g, intravenous (IV) formulation) are aqueous isotonic solutions or suspensions. The parenteral compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are generally prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
The compound of the present disclosure or pharmaceutical composition thereof for use in a subject (e.g., human) is typically administered orally or parenterally at a therapeutic dose. When administered intravenously via infusion, the dosage may depend upon the infusion rate at which an IV formulation is administered. In general, the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, pharmacist, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
DEFINITIONS
As used herein, a “patient,” “subject” or “individual” are used interchangeably and refer to either a human or non-human animal. The term includes mammals such as humans. Typically, the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. Preferably, the subject is a human.
As used herein, the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
As used herein, the term “treat”, “treating” or “treatment” of any disease, condition or disorder, refers to the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a compound of the present invention to obtaining desired pharmacological and/or physiological effect. The effect can be therapeutic, which includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the extent of the disease, condition or disorder; ameliorating or improving a clinical symptom, complications or indicator associated with the disease, condition or disorder; or delaying, inhibiting or decreasing the likelihood of the progression of the disease, condition or disorder; or eliminating the disease, condition or disorder. In certain embodiments, the effect can be to prevent the onset of the symptoms or complications of the disease, condition or disorder.
As used herein, the term “cancer” has the meaning normally accepted in the art. The term can broadly refer to abnormal cell growth.
As used herein, the term “autoimmune disease” has the meaning normally accepted the art. The term can broadly refer to a disease where the host’s immune system targets or attacks normal or healthy tissue of the host.
As used herein, the term “myelination” has the meaning normally accepted in the art. The term can broadly mean the process by which myelin is produced.
As used herein, the term “myelin-related disease or disorder”, “demyelinating disorder”, or “demyelation disorder” has the meaning normally accepted in the art. These terms can broadly refer to diseases or disorders which involve damage to myelin.
As used herein, a subject is “in need of’ a treatment if such subject would benefit biologically, medically or in quality of life from such treatment (preferably, a human).
As used herein, the phrase “optionally substituted” is used interchangeably with the phrase “substituted or un substituted.” In general the term “optionally substituted” refers to the
replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described in the definitions and in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. In some embodiments, an optionally substituted group can be substituted with one or more substituents, each of which can the same or different. In some embodiments, the “one or more” substituents can be 1, 2, 3, 4, 5, 6, etc. substituents, each of which can the same or different. In some embodiment, the “one or more” substituents can be 1 to 6, 1 to 4, 1 to 3 or 1 to 2 substituents, each of which can the same or different.
As used herein, the term “ alkyl” refers to a fully saturated branched or unbranched hydrocarbon moiety. The term “Ci-4alkyl” refers to an alkyl having 1 to 4 carbon atoms. The terms “C1-3alkyl” and “Ci.2alkyl” are to be construed accordingly. Representative examples of “Ci-4alkyl” include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, secbutyl, iso-butyl, and tert-butyl. Similarly, the alkyl portion (i.e., alkyl moiety) of an alkoxy have the same definition as above. When indicated as being “optionally substituted”, the alkane radical or alkyl moiety may be unsubstituted or substituted with one or more substituents (generally, one to three substituents except in the case of halogen substituents such as perchloro or perfluoroalkyls).
As used herein, the term “alkoxy” refers to a fully saturated branched or unbranched alkyl moiety attached through an oxygen bridge (i.e. a — O— Ci-4 alkyl group wherein Ci-4 alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy and the like. Preferably, alkoxy groups have about 1-4 carbons, more preferably about 1-2 carbons. The term “ Ci-2 alkoxy” is to be construed accordingly.
As used herein, the term “Ci-4 alkoxyCi-4 alkyl” refers to a Ci.4allkyl group as defined herein, wherein at least of the hydrogen atoms is replaced by an Ci.4alkoxy. The Ci.4alkoxyCi. 4 alkyl group is connected through the rest of the molecule described herein through the alkyl group.
The number of carbon atoms in a group is specified herein by the prefix “Cx-xx”, wherein x and xx are integers. For example, “C1.3 alkyl” is an alkyl group which has from 1 to 3 carbon atoms.
“Halogen” or “halo” may be fluorine, chlorine, bromine or iodine.
As used herein, the term “halo-substituted-Ci^alkyl” or “ Ci.4haloalkyl” refers to a Ci- 4alkyl group as defined herein, wherein at least one of the hydrogen atoms is replaced by a halo atom. The Ci.4haloalkyl group can be monohalo-Ci-4alkyl, dihalo-Ci.4alkyl or polyhalo-Ci-4 alkyl including perhalo-Ci.4alkyl. A monohalo-Ci.4alkyl can have one iodo, bromo, chloro or fluoro within the alkyl group. Dihalo-Ci-4alkyl and polyhalo-Ci.4alkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl. Typically the polyhalo-Ci.4alkyl group contains up to 9, or 8, or 7, or 6, or 5, or 4, or 3, or 2 halo groups. Non-limiting examples of Ci-4haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, di chloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and di chloropropyl. A perhalo-Ci.4alkyl group refers to a Ci-4alkyl group having all hydrogen atoms replaced with halo atoms.
The term “aryl” refers to an aromatic carbocyclic single ring or two fused ring system containing 6 to 10 carbon atoms. Examples include phenyl and naphthyl.
The term “heteroaryl” refers to a 5- to 12-membered aromatic radical containing 1-4 heteroatoms selected from N, O, and S. In some instances, nitrogen atoms in a heteroaryl may be quaternized. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or “heteroaromatic”. A heteroaryl group may be mono- or bi-cyclic. Monocyclic heteroaryl includes, for example, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, furanyl, oxadiazolyl, thiophenyl, and the like. Bi-cyclic heteroaryls include groups in which a monocyclic heteroaryl ring is fused to one or more aryl or heteroaryl rings. Non-limiting examples include pyrazolopyridinyl, pyrazolopyridinyl, benzotriazolyl, imidazopyridinyl, and indoyl.
The term “carbocyclic ring” or “carbocyclyl” refers to a 4- to 12-membered saturated or partially unsaturated hydrocarbon ring and may exist as a single ring, bicyclic ring (including fused, spiral or bridged carbocyclic rings) or a spiral ring. Bi-cyclic carbocyclyl groups include, e.g., unsaturated carbocyclic radicals fused to another unsaturated carbocyclic radical, cycloalkyl, or aryl, such as, for example, 2,3-dihydroindenyl, decahydronaphthal enyl, and 1,2,3,4-tetrahydronaphthalenyl. Unless specified otherwise, the carbocyclic ring generally contains 4- to 10- ring members.
The term “C3-6 cycloalkyl” refers to a carbocyclic ring which is fully saturated (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl).
The term “heterocycle” or “heterocyclyl” refers to a 4- to 12-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected
from N, O, and S. A heterocyclyl group may be mono- or bicyclic (e.g., a bridged, fused, or spiro bicyclic ring). Examples of monocyclic saturated or partially unsaturated heterocyclic radicals include, without limitation, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, and piperdinyl. Bi-cyclic heterocyclyl groups include, e.g., unsaturated heterocyclic radicals fused to another unsaturated heterocyclic radical, cycloalkyl, aryl, or heteroaryl ring, such as, for example, tetrahydro-3H-[l,2,3]triazolo[4,5-c]pyridinyl, 2-oxa-6-azaspiro[3.3]heptanyl, 5- oxabicyclo[2.1.1]hexanyl and 9-azabicyclo[3.3.1]nonanyl. In some embodiments, the heterocyclyl group is a 4 to 6 membered monocyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 4 to 6 membered monocyclic saturated heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic heterocyclyl group. In some embodiments, the heterocyclyl group is a 8 to 10 membered bicyclic saturated heterocyclyl group.
As used herein the term “spiral” ring means a two-ring system wherein both rings share one common atom. Examples of spiral rings include, 2-oxa-6-azaspiro[3.3]heptanyl and the like.
The term “fused” ring refers to two ring systems share two adjacent ring atoms. Fused heterocycles have at least one the ring systems contain a ring atom that is a heteroatom selected from O, N and S (e.g., 3-oxabicyclo[3.1.0]hexane).
As used herein the term “bridged” refers to a 5 to 10 membered cyclic moiety connected at two non-adjacent ring atoms (e.g. 5-oxabicyclo[2.1.1]hexane).
The phrase “pharmaceutically acceptable” indicates that the substance, composition or dosage form must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
Unless specified otherwise, the term “compounds of the present disclosure” refers to compounds of Formula (I), as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, isotopically labeled compounds (including deuterium substitutions). When a moiety is present that is capable of forming a salt, then salts are included as well, in particular pharmaceutically acceptable salts.
As used herein, the term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
It is also possible that the intermediates and compounds of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. A specific example of a proton tautomer is the imidazole moiety where the proton may migrate between the two ring nitrogens. Valence tautomers include interconversions by reorganization of some of the bonding electrons.
In one embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in free form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in salt form. In another embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in acid addition salt form. In a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable salt form. In yet a further embodiment, the present disclosure relates to a compound of the Formula (I) as defined herein, in pharmaceutically acceptable acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in free form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in acid addition salt form. In yet a further embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable salt form. In still another embodiment, the present disclosure relates to any one of the compounds of the Examples in pharmaceutically acceptable acid addition salt form.
Compounds of the present disclosure may be synthesized by synthetic routes that include processes analogous to those well-known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Sigma- Aldrich or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19, Wiley, New York (1967-1999 ed.), or Beilsteins Handbuch der organischen Chemie, 4, Aufl. ed. Springer-Verlag, Berlin, including supplements (also available via the Beilstein online database)).
For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present disclosure as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below.
Although specific starting materials and reagents are depicted in the schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions.
EXEMPLIFICATION
Abbreviations:
PE = petroleum ether
EtOAc = EA = ethyl acetate
ESI = electrospray ionisation
MeOH = methanol
EtOH = ethanol
DCE = 1,2-di chloroethane
DCM = dichloromethane
CHCh = chloroform
HC1 = hydrochloric acid
H2O = water
IPA = isopropyl alcohol
LCMS = liquid chromatography mass spectrometry
HFIP = hexafluoro-2-propanol
HPLC = high pressure liquid chromatography
THF = tetrahydrofuran
MeCN = ACN = acetonitrile
MgSCU = magnesium sultate
DMSO = dimetylsulfoxide
AcOH = acetic acid
TFA = tri fluoroacetic acid
DIPEA = diisopropylethyl amine
N2 = Nitrogen
NH4HCO3 = Ammonium Bicarbonate t-BuOH = tert-butanol
NH4CI = ammonium chloride
NaH = sodium hydride
Na2SO4 = sodium sulfate
K2CO3 = potassium carbonate NaHCO3 = sodium bicarbonate
NaBH(0Ac)3 = STAB = sodium triacetoxyborohydride
SiCh = silicon dioxide or silica
PDA = Photo Diode Array Detection
TosMIC = toluenesulfonylmethyl isocyanide
TLC = Thin Layer Chromatography
LiHMDS = Lithium bis(trimethylsilyl)amide
GENERAL METHODS
LCMS instrumentation specifications:
• Agilent Technologies 1200 Series LC/MSD system: DAD\ELSD Alltech 3300 and Agilent LC\MSD G6130A, G6120B mass-spectrometer.
• Agilent Technologies 1260 Infinity LC/MSD system: DAD\ELSD Alltech 3300 and Agilent LC\MSD G6120B mass-spectrometer.
• Agilent Technologies 1260 Infinity II LC/MSD system: DAD\ELSD G7102A 1290 Infinity II and Agilent LC\MSD G6120B mass-spectrometer.
• Agilent 1260 Series LC/MSD system: DAD\ELSD and Agilent LC\MSD (G6120B) mass-spectrometer.
• UHPLC Agilent 1290 Series LC/MSD system: DAD\ELSD and Agilent LC\MSD (G6125B) mass-spectrometer.
HPLC analytical method specifications:
• Column: Agilent Poroshell 120 SB-C18 4.6 x 30mm 2.7 pm, with UHPLC Guard Infinity Lab Poroshell 120 SB-C18 4.6 x 5mm 2.7 pm
• Column Temperature, 60 C
• Injection volume 0.5 pL
• Modifier: Formic acid 0.1% (v/v) cone.
• Method: 99% water / 1% MeCN (initial conditions), HOLD initial conditions for 0.1 min, linear gradient to 0% water / 100% MeCN at 1.5min, HOLD 0% water / 100% MeCN to 1.73 min, linear gradient to 99% water / 1% MeCN at 1.74 min. Flow rate, 3.0 mL/min.
UV scan: 207-223 nm, 246-262 nm, 272-288 nm
QC Analysis LC/MS method conditions:
Ammonium hydroxide (basic pH) conditions
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters ACQUITY UPLC BEH C18 2.1x50 mm, 1.7 gm; Part No. 186002350
Modifier: Ammonium hydroxide 0.2% (v/v) cone.
Method: 95% water/5% MeCN (initial conditions) linear gradient to 5% water/95% MeCN at 3.75 min, HOLD 5% water/95% MeCN to 4 min. Flow rate, 0.8 mL/min.
Trifluoroacetic acid (acidic pH) conditions
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters ACQUITY UPLC BEH C18 2.1x50 mm, 1.7 gm; Part No. 186002350
Modifier: Trifluoroacetic acid 0.1% (v/v) cone.
Method: 95% water/5% MeCN (initial conditions) linear gradient to 5% water/95% MeCN at 3.75 min, HOLD 5% water/ 95% MeCN to 4 min. Flow rate, 0.8 mL/min.
General prep HPLC conditions:
Ammonium hydroxide (basic pH) conditions
Flow rate: 30 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters XSELECT CSH C18 PREP 19x100 mm, 5 gm; Part No. 186005421
Modifier: 0.2% Ammonium hydroxide (v/v) cone.
Method: A% water/ B% MeCN (initial conditions) linear gradient to A% water/B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5 min, HOLD 5% water/95% MeCN to 10 min.
Flow rate: 50 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters XSELECT CSH C18 PREP 30x100 mm, 5 pm; Part No. 186005425 Modifier: 0.2% NH4OH (v/v) cone.
Method: A% water/ B% MeCN (initial conditions) linear gradient to A% water/B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5min, HOLD 5% water/95% MeCN to 10 min.
Flow rate, 60 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters XSELECT CSH C18 PREP 30x50 mm, 5 pm; Part No. 186005423
Modifier: 0.2% NH4OH (v/v) cone.
Method: A% water/B% MeCN (initial conditions) linear gradient to A% water/ B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5min, HOLD 5% water/95% MeCN to 10 min.
Trifluoroacetic acid (acidic pH) conditions
Flow rate, 30 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters Sunfire OBD C18 PREP 19x100 mm, 5 pm; Part No. 186002567
Modifier: 0.1% Trifluoroacetic acid (v/v) cone.
Method: A% water/B% MeCN (initial conditions) linear gradient to A% water/B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5 min, HOLD 5% water/95% MeCN to 10 min.
Flow rate, 50 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters Sunfire OBD C18 PREP 30x100 mm, 5 pm; Part No. 186002572
Modifier: 0.1% Trifluoroacetic acid (v/v) cone.
Method: A% water/B% MeCN (initial conditions) linear gradient to A% water/B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5 min, HOLD 5% water/95% MeCN to 10 min.
Flow rate, 60 mL/min
MS mode: MS:ESI+ scan range 165-650 daltons
PDA: 200-400 nm scan range
Column: Waters Sunfire OBD C18 PREP 30x50 mm, 5 pm; Part No. 186002570
Modifier: 0.1% Trifluoroacetic acid (v/v) cone.
Method: A% water/B% MeCN (initial conditions) linear gradient to A% water/B% MeCN at 8 min, ramp to 5% water/95% MeCN at 8.5 min, HOLD 5% water/ 95% MeCN to 10 min.
EXPERIMENTAL PROCEDURES
Example 1
6-(2-((6-(l,l-Difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-
To a solution of 3,6-dibromo-2-methylpyridine (10 g, 39.9 mmol) in toluene (200 mL) was added w-BuLi (2.5 M, 17.5 mL) at -78 °C under a N2 atmosphere and the solution stirred for 1 h. DMA (10.4 g, 119.6 mmol) was added, the mixture was stirred at -78 °C for 1 h and slowly warmed to 20 °C. The reaction was poured into saturated aqueous NH4CI solution, extracted with EtOAc and the combined organic extracts concentrated in vacuo. The extract was purified by silica gel column chromatography (PE/EtOAc = 1/0 to 8/1) to give l-(5- bromo-6-methylpyridin-2-yl)ethan-l-one (8.1 g, 95%) as a yellow solid. 'H NMR (400 MHz, CDCL): δ ppm 7.92 (d, J= 8.0 Hz, 1H), 7.72 (d, J= 8.0 Hz, 1H), 2.72 (s, 3H), 2.69 (s, 3H).
A solution of l-(5-bromo-6-methylpyridin-2-yl)ethan-l-one (8.1 g, 37.8 mmol) in DAST (30 mL, 227.1 mmol) was stirred at 60 °C for 4 h. The reaction was quenched with saturated NaHCO3 aq. until pH = 7 and was extracted with DCM (100 mL x 3). The combined organic layer was washed with brine (100 mL), dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by CombiFlash® (PE/EtOAc = 20/1 to 10/1) to give 3-bromo-6-(l,l-difluoroethyl)-2 -methylpyridine (4.5 g, 50%) as colorless oil. LCMS m/z = 236.0 [M+H]+.
3. Synthesis of 3-(benzylthio)-6-( 1, l-difluoroethyl)-2-methylpyridine
To a solution of 3-bromo-6-(l,l-difluoroethyl)-2-methylpyridine (2.2 g, 9.3 mmol) in dioxane (20 mL) was added DIPEA (4.9 mL, 28.0 mmol), Pd(tBu3P)2 (476 mg, 0.9 mmol) and BnSH (2.3 mL, 19.7 mmol) and the mixture was stirred at 100 °C for 16 h under N2. The mixture was quenched with H2O (100 mL) and extracted with DCM (50 mL x 5). The combined organic phases were washed with brine (50 mL), dried over Na2SO4 , filtered and concentrated to give 3-(benzylthio)-6-(l,l-difluoroethyl)-2-methylpyridine (4 g, crude) as yellow oil. LCMS m/z = 280.1 [M+H]+.
To a solution of 3-(benzylthio)-6-(l,l-difluoroethyl)-2-methylpyridine (1 g, 3.6 mmol) in DCM (10 mL) and water (2 mL), was added SO2CI2 (2.1 mL, 25.1 mmol) at 0 °C and the reaction was stirred at 0 °C for 1 h under N2. The mixture was diluted with water (50 mL) and extracted with DCM (50 mL x 5). The combined organic phase was dried over anhydrous sodium sulfate, and concentrated in vacuo to give 2-((6-(l,l-difluoroethyl)-2-methylpyridin- 3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (650 mg, crude) as yellow oil. 'H NMR (400 MHz, CDCL): δ ppm 8.44 (d, J= 8.4 Hz, 1H), 7.74 (d, J= 8.4 Hz, 1H), 3.05 (s, 3H), 2.05 (t, J= 18.8 Hz, 3H).
5. Synthesis of 2-((6-(l, 1 -difluor oethyl)-2-methylpyr idin-3-yl) sulfonyl)-2- azaspiro[ 3.3 ]heptan-6-one
To a solution of 2-azaspiro[3.3]heptan-6-one TFA salt (530 mg, 2.4 mmol) in DCM (10 mL) was added DIPEA (6820 pL, 4.7 mmol), followed by 2-((6-(l,l-difluoroethyl)-2- methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (605 mg, 2.36 mmol) in DCM (2 mL). The mixture was stirred at 20 °C for 1 h then diluted with water (30 mL) and extracted with DCM (30 mL x 3). The combined organic phase was washed with water (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by column chromatography (0% to 6% MeOH in DCM) to give 2-((6-(l,l-difluoroethyl)-2-
methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (260 mg, 33%) as yellow solid.
LCMS m/z = 331.1 [M+H]+.
6. Synthesis of 6-(2-( ( 6-( 1, l-dijluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2- azaspiro [ 3.3 ]heptan-6-yl)-2-oxa-6-azaspiro[ 3.3 ] heptane
A solution of 2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan- 6-one (80 mg, 0.2 mmol) and 2-oxa-6-azaspiro[3.3]heptane oxalate (68 mg, 0.4 mmol) in MeOH (3 mL) was adjusted to pH 5-6 using AcOH and the solution stirred for 0.5 h at 20 °C. NaBH3CN (76 mg, 1.2 mmol) was added and the mixture was stirred for 1 h at 20 °C. The mixture was purified by prep-HPLC (Welch Xtimate C18 150 x 25mm x 5pm, Condition: water (NH4HCO3)-MeCN, 28% to 48%, Flow Rate (mL/min): 25) to give 6-(2-((6-(l , 1 - difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-2-oxa-6- azaspiro[3.3]heptane (32 mg, 32%) as white solid. LCMS m/z = 414.1 [M+H]+. 1H NMR (400 MHz, MeOH-d4): δ ppm 8.34 (d, J= 8.0 Hz, 1H), 7.70 (d, J= 8.0 Hz, 1H), 4.70 (s, 4H), 3.89 (s, 2H), 3.82 (s, 2H), 3.32 (s, 4H), 2.97 - 2.92 (m, 1H), 2.83 (s, 3H), 2.23 - 2.19 (m, 2H), 2.04 - 1.93 (m, 5H).
Example 2
2-((6-( l,l-Difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N -(tetrahydro-2Z/-pyran-4-yl)-
A solution of 2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan- 6-one (Example 1, step 5, 80 mg, 0.2 mmol) and tetrahydropyran-4-amine (37 mg, 0.4 mmol) in MeOH (3 mL) was adjusted to pH 5-6 using acetic acid and stirred for 0.5 h at 20 °C. NaBH3CN (76 mg, 1.2 mmol) was added and the mixture was stirred for 1 h at 20 °C. The mixture was purified by prep-HPLC (Welch Xtimate Cl 8 150 x 25mm x 5pm, Condition: water (NH4HCO3)-MeCN, 37% to 52%, Flow Rate (mL/min): 25) to give 2-((6-(l,l- difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N -(tetrahydro-2//-pyran-4-yl)-2-
azaspiro[3.3]heptan-6-amine (25 mg, 25%) as white solid. LCMS m/z = 416.2 [M+H]+. 'H NMR (400 MHz, MeOH-d4): 6 ppm 8.36 (d, J= 8.0 Hz, 1H), 7.71 (d, J= 8.0 Hz, 1H), 3.93 (s, 2H), 3.90 - 3.88 (m, 2H), 3.81 (s, 2H), 3.40 - 3.34 (m, 2H), 3.28 - 3.25 (m, 1H), 2.84 (s, 3H), 2.70 - 2.65 (m, 1H), 2.45 - 2.43 (m, 2H), 2.05 - 1.94 (m, 5H), 1.77 - 1.72 (m, 2H), 1.37 - 1.35 (m, 2H).
Example 3
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -(tetrahydro-2Z/-pyran-4-yl)-2- azaspiro[3.3]heptan-6-amine
1. Synthesis of 2-((2-methyl-6-(trijluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[ 3.3 ]heptan-6-one
To a vial containing 2-azaspiro[3.3]heptan-6-one hydrochloride (300 mg, 2.0 mmol) in anhydrous DCM (8 mL) was added DIPEA (1.1 mL, 6.3 mmol) dropwise at < 5 °C. After 5 mins, 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (704 mg, 2.7 mmol) was added and the reaction was allowed to warm to 23 °C. After 30 mins, the reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 20 mins, then the biphasic mixture was extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSCh, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10 - 60 % EtOAc in heptane) to give 2-((2- methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (450 mg, 67%) as a white solid. LCMS m/z = 335.0 [M+H]+.
2. Synthesis of 2-((2-methyl-6-(trijluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro [ 3.3 ]heptan-6-amine
To a mixture of 2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan- 6-one (67 mg, 0.2 mmol) and tetrahydropyran-4-amine HC1 salt (46 mg, 0.3 mmol) in DCM (3 mL) was added AcOH (34 pL, 0.6 mmol). NaBH(OAc)3 (170 mg, 0.8 mmol) was added in one portion and the reaction mixture was stirred at rt for 3 days. The reaction was quenched with satd. NaHCO3, stirred at rt for 5 min, more DCM and water added, and the mixture stirred for a further 5 min. The aqueous layer was removed, the organic phase was washed with water and concentrated. The residue was purified by silica gel column (50 to 100% EtOAc/EtOH (3/1)) to give 2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran- 4-yl)-2-azaspiro[3.3]heptan-6-amine (61 mg, 73%) as a white solid. LCMS m/z = 420.2 [M+H]+. 1H NMR (400 MHz, MeOH-d4): 6 (ppm) 8.47 (d, J= 8.0 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 4.01 (s, 2H), 3.95 (dd, J= 11.0, 4.0 Hz, 2H), 3.89 (s, 2H), 3.50 - 3.36 (m, 3H), 2.89 (s, 3H), 2.85 (s, 1H), 2.58 - 2.48 (m, 2H), 2.16 - 2.06 (m, 2H), 1.88 - 1.77 (m, 2H), 1.44 (qd, J = 12.2, 4.5 Hz, 2H)
Example 4
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-2- oxa-6-azaspiro[3.3]heptane
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one
(Example 3, step 1, 75 mg, 0.2 mmol) and 2-oxa-6-azaspiro[3.3]heptane (22 mg, 0.2 mmol) were dissolved in MeOH (6 mL). NaBHsCN (71 mg, 1.1 mmol) and AcOH (30 pL, 0.5 mmol) were added and the reaction stirred at rt for 6 h. The reaction was quenched with ammonium chloride (sat. aq.), the mixture diluted with DCM and the layers separated. The organic phase was washed with water and brine and the solvent removed in vacuo. The crude product was purified by silica gel column (0-100% EtOAc to 3 : 1 EtOAc:EtOH (w/2% NH3OH)) to give 6- (2-((2-methyl-6-(trifhioromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-2-oxa-6- azaspiro[3.3]heptane (65 mg, 69%). LCMS m/z = 418.3 [M+H]+. XHNMR (500 MHz, CDC13): δ ppm 8.36 - 8.13 (m, 1H), 7.58 (d, J= 8.2 Hz, 1H), 4.64 (s, 4H), 3.83 (d, J= 16.5 Hz, 4H), 3.20 (s, 4H), 2.86 - 2.70 (m, 4H), 2.22 - 2.05 (m, 2H), 1.86 (m, 2H).
Example 5
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6- yl)morpholine was obtained (9 mg, 10%), from 2-((2-methyl-6-(trifluoromethyl)pyri din-3 - yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 3, step 1) and morpholine, following the procedure described in Example 4. LCMS m/z = 406.3 [M+H]+. 'H NMR (500 MHz, CDC13): δ ppm 8.29 (d, J= 7.9 Hz, 1H), 7.58 (d, J= 7.9 Hz, 1H), 3.92 (s, 2H), 3.81 (s, 2H), 3.63 (br s, 4H), 2.83 (s, 3H), 2.55 (br t, J= 7.6 Hz, 1H), 2.32 - 2.15 (m, 6H), 1.99 (br t, J= 9.5 Hz, 2H).
Example 6
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-l- oxa-6-azaspiro[3.3]heptane
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-l-oxa- 6-azaspiro[3.3]heptane was obtained (67 mg, 72%), from 2-((2-methyl-6- (trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 3, step 1) and l-oxa-6-azaspiro[3.3]heptane, following the procedure described in Example 4. LCMS m/z = 418.3 [M+H]+. XH NMR (500 MHz, CDC13): 6 ppm 8.28 (d, J= 8.2 Hz, 1H), 7.57 (d, J= 7.9 Hz, 1H), 4.43 (t, J= 7.6 Hz, 2H), 3.92 - 3.74 (m, 4H), 3.45 (br d, J = 8.6 Hz, 2H), 3.02 (br d, J = 9.2 Hz, 2H), 2.92 - 2.85 (m, 1H), 2.82 (s, 3H), 2.76 (t, J = 7.5 Hz, 2H), 2.26 - 2.10 (m, 2H), 1.92 - 1.81 (m, 2H).
Example 7
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -(l-(tetrahydro-2H-pyran-4- yl)cyclopropyl)-2-azaspiro[3.3]heptan-6-amine
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -(l-(tetrahydro-2 -pyran-4- yl)cyclopropyl)-2-azaspiro[3.3]heptan-6-amine was obtained (80 mg, 39%), from 2-((2- methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3 ,3]heptan-6-one (Example 3, step 1) and l-(tetrahydro-2J/-pyran-4-yl)cyclopropan-l -amine following the procedure described in Example 4. LCMS m/z = 460.3 [M+H]+. 'H NMR (400 MHz, MeOH-d4): 8 ppm 8.38 (d, J= 8.5 Hz, 1H), 7.77 (d, J= 8.0 Hz, 1H), 4.70 (br s, 1H), 4.00 - 3.70 (m, 5H), 3.36 - 3.14 (m, 4H), 2.80 (s, 3H), 2.46 - 2.31 (m, 2H), 1.97 - 1.85 (m, 2H), 1.72 - 1.55 (m, 1H), 1.54 - 1.43 (m, 2H), 1.27 - 1.03 (m, 2H), 0.45 - 0.33 (m, 4H).
Example 8
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 3, step 1) (80 mg, 0.2 mmol) was dissolved in MeOH (1 mL) and DCM (3 mL). AcOH (30 pL, 0.5 mmol) was added, followed 15 mins later by NaBHsCN (75 mg, 1.2 mmol) and the reaction stirred at rt for 24 h. The reaction was diluted with EtOAc and quenched with NaHCO3 (sat. aq.) and the mixture extracted with EtOAc (3x). The combined organic extracts were washed with water, then concentrated in vacuo. The residue was purified by silica gel column chromatography with 0-100% EtOAc to 3: 1 EtOAc:EtOH (w/2% NH3OH) to give 2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -(oxetan-3- yl)-2-azaspiro[3.3]heptan-6-amine (63 mg, 67%). LCMS m/z = 392.0 [M+H]+. ^ NMR (500 MHz, CDCL): 6 ppm 8.28 (d, J= 8.2 Hz, 1H), 7.58 (d, J= 8.2 Hz, 1H), 4.71 (t, J= 6.7 Hz,
2H), 4.32 (t, J= 6.4 Hz, 2H), 3.94 - 3.77 (m, 5H), 3.10 (t, J= 7.3 Hz, 1H), 2.83 (s, 3H), 2.36 (m, 2H), 1.84 (m, 3H).
Example 9
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N -((3-methyloxetan-3-yl)methyl)-
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one
(Example 3, step 1) (69 mg, 0.2 mmol) was dissolved in MeOH (1 mL) and DCM (3 mL). (3- Methyloxetan-3-yl)methanamine (25 mg, 0.3 mmol) and AcOH (25 pL, 0.4 mmol) were added and the solution stirred for 15 mins. NaBH(OAc)3 (220 mg, 1.0 mmol) was added and the reaction stirred at rt for 24 h. The reaction was diluted with EtOAc and quenched with aq. NaHCO3 solution. The solution was extracted with EtOAc (3x), the combined organic extracts were washed with water and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with (0 - 100%: EtOAc:EtOH (3: 1) with 0.2% NH3OH) in EtOH to give 2-((2-methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-A-((3 -methyl ox etan-
3-yl)methyl)-2-azaspiro[3.3]heptan-6-amine (60 mg, 69%). LCMS m/z = 420.1 [M+H]+. 'H NMR (500 MHz, CDC13): 8 ppm 8.36 (br d, J= 7.9 Hz, 1H), 7.65 (br d, J= 7.9 Hz, 1H), 4.51
- 4.28 (m, 4H), 4.04 - 3.78 (m, 4H), 3.19 (m, 1H), 2.91 (s, 3H), 2.67 (s, 2H), 2.46 (m, 2H), 2.03
- 1.77 (m, 2H), 1.27 (s, 4H).
Example 10
4-(2-(( l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6- yl)morpholine
1. Synthesis of 2-((l -methyl-3-(trijluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro [ 3.3 ]heptan-6-one
2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one was obtained as a colorless film(404 mg, 62%), from 2-azaspiro[3.3]heptan-6-one and 2-methyl- 5-(trifluoromethyl)pyrazole-3-sulfonyl chloride, following the procedure described in Example 3, step 1. XH NMR (400 MHz, DCM-d2): 8 ppm 7.05 (s, 1H), 4.16 (s, 3H), 4.12 (s, 4H), 3.28 (s, 4H).
2. Synthesis of 4-(2-((l-methyl-3-(trijluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[ 3.3 ]heptan-6-yl)morpholine
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (75 mg, 0.2 mmol) and morpholine hydrochloride (32 mg, 0.3 mmol) were dissolved in DCM (4 mL). NaBHsCN (73 mg, 1.2 mmol) and AcOH (30 pL, 0.5 mmol) were added and the reaction stirred at rt for 6 h. The reaction was quenched with ammonium chloride (sat. aq.) and diluted with DCM. The layers were separated, the organic phase was washed with water and brine and then concentrated in vacuo. The residue was purified by silica gel column (0- 100% EtOAc to 3: 1 EtOAc:EtOH (w/2% NH3OH)) to give 4-(2-((l-methyl-3- (trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)morpholine (25 mg, 27%). LCMS m/z = 395.3 [M+H]+. 'H NMR (500 MHz, CDC13): 6 ppm 6.92 (s, 1H), 4.07 (s, 3H), 3.87 (s, 2H), 3.78 (s, 2H), 3.62 (br s, 4H), 2.54 (br t, J= 7.6 Hz, 1H), 2.32 - 2.16 (m, 6H), 1.98 (br d, J= 7.9 Hz, 2H).
Example 11
2-((l-Methyl-3-(trifluoromethyl)-lZZ-pyrazol-5-yl)sulfonyl)-N -(oxetan-3-ylmethyl)-2- azaspiro[3.3]heptan-6-amine
2-(( 1 -Methyl-3 -(tri fluoromethyl )- 1H -pyrazol-5-yl)sulfonyl)-N -(oxetan-3-ylmethyl)-2- azaspiro[3.3]heptan-6-amine was obtained (67 mg, 68%), from 2-(( 1 -methyl -3- (trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 10, step 1) and ox etan-3 -ylmethanamine, following the procedure described in Example 8. LCMS m/z = 395.1 [M+H]+. 1H NMR (500 MHz, CDC13): δ ppm 6.99 (s, 1H), 5.55 (br s, 1H), 4.79 (br t, J =6.9 Hz, 2H), 4.36 (br t, J= 6.0 Hz, 2H), 4.15 (s, 3H), 3.92 (s, 2H), 3.86 (s, 2H), 3.22 - 3.11 (m, 1H), 3.06 - 2.95 (m, 1H), 2.82 (br d, = 7.3 Hz, 2H), 2.43 (m, 2H), 1.90 - 1.81 (m, 2H).
Example 12
2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-N -((3-methyloxetaii-3- yl)methyl)-2-azaspiro[3.3]heptan-6-amine
2-((l -Methyl-3 -(trifluoromethyl)-lZ7-pyrazol-5-yl)sulfonyl)-A-((3-methyloxetan-3- yl)methyl)-2-azaspiro[3.3]heptan-6-amine was obtained (60 mg, 59%), from 2-((l-methyl-3- (trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 10, step 1) and (3 -m ethyl ox etan-3 -yl)methanamine, following the procedure described in Example 8. LCMS m/z = 409.1 [M+H]+. 1H NMR (500 MHz, CDC13): 6 ppm 7.00 (s, 1H), 4.43 - 4.33 (m, 4H), 4.15 (s, 3H), 3.92 (s, 2H), 3.90 - 3.85 (m, 2H), 3.18 (m, 1H), 2.66 (s, 2H), 2.46 - 2.38 (m, 2H), 1.91 - 1.83 (m, 2H), 1.27 (s, 4H).
Example 13
2-((l-Methyl-3-(trifluoromethyl)-lZ/-pyrazol-5-yl)sulfonyl)-N -(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine
2-((l-Methyl-3-(trifluoromethyl)-lZ7-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 10, step 1, 80 mg, 0.3 mmol) was dissolved in MeOH (1 mL) and DCM (3 mL). Oxetan-3 -amine (22 mg, 0.3 mmol) and AcOH (30 pL, 0.5 mmol) were added, the solution
stirred for 15 mins, then NaBH3CN (78 mg, 1.2 mmol) added. The reaction was stirred at rt for 24 h, then diluted with EtOAc and quenched with aq. NaHCO3 solution. The solution was extracted with EtOAc (3x), the combined organic extracts washed with water and concentrated in vacuo. The crude product was purified by column chromatography eluting with (0 - 100%: EtOAc:EtOH (3 : 1) with 0.2%NH3OH) in EtOH to give 2-((l-methyl-3- (tri fluoromethyl )-17/-pyrazol-5-yl)sulfonyl)-/'/-(oxetan-3-yl)-2-azaspiro[3.3]heptan-6-amine (52 mg, 55%). LCMS m/z = 381.0 [M+H]+. 'H NMR (500 MHz, CDC13): 8 ppm 6.92 (s, 1H), 5.59 - 5.35 (m, 1H), 4.71 (t, J= 6.9 Hz, 2H), 4.31 (t, J= 6.4 Hz, 2H), 4.07 (s, 3H), 3.89 - 3.73 (m, 5H), 3.14 - 3.03 (m, 1H), 2.32 (m, 2H), 1.81 (m, 2H).
Example 14
6-(2-(( l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6- yl)-2-oxa-6-azaspiro [3.3] heptane
6-(2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)- 2-oxa-6-azaspiro[3.3]heptane was obtained(8 mg, 8%), from 2-((l-methyl-3-(trifluoromethyl)- 1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 10, step 1) and 2-oxa-6- azaspiro[3.3]heptane, following the procedure described in Example 4. LCMS m/z = 407.3 [M+H]+. 1H NMR (500 MHz, CDC13): 6 ppm 6.91 (s, 1H), 4.64 (s, 4H), 4.07 (s, 3H), 3.79 (d, J= 7.9 Hz, 4H), 3.18 (s, 4H), 2.76 (m, 1H), 2.17 - 2.01 (m, 2H), 1.86 - 1.72 (m, 2H).
Example 15
6-(2-(( l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6- yl)-l-oxa-6-azaspiro [3.3] heptane
6-(2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)- l-oxa-6-azaspiro[3.3]heptane was obtained (37 mg, 39%), from 2-((l-methyl-3-
(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 10, step
1) and l-oxa-6-azaspiro[3.3]heptane following the procedure described in Example 4. LCMS m/z = 407.3 [M+H]+. 'H NMR (500 MHz, CDC13): 6 ppm 6.91 (s, 1H), 4.43 (t, J= 7.5 Hz, 2H), 4.14 - 3.95 (m, 3H), 3.79 (d, J= 13.1 Hz, 4H), 3.49 - 3.32 (m, 2H), 2.99 (br d, J= 9.5 Hz, 2H), 2.90 - 2.79 (m, 1H), 2.76 (t, J= 7.5 Hz, 2H), 2.26 - 2.06 (m, 2H), 1.88 - 1.75 (m, 2H).
Example 16
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)- l-oxa-6-azaspiro [3.3] heptane
To a solution of 5-bromo-4-methyl-2-(trifluoromethyl)pyrimidine (600 mg, 2.5 mmol) and BnSH (550 pL, 4.5 mmol) in dioxane (15 mL) was added DIPEA (1.3 mL, 7.5 mmol) and Pd(tBu3P)2 (190.8 mg, 0.373 mmol) and the reaction mixture was stirred at 100 °C for 12 h under N2 atmosphere. The mixture was diluted with water (15 mL) and extracted with EtOAc (10 mL x 3). The combined organic phase was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude was purified by column chromatography (EtOAc in PE = 0 to 8%) to give 5-(benzylthio)-4-methyl-2- (trifluoromethyl)pyrimidine (670 mg, 95% yield) as yellow solid. LCMS m/z = 285.0 [M+H]+
To a solution of 5-(benzylthio)-4-methyl-2-(trifluoromethyl)pyrimidine (550 mg, 1.9 mmol) in DCM (5 mL) and water (1 mL) was added a solution of SO2CI2 ( 1.10 mL, 13.6 mmol) in DCM (1 mL) dropwise over 5 mins at <5 °C and the reaction then stirred at <5 °C for 15 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL x 4). The combined organic phase was dried over anhydrous sodium sulfate, and concentrated in vacuo
to give 4-methyl-2-(trifluoromethyl)pyrimidine-5-sulfonyl chloride (350 mg, crude) as a yellowish oil. 'H NMR (400 MHz, CDC13): 6 ppm 9.36 (s, 1H), 3.10 (s, 3H).
3. Synthesis of 2-tf4-methyl-2-(trijluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[ 3.3 ]heptan-6-one
2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one was obtained(1.0 g, 34%), as a yellow solid, from 2-azaspiro[3.3]heptan-6-one (TFA salt) and 4- methyl-2-(trifluoromethyl)pyrimidine-5-sulfonyl chloride, following the procedure described in Example 1, step 4. LCMS m/z = 336.0 [M+H]+. XH NMR (500 MHz, CDC13): 8 ppm 9.21 (s, 1H), 4.25 (s, 4H), 3.36 (s, 4H), 2.93 (s, 3H).
A solution of 2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-one (70 mg, 0.2 mmol) and l-oxa-6-azaspiro[3.3]heptane hemioxalate (51 mg, 0.3 mmol) in MeOH (10 mL) was adjusted to pH 5-6 by the addition of AcOH and the reaction stirred for 0.5 h at 20 °C. NaBHsCN (39 mg, 0.6 mmol) was added and the reaction was stirred for 1 h at 20 °C. The mixture was diluted with water (30 mL) and extracted with DCM (30 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC (Phenomenex C18 150*40mm*5pm, Condition: water (NH4HCO3)-MeCN, 23% to 53%, Flow Rate (mL/min): 60) to give 6-(2-((4-methyl-2-(trifluoromethyl)pyrimidin-5- yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane (25 mg, 29 %) as white solid. LCMS m/z = 419.1 [M+H]+. XH NMR (400 MHz, CDC13): 6 ppm 9.17 (s, 1H), 4.50 (t, J= 7.6 Hz, 2H), 3.98 (s, 2H), 3.95 (s, 2H), 3.51 - 3.49 (m, 2H), 3.08 - 3.06 (m, 2H), 2.96 - 2.93 (m, 1H), 2.90 (s, 3H), 2.83 (t, J= 7.6 Hz, 2H), 2.26 - 2.21 (m, 2H), 1.98 - 1.93 (m, 2H).
Example 17
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-2- oxa-6-azaspiro[3.3]heptane was obtained (27 mg, 31%), as a white solid, from 2-((4-methyl- 2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (Example 16, step 3) and 2-oxa-6-azaspiro[3.3]heptane oxalate following the procedure described in Example 1, step 4. LCMS m/z = 419.1 [M+H]+. XH NMR (400 MHz, CDC13): 8 ppm 9.17 (s, 1H), 4.71 (s, 4H), 3.99 - 3.95 (m, 4H), 3.26 (s, 4H), 2.90 (s, 3H), 2.87 - 2.82 (m, 1H), 2.23 - 2.18 (m, 2H), 1.95 - 1.90 (m, 2H).
Example 18
2-Methyl-N -(2-(tetrahydro-2Z/-pyran-4-yl)-2-azaspiro[3.3]heptan-6-yl)-6-
1. Synthesis of tert-butyl 6-((2-methyl-6-(trijluoromethyl)pyridine)-3-sulfonamido)-2- azaspiro [ 3.3 ]heptane-2-carboxylate
To a solution of tert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate (1.24 g, 5.9 mmol) in anhydrous DCM (20 mL) was added DIPEA (4.0 mL, 23.0 mmol) dropwise at <5 °C. After 5 mins, 2-methyl-6-(trifluoromethyl)pyridine-3-sulfonyl chloride (2.01 g, 7.7 mmol) was added to the cold solution and upon complete addition, the reaction was allowed to warm to 23 °C and stirred for 90 mins. The reaction was quenched by slow addition of aqueous 1 M
NaOH solution. The mixture was stirred at 23 °C for 20 mins, then the biphasic mixture was extracted with DCM (3x). The combined organic extracts were dried over anhydrous magnesium sulfate, the mixture filtered and concentrated under reduced pressure. The residue was loaded onto a silica gel column and purified with (10-60 % EtOAc in heptane) to afford tert-butyl 6-((2-methyl-6-(trifluoromethyl)pyridine)-3-sulfonamido)-2-azaspiro[3.3]heptane- 2-carboxylate (1.95 g, 77%) as a white solid. TH NMR (500 MHz, DMSO-d6): 8 ppm 8.56 (d, J= 8.2 Hz, 1H), 8.38 (d, J= 8.2 Hz, 1H), 7.96 (d, J= 8.2 Hz, 1H), 3.82 - 3.65 (m, 4H), 3.58 - 3.51 (m, 1H), 2.82 (s, 3H), 2.26 - 2.20 (m, 2H), 2.01 - 1.95 (m, 2H), 1.32 (s, 9H).
2. Synthesis of 2-methyl-N-(2-azaspiro [ 3.3 ]heptan-6-yl)-6-(trifluoromethyl)pyridine-3- sulfonamide
To a solution of tert-butyl 6-((2-methyl-6-(trifluorom ethyl )pyridine)-3 -sulfonamido)-2- azaspiro[3.3]heptane-2-carboxylate (522 mg, 1.2 mmol) in anhydrous DCM (8 mL) was added TFA (0.6 mL, 7.8 mmol), dropwise at <5 °C. The reaction was stirred at rt for 21 h, then concentrated under reduced pressure to afford 2-methyl-A-(2-azaspiro[3.3]heptan-6-yl)- 6-(trifluoromethyl)pyridine-3-sulfonamide as a light brown residue (606 mg, crude, TFA salt) that was used without purification. LCMS m/z = 336.2 [M+H]+
3. Synthesis of 2-methyl-N-(2-(tetrahydro-2H-pyran-4-yl)-2-azaspiro[ 3.3 ]heptan-6-yl)~ 6-(trifluoromethyl)pyridine-3-sulfonamide
A solution of 2-methyl-A-(2-azaspiro[3.3]heptan-6-yl)-6-(trifluoromethyl)pyridine-3- sulfonamide (269 mg, 0.6 mmol, TFA salt) in anhydrous MeOH (4 mL) was cooled in an ice water bath, then DIPEA (0.7 mL, 4.0 mmol) was added and the solution stirred for 20 mins. Tetrahydropyran-4-one (120 pL, 1.30 mmol) and AcOH (300 pL, 4.9 mmol) were added to the cooled mixture, the solution stirred for 15 mins, then NaBH(OAc)3 (803.3 mg, 3.79 mmol) was added in portions. The reaction was maintained at <5 °C and stirred for 2 h. The reaction was quenched by slow addition of aqueous saturated NaHCO3 solution, the mixture
was stirred at 23 °C for 30 mins, then extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSCU, filtered and concentrated under reduced pressure. The residue was purified by silica gel column and purified with (40-100 % 3: 1 EtOAc:EtOH in heptane) to give 2-methyl-M(2-(tetrahydro-2//-pyran-4-yl)-2-azaspiro[3.3]heptan-6-yl)-6- (trifluoromethyl)pyridine-3-sulfonamide (88 mg, 33.3% yield) as a colorless film. LCMS m/z = 420.3 [M+H]+. 1H NMR (500 MHz, DMSO-d6): δ ppm 8.54 (br d, J= 8.2 Hz, 1H), 8.38 (d, J= 7.9 Hz, 1H), 7.97 (d, J= 8.2 Hz, 1H), 3.75 (br dd, J= 5.3, 1.1 Hz, 2H), 3.59 - 3.52 (m, 1H), 3.24 - 3.18 (m, 2H), 3.03 - 2.89 (m, 3H), 2.83 (s, 3H), 2.12 (br s, 2H), 2.05 - 1.87 (m, 4H), 1.59 - 1.41 (m, 2H), 1.07 - 1.00 (m, 2H).
Example 19
To a mixture of 4-(2-azaspiro[3.3]heptan-6-yl)morpholine 2HC1 salt (29 mg, 0.2 mmol) and 3-isopropyl-l-methyl-1H -pyrazole-5-sulfonyl chloride (36 mg, 0.2 mmol) in DCM (5 mL) was added DIPEA (110 pL, 0.6 mmol) and the reaction mixture was stirred at rt for 3h. The reaction was quenched with satd. NaHCCL, diluted with water, and stirred at rt for 5 min. The aqueous layer was removed and the organic phase was washed with water and concentrated. The residue was purified by silica gel column (50-100% EtOAcZEtOH 3/1 in heptane) to give 4-(2-((3-isopropyl-l -methyl- 1H -pyrazol-5-yl)sulfonyl)- 2-azaspiro[3.3]heptan-6-yl)morpholine (18 mg, 31%) as an off-white solid after lyophilization. LCMS m/z = 369.2 [M+H]+. XH NMR (400 MHz, MeOH-d4): 6 (ppm) 6.68 (s, 1H), 4.04 (s, 3H), 3.89 (s, 2H), 3.78 (s, 2H), 3.72 - 3.63 (m, 4H), 3.08 - 2.90 (m, 1H), 2.73 - 2.57 (m, 1H), 2.32 (br s, 4H), 2.26 - 2.18 (m, 2H), 2.03 - 1.94 (m, 2H), 1.28 (d, J = 7.0 Hz, 6H).
Example 20
NaBH(OAc)3 (307 mg, 1.5 mmol) was added to a mixture of 4-methylpiperidine (79 mg, 0.8 mmol), tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (153 mg, 0.7 mmol) and AcOH (50 pL, 0.8 mmol) in DCM (5 mL) and the reaction was stirred for 3 days at rt. The reaction mixture was washed with 10% aqueous solution of KOH and water, dried over Na2SO4 and the solvent was evaporated to give tert-butyl 6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane- 2-carboxylate, that was used in the next step without purification.
2. Synthesis of 6-(4-methylpiperidin-l-yl)-2-azaspiro[ 3.3 ] heptane
tert-Butyl 6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane-2-carboxylate was dissolved in DCM (2 mL) and 10% HC1 in dioxane (1.5 mL) was added. The solution was placed in an ultrasonic bath (40 °C) for 4 h, then was stirred for 16 h at rt. The solvent was evaporated in vacuo to give 6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane as HC1 salt that was used in the next step without purification.
3. Synthesis of 2-((4-(difluoromethoxy)phenyl)sulfonyl)-6-(4-methylpiperidin-l-yl)-2- azaspiro[ 3.3 ] heptane
4-(Difluoromethoxy)benzene-l-sulfonyl chloride (176 mg, 0.7 mmol) was added to a mixture of 6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane as hydrochloride salt and TEA (500 pL, 3.6 mmol) in dry DCM (5 mL) at -10 °C. The reaction was warmed to rt and stirred for 16 h
at this temperature. The reaction mixture was washed with water, the solvent was removed in vacuo, the residue was dissolved in DMSO (1 mL) and purified by prep. HPLC (Waters SunFire Cl 8 19*100 5 mkm column; H2O-MeCN as a mobile phase) to afford 2-((4- (difluoromethoxy)phenyl)sulfonyl)-6-(4-methylpiperidin-l-yl)-2-azaspiro[3.3]heptane. LCMS m/z = 401.2 [M+H]+ 'H NMR (400 MHz, CDC13): δ ppm 8.23 (d, J= 1.6 Hz, 1H), 7.99 (d, J= 2.0 Hz, 1H), 4.03 (s, 3H), 4.03 - 3.96 (m, 2H), 3.95 - 3.89 (m, 5H), 3.58 - 3.50 (m, 2H), 3.43 - 3.36 (m, 2H), 2.70-2.65 (m, 1H), 2.40-2.34 (m, 1H), 2.33 (s, 3H), 1.98 - 1.92 (m, 1H), 1.85-1.79 (m, 2H), 1.38 - 1.30 (m, 2H).
Example 21
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)- N -(tetrahydro-2H -pyran-4-yl)-5-oxa-2- azaspiro[3.4]octan-7-amine
To a solution of tert-butyl 7-oxo-5-oxa-2-azaspiro[3.4]octane-2-carboxylate (900 mg, 4.0 mmol) in DCM (9 mL) was added TFA (3.0 mL, 39.2 mmol) and the reaction stirred at 25 °C for 3 h. The mixture was concentrated in vacuo to give 5-oxa-2-azaspiro[3.4]octan-7-one (900 mg, crude, TFA salt) as white oil which was used directly for the next step without further purification. 'H NMR (400 MHz, MeOH-d4): 6 ppm 4.32 - 4.28 (m, 1H), 4.26 - 4.22 (m, 1H), 4.18 - 4.15 (m, 2H), 3.88 (d, J= 8.8 Hz, 1H), 3.75 (d, J= 8.8 Hz, 1H), 2.38 (s, 2H).
2. Synthesis of 2-( (2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro [ 3.4]octan- 7 -one
To a solution of 5-oxa-2-azaspiro[3.4]octan-7-one (750 mg, 3.1 mmol, TFA salt) and DIPEA (1.6 mL, 9.4 mmol) in DCM (3 mL) was added 2-methoxy-5-methylpyridine-3-sulfonyl chloride (761.47 mg, 3.44 mmol) at 0 °C, then the mixture was stirred at 20 °C for 2 h under N2. The mixture was diluted with water (10 mL) and extracted with DCM (15 mL x 3). The combined organic phase was washed with brine (15 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude was purified by silica gel chromatography (2- 5% MeOH in DCM) to give 2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-one (650 mg, 67%) as brown oil. LCMS m/z = 313.0 [M+H]+. 'H NMR (500 MHz, MeOH-d4): δ ppm 8.16 - 8.14 (m, 1H), 7.97 (s, 1H), 4.22 (d, J= 9.5 Hz, 2H), 4.09 (d, J= 9.5 Hz, 2H), 4.06 (s, 3H), 3.99 (s, 2H), 2.73 (s, 2H), 2.32 (s, 3H).
3. Synthesis of 2-( (2-methoxy-5-methylpyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4- yl)-5-oxa-2-azaspiro [ 3.4 octan- 7 -amine
To a solution of 2-((2-methoxy-5-methylpyri din-3 -yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7- one (120 mg, 0.4 mmol) and tetrahydro-2H-pyran-4-amine (58 mg, 0.6 mmol) in MeOH (6 mL) was added AcOH (25 pL, 0. 4 mmol) and NaBHsCN (121 mg, 1.9 mmol) at 20 °C, then the mixture was stirred at 20 °C for 15 h under N2. The mixture was concentrated in vacuo and purified by prep-HPLC (Column: Boston Prime C18 150*30mm*5pm, Condition: water (NH4HCO3)-MeCN, 22% to 52%, Flow Rate (mL/min): 25) to give 2-((2-methoxy-5- methylpyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-5-oxa-2-azaspiro[3.4]octan-7- amine (52 mg, 34%) as a white solid. LCMS m/z = 398.1 [M+H]+. 'H NMR (400 MHz, MeOH-d4): δ ppm 8.23 (d, J= 2.0 Hz, 1H), 7.99 (d, J= 1.6 Hz, 1H), 4.03 (s, 3H), 4.03 - 3.96 (m, 2H), 3.95 - 3.89 (m, 5H), 3.58 - 3.50 (m, 2H), 3.43 - 3.36 (m, 2H), 2.70 - 2.65 (m, 1H), 2.40 - 2.34 (m, 1H), 2.33 (s, 3H), 1.98 - 1.92 (m, 1H), 1.85 - 1.79 (m, 2H), 1.38-1.30 (m, 2H).
Example 22
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-5- oxa-2-azaspiro [3.4] octane
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-5-oxa-2- azaspiro[3.4]octane was obtained as a brown oil (64 mg, 42%), from 2-((2-methoxy-5- methylpyridin-3-yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 2- oxa-6-azaspiro[3.3]heptane oxalate, following the procedure described in Example 21, step 4. LCMS m/z = 396.1 [M+H]+. 'H NMR (400 MHz, CDC13): 6 ppm 8.23 (d, J= 2.4 Hz, 1H), 7.99 (s, 1H), 4.70 (s, 4H), 4.03 (s, 3H), 4.01 - 3.98 (m, 1H), 3.95 - 3.89 (m, 3H), 3.68 - 3.66 (m, 1H), 3.58 - 3.55 (m, 1H), 3.38 - 3.35 (m, 2H), 3.32 - 3.30 (m, 2H), 2.99 - 2.95 (m, 1H), 2.33 (s, 3H), 2.09 - 2.04 (m, 1H), 1.98 - 1.93 (m, 1H).
Example 23
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(3-methoxyazetidin-l-yl)-5-oxa-2- azaspiro[3.4]octane
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(3-methoxyazetidin-l-yl)-5-oxa-2- azaspiro[3.4]octane was obtained as a brown oil(58 mg, 39%), from 2-((2-methoxy-5- methylpyridin-3-yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 3- methoxyazetidine hydrochloride, following the procedure described in Example 21, step 4. LCMS m/z = 384.1 [M+H]+. 'H NMR (400 MHz, CDC13): 8 ppm 8.22 (s, 1H), 7.98 (d, J= 2.0 Hz, 1H), 4.03 (s, 3H), 4.01 - 3.98 (m, 2H), 3.98 - 3.96 (m, 1H), 3.95 - 3.91 (m, 2H), 3.72 - 3.69 (m, 1H), 3.60 - 3.51 (m, 3H), 3.23 (s, 3H), 3.07 - 3.03 (m, 1H), 2.95 - 2.91 (m, 1H), 2.89 - 2.86 (m, 1H), 2.33 (s, 3H), 2.12 - 2.07 (m, 1H), 1.99 - 1.95 (m, 1H).
Example 24
N -(4,4-Difluorocyclohexyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine
N -(4,4-Difluorocyclohexyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine was obtained as a white solid (42 mg, 19%), from 2-((2-methoxy- 5-methylpyri din-3 -yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 4,4-difluorocyclohexan-l -amine hydrochloride, following a similar procedure to that described in Example 21, step 4, except the crude product was purified by prep-HPLC (Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NEEElCOs^MeCN, 32% to 62%, Flow Rate (mL/min): 25). LCMS m/z = 432.1 [M+H]+. 'H NMR (400 MHz, CDC13): δ ppm 8.13 (d, J= 2.0 Hz, 1H), 7.95 (d, J= 2.4 Hz, 1H), 4.07 - 4.04 (m, 1H), 4.03 (s, 3H), 4.03 - 4.00 (m, 2H), 3.96 - 3.88 (m, 2H), 3.54 - 3.46 (m, 2H), 2.60 - 2.56 (m, 1H), 2.29 (s, 3H), 2.28 - 2.23 (m, 1H), 2.10 - 1.99 (m, 3H), 1.90 - 1.71 (m, 4H), 1.45 - 1.36 (m, 3H).
Example 25
N -(3,3-Difluorocyclobutyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine
N -(3,3-Difluorocyclobutyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2- azaspiro[3.4]octan-7-amine was obtained as a white solid(78 mg, 31% yield), from 2-((2- methoxy-5-methylpyridin-3-yl)sulfonyl)-5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 3) and 3,3-difluorocyclobutylamine, following a similar procedure to that described in Example 21, step 4, except the crude product was purified by prep-HPLC (Column: Boston
Prime C18 150 x 30mm x 5 pm, Condition: water (NH4HCO3)-MeCN, 28% to 58%, Flow Rate (mL/min): 25). LCMS m/z = 404.1 [M+H]+ 'H NMR (400 MHz, CDC13): 6 ppm 8.14 - 8.12 (m, 1H), 7.96 (d, J =2.0 Hz, 1H), 4.08 - 4.06 (m, 1H), 4.04 (s, 3H), 4.04 - 4.01 (m, 1H), 3.96 (d, <7=8.4 Hz, 1H), 3.89 - 3.86 (m, 1H), 3.58 - 3.55 (m, 1H), 3.40 - 3.31 (m, 1H), 3.24 - 3.14 (m, 1H), 2.88 - 2.74 (m, 2H), 2.30 (s, 3H), 2.29 - 2.15 (m, 3H), 2.06 - 1.99 (m, 1H), 1.58 (br s, 2H).
Example 26
3-((7-((4,4-Difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)-4- fluorobenzonitrile
To a solution of 5-oxa-2-azaspiro[3.4]octan-7-one (Example 21, step 1, 900 mg, 3.8 mmol, TFA salt) in DCM (10 mL) was added DIPEA (2.0 mL, 11.2 mmol) and 5-cyano-2- fluorobenzenesulfonyl chloride (988 mg, 4.5 mmol) at 0 °C and the reaction stirred at 0 °C for Ih. Water (50 mL) was added and the mixture extracted with DCM (30 mL x 3). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered and concentrated. The crude product was purified by column chromatography (EtOAc in PE from 30% to 50%) to give 4-fluoro-3-((7-oxo-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile (750 mg, 65 %) as a white solid. LCMS m/z = 311.0 [M+H]+
2. Synthesis of 3-( (7-( 4, 4-difluorocyclohexyl)amino)-5-oxa-2-azaspiro[ 3.4 ] octaneyl) sulfonyl) -4-fluorobenzonitrile
To a solution of 4-fluoro-3-((7-oxo-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile (130 mg, 0.4 mmol) and 4,4-difluorocyclohexylamine (86 mg, 0.5 mmol, HC1 salt) in MeOH (5 mL) was added TEA (120 pL, 0.8 mmol) and the solution was stirred at 20 °C for 20 mins. The pH of the solution was adjusted to 5~6 using AcOH and the solution stirred for 30 mins at 20 °C. NaBHsCN (132 mg, 2.1 mmol) was added and the reaction stirred at 20 °C for 14 h. The mixture was diluted with water (50 mL) and extracted with DCM (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by prep-HPLC ((Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NHvHzO+NH-tHCOsj-MeCN, 41% to 71%, Flow Rate (mL/min): 25)) to give 3-((7-((4,4-difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile (56 mg, 31%) as a white solid. LCMS m/z = 430.1 [M+H]+. 1H NMR (500 MHz, MeOH-d4): 6 ppm 8.24 (dd, J= 6.5, 2.5 Hz, 1H), 8.15 - 8.11 (m, 1H), 7.61 (t, J= 9.0 Hz, 1H), 4.05 (d, J= 8.5 Hz, 1H), 3.99 - 3.95 (m, 2H), 3.92 - 3.87 (m, 2H), 3.53-3.48 (m, 2H), 2.62 - 2.57 (m, 1H), 2.37 - 2.32 (m, 1H), 2.06 - 2.00 (m, 2H), 1.98 - 1.94 (m, 1H), 1.93 - 1.88 (m, 2H), 1.86 - 1.72 (m, 2H), 1.44 - 1.32 (m, 2H).
Example 27
4-Fluoro-3-((7-((tetrahydro-2H-pyran-4-yl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile
To a solution of 4-fluoro-3-((7-oxo-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile (Example 26, step 1, 130 mg, 0.4 mmol) and tetrahydro-2H-pyran-4-amine (64 mg, 0.6 mmol) in MeOH (5 mL) was adjusted to pH = 6 using AcOH and the solution stirred for 30 minutes at 20 °C. NaBHsCN (132 mg, 2.1 mmol) was added and the reaction mixture was stirred at 20 °C for 14 h. The mixture was diluted with water (50 mL) and extracted with
DCM (50 mL x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude was purified by prep-HPLC ((Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NH3 H2O+NH4HCO3)-MeCN, 31% to 61%, Flow Rate (mL/min): 25)) to give 4-fluoro-3-((7-((tetrahydro-2J/-pyran-4- yl)amino)-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile (54 mg, 32%) as a white solid. LCMS m/z = 396.0 [M+H]+. 'H NMR (500 MHz, CDC13): 8 ppm 8.20 - 8.17 (m, 1H), 7.92 - 7.88 (m, 1H), 7.39 (t, J= 8.5 Hz, 1H), 4.09 (d, J= 9.0 Hz, 1H), 4.00 (s, 3H), 3.99 - 3.94 (m, 3H), 3.93 - 3.90 (m, 1H), 3.59 - 3.53 (m, 2H), 3.41 - 3.34 (m, 2H), 2.67 - 2.60 (m, 1H), 2.27 - 2.25 (m, 1H), 2.09 - 2.05 (m, 1H), 1.82 - 1.78 (m, 2H), 1.50 - 1.27 (m, 2H).
Example 28
3-((7-(2-Oxa-6-azaspiro [3.3] heptan-6-yl)-5-oxa-2-azaspiro [3.4] octan-2-yl)sulfonyl)-5- fluorobenzonitrile
3-Fluoro-5-((7-oxo-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile was obtained as a light yellow film (86 mg, 32%) from 5-oxa-2-azaspiro[3.4]octan-7-one HC1 salt and 3-cyano- 5-fluoro-benzenesulfonyl chloride following a similar procedure to that described in Example 18, step 1. 'H NMR (500 MHz, DCM-d2): 6 ppm 7.96 (s, 1H), 7.81 (td, J= 1.9, 7.6 Hz, 1H), 7.69 (td, J= 1.2, 7.7 Hz, 1H), 4.04 - 4.01 (m, 2H), 3.97 - 3.94 (m, 4H), 2.72 (s, 2H).
2. Synthesis of 3-( (7 -(2-oxa-6-azaspiro[ 3.3 ]heptan-6-yl)-5-oxa-2-azaspiro[ 3.4 ] octaneyl) sulfonyl) -5-fluorobenzonitrile
To a vial containing 3-fluoro-5-((7-oxo-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile (86 mg, 0.3 mmol) in anhydrous DCM (3 mL) was added AcOH (20 pL, 0.4 mmol) then 2- oxa-6-azaspiro[3.3]heptane (58 mg, 0.6 mmol) dropwise at 23 °C. After 15 mins, NaBH(OAc)3 (223 mg, 1.1 mmol) was added in portions and the reaction was stirred at 23 °C for 1 h. The reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 20 mins, then the biphasic mixture was extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSC , filtered and concentrated under reduced pressure. The residue was purified by silica gel column (50 - 100% 3: 1 EtOAc: EtOH in heptane) to give 3-((7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-5-oxa- 2-azaspiro[3.4]octan-2-yl)sulfonyl)-5-fluorobenzonitrile as a colorless film (25 mg, 22%). LCMS m/z = 394.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 8 ppm 8.34 (br d, J= 8.5 Hz, 1H), 8.22 (s, 1H), 8.13 - 8.10 (m, 1H), 4.56 (s, 4H), 3.89 (d, J= 9.5 Hz, 1H), 3.82 (d, J= 92 Hz, 1H), 3.76 (d, J= 9.5 Hz, 1H), 3.65 (d, J= 9.5 Hz, 1H), 3.50 (dd, J= 9.0, 4.4 Hz, 1H), 3.39 - 3.36 (m, 1H), 3.31 - 3.29 (m, 1H), 3.21 - 3.15 (m, 4H), 2.80 (br s, 1H), 1.81 - 1.77 (m, 1H).
Example 29
To a solution of tert-butyl 6-oxo-2-azaspiro[3.4]octane-2-carboxylate (600 mg, 2.7 mmol) in HFIPA (20 mL) was added TFA (810 pL, 10.7 mmol) and the reaction was stirred for
2 h at 25 °C. The mixture was evaporated in vacuo to give 2-azaspiro[3.4]octan-6-one as TFA salt as a colorless oil and was used without further purification. TH NMR (400 MHz, MeOH-d4): 6 ppm 4.11 - 4.08 (m, 2H), 4.04 - 4.01 (m, 2H), 2.57 (s, 2H), 2.31 (s, 4H).
To a solution of 2-azaspiro[3.4]octan-6-one (132 mg, 0.5 mmol, TFA salt) in anhydrous THF (1 mL) was added DIPEA (300 pL, 1.7 mmol) dropwise at rt, the solution stirred for 10 mins, then concentrated to afford a brown film. 2 -Methyl -2 -butanol (1 mL), 3,5- dimethylpyridine-2-sulfonyl fluoride (51 mg, 0.3 mmol) then Ca(NTf2)2 (169 mg, 0.3 mmol) were added in portions and the reaction was heated to 60 °C and stirred for 19 h. The reaction mixture was cooled to rt then quenched by slow addition of aqueous 2 M NaOH. The heterogeneous mixture was loaded onto a silica gel column and purified with (20 - 80% EtOAc in heptane) to afford 2-((3,5-dimethylpyridin-2-yl)sulfonyl)-2- azaspiro[3.4]octan-6-one as a colorless film (42 mg, 53%) that was used without further purification. LCMS m/z = 295.0 [M+H]+.
To a solution of 2-((3,5-dimethylpyridin-2-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one (42 mg, 0.1 mmol) in anhydrous DCM (1 mL) was added AcOH (10 pL, 0.2 mmol) then morpholine (30 pL, 0.3 mmol) dropwise at 23 °C. After 15 mins, NaBH(OAc)3 (116 mg, 0.6 mmol) was added in portions and the reaction was stirred at 23 °C for 2 h. The reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 20 mins, then the biphasic mixture was extracted with DCM (3 x). The combined organic extracts were dried over anhydrous magnesium sulfate, the mixture filtered and concentrated under reduced pressure. The residue was purified by silica gel column eluting with (20-100% 3: 1
EtOAc:EtOH in heptane). The product was further purified by HPLC using a Waters XSelect
CSH Cl 8, 5 pm, 50 mm * 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 50% B (0.2% NH4OH final v/v % modifier) with flow rate at 80 mL/min to afford 4-(2-((3,5-dimethylpyridin-2-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine as a white solid (101 mg, 21 %). LCMS m/z = 366.1 [M+H]+. XH NMR (600 MHz, DMSO-d6): 8 ppm 8.39 - 8.36 (m, 1H), 7.76 - 7.73 (m, 1H), 4.05 - 4.02 (m, 2H), 4.00 - 3.96 (m, 4H), 3.95 - 3.93 (m, 2H), 2.48 (s, 3H), 2.36 - 2.35 (m, 3H), 2.06 (br dd, J= 13, 12.4 Hz, 2H), 1.92 - 1.87 (m, 2H), 1.83 - 1.78 (m, 2H), 1.77 - 1.74 (m, 1H), 1.69 - 1.63 (m, 2H), 1.45 - 1.37 (m, 2H).
Example 30
6-(2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)-2-oxa-6- azaspiro[3.3]heptane
A flask containing tert-butyl 6-oxo-2-azaspiro[3.4]octane-2-carboxylate (1.03 g, 4.6 mmol) in MeOH (10 mL) was cooled in an ice water bath, then 4M HC1 in dioxane (4 M, 3.6 mL) was added dropwise. The reaction was allowed to warm to 23 °C and stirred for 6 h. The reaction was concentrated under reduced pressure, the residue was triturated with EtOAc and a couple of drops of MeOH added to afford 2-azaspiro[3.4]octan-6-one as HC1 salt, as an off- white solid (721 mg, 97%) that was used without purification. 'H NMR (500 MHz, DMSO- d6): 6 ppm 9.40 - 9.09 (m, 2H), 3.95 - 3.89 (m, 2H), 3.86 - 3.80 (m, 2H), 3.65 - 3.36 (m, 2H), 2.23 - 2.17 (m, 3H).
2. Synthesis of 2-(( 6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[ 3.4 octan-
To a solution of 2-azaspiro[3.4]octan-6-one (333 mg, 2.1 mmol, HC1 salt) in anhydrous DCM (10 mL) was added DIPEA (1.5 mL, 8.6 mmol) dropwise at <5°C and the solution stirred for 5 mins. 6-Methoxy-2-methyl-pyridine-3-sulfonyl chloride (577.1 mg, 2.60 mmol) was added and the reaction was allowed to warm to 23 °C and stirred for 30 mins. The reaction mixture was quenched by slow addition of aqueous 1 M NaOH solution. The mixture was stirred at 23 °C for 10 mins, then the biphasic mixture was loaded onto a silica gel column and purified with (10 - 55% EtOAc in heptane) to give 2-((6-m ethoxy-2 -methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.4]octan-6-one as a white solid (190 mg, 30% yield) that was used without further purification. LCMS m/z = 311.1 [M+H]+.
6-(2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)-2-oxa-6- azaspiro[3.3]heptane was obtained as a colorless film (34 mg, 29%) from 2-((6-methoxy-2- methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one (Example 30, step 2) and 2-oxa-6- azaspiro[3.3]heptane, following the procedure described in Example 29, step 2. LCMS m/z =
394.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 8 ppm 8.02 (d, J= 8.5 Hz, 1H), 6.85 (d, J=
9.2 Hz, 1H), 4.54 (s, 4H), 3.93 (s, 3H), 3.60 - 3.54 (m, 4H), 3.12 (q, J = 7.3 Hz, 4H), 2.67 (s, 3H), 2.54 - 2.52 (m, 1H), 1.79 - 1.72 (m, 1H), 1.66 - 1.59 (m, 2H), 1.52 - 1.41 (m, 2H), 1.27 - 1.21 (m, 1H).
Example 31
N -(4,4-Difluorocyclohexyl)-2-((6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-amine
4,4-Difluorocyclohexanamine (165 mg, 1.0 mmol, HC1 salt) was added to a solution of 2-((6- methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one (Example 30, step 2, 149 mg, 0.5 mmol) in DCM (3.1 mL) and the solution stirred at rt for 5 min. AcOH (230 pL, 3.8 mmol) was added dropwise, the solution stirred an additional 15 mins then NaBH(OAc)3 (407 mg, 1.9 mmol) was added and the reaction stirred at rt for 3 days. The reaction was quenched by slow addition of aq. IM NaOH solution, the mixture was stirred at ambient temperature for 20 min, then the biphasic mixture was extracted with DCM (3x). The combined organics were washed with water and brine then concentrated in vacuo. The crude was purified by silica gel column (0 - 100% EtOAc to 3: 1 EtOAc:EtOH (w/2% NH4OH)) to give A-(4,4-difluorocyclohexyl)-2-((6-methoxy-2-methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.4]octan-6-amine as a white solid (126 mg, 61%). LCMS m/z = 430.1 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 8.03 (d, J= 92 Hz, 1H), 6.85 (d, J= 9.2 Hz, 1H), 5.09 (br d, J= 16.5 Hz, 1H), 3.98 - 3.89 (m, 3H), 3.69 - 3.52 (m, 4H), 3.09 (br s, 1H), 2.68 (s, 3H), 2.17 (br d, = 7.3 Hz, 1H), 2.02 - 1.85 (m, 3H), 1.85 - 1.67 (m, 6H), 1.66 - 1.60 (m, 1H), 1.46 (br dd, J= 12.8, 6.1 Hz, 1H), 1.36 - 1.20 (m, 3H).
Example 32
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-N -(2-methoxyethyl)-A-methyl-2- azaspiro[3.4]octan-6-amine
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-A-(2-methoxyethyl)-A-methyl-2- azaspiro[3.4]octan-6-amine was obtained as an orange oil (75 mg, 41%), from 2-((6-
methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one (Example 30, step 2) and 2-methoxy-N -m ethyl ethanamine, following the procedure described in Example 31. LCMS m/z = 384.0 [M+H]+ 'H NMR (500 MHz, DMSO-d6): 6 ppm 8.03 (d, J= 92 Hz, 1H), 6.85 (d, J= 8.5 Hz, 1H), 3.93 (s, 3H), 3.66 - 3.51 (m, 4H), 3.39 - 3.33 (m, 2H), 3.20 (s, 3H), 2.72 - 2.62 (m, 4H), 2.46 - 2.35 (m, 2H), 2.09 (br s, 3H), 1.94 - 1.82 (m, 1H), 1.79 - 1.61 (m, 3H), 1.55 - 1.46 (m, 1H), 1.38 - 1.29 (m, 1H).
Example 33
N -(2-Methoxyethyl)-N -methyl-2-(( l-methyl-3-(trifluoromethyl)-lZ/-pyrazol-5- yl)sulfonyl)-2-azaspiro[3.4]octan-6-amine
1. Synthesis of 2-((l -methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl )sulfonyl)-2- azaspiro[ 3.4 ]octan-6-one
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one was obtained, (161 mg 28%), from 2-azaspiro[3.4]octan-6-one HC1 salt (Example 30, step 1) and 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride, following a similar procedure to that described in Example 18, step 1. 'H NMR (500 MHz, DCM-d2): 8 ppm 7.07 -7.03 (m, 1H), 4.22 - 4.14 (m, 3H), 3.90 - 3.82 (m, 4H), 2.40 (s, 2H), 2.28 - 2.22 (m, 2H), 2.20 - 2.13 (m, 2H).
2. Synthesis of N-(2-methoxyethyl)-N-methyl-2-( ( 1 -methyl-3-(trifluoromethyl)-lH- pyrazol-5-yl )sulfonyl)-2-azaspiro [ 3.4 ] octan-6-amine
N -(2-Methoxyethyl)- N -methyl-2-((l -methyl -3-(trifluoromethyl)- l 7/-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-amine was obtained as a colorless film(50 mg, 47%) from 2-((l -methyl - 3-(trifluoromethyl)- l 7/-pyrazol-5-yl )sulfonyl)-2-azaspiro[3 ,4]octan-6-one and 2-methoxy-/'/- m ethyl ethan-1 -amine, following a similar procedure to that described in Example 29, step 3, except the crude product was purified by HPLC using a Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 65% B (0.2% NH4OH final v/v % modifier) at 60 mL/min. LCMS m/z = 411.3 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 7.53 (s, 1H), 4.14 (s, 3H), 3.80 - 3.76 (m, 2H), 3.74 - 3.69 (m, 2H), 3.37 - 3.33 (m, 2H), 3.20 (s, 3H), 2.69 - 2.63 (m, 1H), 2.43 - 2.39 (m, 2H), 2.08 (s, 3H), 1.84 - 1.78 (m, 1H), 1.73 - 1.66 (m, 2H), 1.63 - 1.57 (m, 1H), 1.49 - 1.44 (m, 1H), 1.38 - 1.30 (m, 1H).
Example 34
2-((3-Methoxy-l-methyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one was obtained as a white solid (420 mg, 71%) from 2-azaspiro[3.4]octan-6-one (Example 29, Step 1) and 3- methoxy-l-methyl-1H -pyrazole-5-sulfonyl chloride, following a similar procedure to that described in Example 26, step 1. LCMS m/z = 300.1 [M+H]+. 1HNMR (400 MHz, CDC13) 6 ppm 6.17 (s, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 3.81 (s, 4H), 2.39 (s, 2H), 2.29 - 2.25 (m, 2H), 2.17 - 2.14 (m, 2H).
2. Synthesis of 4-(2-((3-methoxy-l-methyl-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[ 3.4 octan-6-yl)morpholine
A solution of 2-((3-methoxy-l-methyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-one (200 mg, 0.668 mmol) and morpholine (90 pL, 1.0 mmol) in MeOH (10 mL) was adjusted to pH 5-6 with AcOH at 25 °C. The mixture was stirred at 25-30 °C for 0.5 h then NaBHsCN (126 mg, 2.0 mmol) was added and the reaction was stirred at 25 °C for 1 h. The mixture was concentrated under reduced pressure and the residue was purified by prep-HPLC (Boston Green ODS 150 x 30mm x 5pm, Condition: water (NH4HCO3)-MeCN, Flow Rate (mL/min) 25) to give 4-(2-((3-methoxy-l-methyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine (140 mg, 57%) as colorless oil. LCMS m/z = 371.1 [M + H]+. 'H NMR (400 MHz, CDC13) 6 ppm 6.14 (s, 1H), 3.95 (s, 3H), 3.89 (s, 3H), 3.77 - 3.70 (m, 4H), 3.69-3.65 (m, 4H), 2.51 - 2.44 (m, 2H), 2.42 - 2.41 (m, 2H), 2.04 - 2.00 (m, 1H), 1.92 - 1.82 (m, 2H), 1.77 - 1.73 (m, 2H), 1.64 - 1.60 (m, 1H), 1.51 - 1.43 (m, 1H).
Example 35
4-(2-(( l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine
To a vial containing tert-butyl 6-oxo-2-azaspiro[3.4]octane-2-carboxylate (904 mg, 4.0 mmol) in anhydrous DCM (20 mL) was added AcOH (250 pL, 4.2 mmol) then morpholine (730 pL, 8.4 mmol) was added dropwise at 23 °C and the solution stirred for 15 mins. NaBH(OAc)3 (2.9 g, 13.7 mmol) was added in portions and the reaction was stirred at 23 °C for 7 h. The
reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 20 mins, then the biphasic mixture was extracted with DCM (3x). The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure to give tert-butyl 6-morpholino-2-azaspiro[3.4]octane-2- carboxylate (1.19 g, crude) that was used without further purification. LCMS m/z = 297.1 [M+H]+
A solution of tert-butyl 6-morpholin-4-yl-2-azaspiro[3.4]octane-2-carboxylate (1.19 g, 4.0 mmol) in MeOH (2.50 mL) was cooled in an ice water bath, then 1 M HC1 in EtOAc (1 M, 14 mL) was added dropwise. Upon complete addition, the mixture was allowed to warm to 23 °C and stirred at rt for 5 days. The reaction was concentrated under reduced pressure, the residue was triturated with heptane and EtOAc to afford 4-(2-azaspiro[3.4]octan-6- yl)morpholine as the HC1 salt, as a gummy white solid that was used without purification. LCMS m/z = 197.1 [M+H]+
To a solution of 4-(2-azaspiro[3.4]octan-6-yl)morpholine (79 mg, 0.3 mmol, HC1 salt) in anhydrous THF (2 mL) was added DIPEA (390 pL, 2.3 mmol) dropwise at < 5 °C. After 5 mins, 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride (124 mg, 0.5 mmol) was added to the cold solution and the reaction was allowed to warm to 23 °C and stirred for 30 mins. The reaction was quenched by slow addition of aqueous 1 M NaOH solution and the mixture was stirred at 23 °C for 10 mins. The biphasic mixture was loaded onto a silica gel column and purified with (15-75% 3: 1 EtOAc:EtOH in heptane) to give 4-(2-((l-methyl-3- (trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine as a colorless film (83 mg, 54%). LCMS m/z = 409.2 [M+ H]+. 'H NMR (500 MHz, DMSO-d6):
δ ppm 7.53 (s, 1H), 4.14 (s, 3H), 3.77 (s, 2H), 3.75 - 3.71 (m, 2H), 3.54 - 3.50 (m, 4H), 2.46 - 2.39 (m, 1H), 2.34 - 2.21 (m, 4H), 1.87 -1.83 (m, 1H), 1.76 - 1.68 (m, 2H), 1.65 - 1.59 (m, 1H), 1.52 - 1.47 (m, 1H), 1.39 - 1.30 (m, 1H).
Example 36
4-(2-((l,3-Dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a colorless film (43 mg, 33% yield) from 4-(2-azaspiro[3.4]octan-6- yl)morpholine (Example 35, step 2, HC1 salt) and 2,5-dimethylpyrazole-3-sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 355.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 6 ppm 6.70 (s, 1H), 3.96 (s, 3H), 3.66 (s, 2H), 3.64 - 3.60 (m, 2H), 3.52 (br t, J= 4.6 Hz, 4H), 2.45 - 2.39 (m, 1H), 2.34 - 2.24 (m, 4H), 2.21 (s, 3H), 1.86 - 1.81 (m, 1H), 1.75 - 1.68 (m, 2H), 1.63 - 1.57 (m, 1H), 1.52 - 1.46 (m, 1H), 1.38 - 1.31 (m, 1H).
Example 37
4-(2-((4-Chloro-l,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine was obtained as a light orange film (68 mg, 36 %) from 4-(2- azaspiro[3.4]octan-6-yl)morpholine (Example 35, step 2, HC1 salt) and 4-chloro-2,5- dimethylpyrazole-3-sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 389.2 [M+ H]+. 1H NMR (500 MHz, DMSO-d6): δ ppm 3.99 (s, 3H), 3.78 -
3.74 (m, 2H), 3.74 - 3.69 (m, 2H), 3.52 (t, J= 4.6 Hz, 4H), 2.47 - 2.40 (m, 1H), 2.34 - 2.24 (m, 4H), 2.21 (s, 3H), 1.87 (dd, J= 12.8, 7.3 Hz, 1H), 1.78 - 1.68 (m, 2H), 1.67 - 1.61 (m, 1H), 1.54 - 1.49 (m, 1H), 1.40 - 1.32 (m, 1H).
Example 38
4-(2-((4-(Difluoromethyl)-l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-
4-(2-((4-(Difluoromethyl)-l,3-dimethyl-l//-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine was obtained as a light orange film (69 mg, 37%) from 4-(2- azaspiro[3.4]octan-6-yl)morpholine (Example 35, step 2, HC1 salt) and 4-(difluoromethyl)- l,3-dimethyl-lH-pyrazole-5-sulfonyl chloride following the procedure described in Example 35, step 3. LCMS m/z = 405.2 [M+ H]+. 'H NMR (500 MHz, DMSO-d6): 8 ppm 7.07 (t, J= 54.0 Hz, 1H), 4.00 (s, 3H), 3.75 - 3.73 (m, 2H), 3.72 - 3.67 (m, 2H), 3.52 (t, J= 4.6 Hz, 4H), 2.46 - 2.40 (m, 1H), 2.38 - 2.25 (m, 7H), 1.90 (dd, J= 12.8, 6.7 Hz, 1H), 1.80 - 1.62 (m, 3H), 1.53 (dd, J= 12.8, 8.5 Hz, 1H), 1.41 - 1.32 (m, 1H).
Example 39
4-(2-((6-Methoxy-2-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine was obtained as a colorless film (77 mg, 43%) from 4-(2-azaspiro[3.4]octan-6- yl)morpholine (Example 35 step 2, HC1 salt) and 6-methoxy-2-(trifluorom ethyl )pyridine-3-
sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z =
436.5 [M+H]+; XH NMR (500 MHz, DMSO-d6): 6 ppm 8.34 (d, J= 8.5 Hz, 1H), 7.33 (d, J=
8.5 Hz, 1H), 4.00 (s, 3H), 3.74 - 3.69 (m, 3H), 3.68 - 3.65 (m, 1H), 3.52 (t, J= 4.6 Hz, 4H), 2.46 - 2.40 (m, 1H), 2.34 - 2.25 (m, 4H), 1.94 (dd, J= 13.1, 7.0 Hz, 1H), 1.82 - 1.77 (m, 1H), 1.76 - 1.68 (m, 2H), 1.55 (dd, J= 12.8, 9.2 Hz, 1H), 1.40 - 1.32 (m, 1H).
Example 40
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine
yl)morpholine was obtained as a colorless film (65 mg, 43%) from 4-(2-azaspiro[3.4]octan-6- yl)morpholine (Example 35, step 2, HC1 salt) and 2-methyl-6-(trifluoromethyl)pyridine-3- sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z =
420.5 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 8 ppm 8.45 (d, J= 8.5 Hz, 1H), 7.99 (d, J=
8.5 Hz, 1H), 3.78 - 3.73 (m, 3H), 3.72 - 3.69 (m, 1H), 3.52 (t, J= 4.6 Hz, 4H), 2.83 (s, 3H), 2.47 - 2.41 (m, 1H), 2.36 - 2.22 (m, 4H), 1.96 (dd, J= 12.8, 6.7 Hz, 1H), 1.85 - 1.79 (m, 1H), 1.77 - 1.68 (m, 2H), 1.59 - 1.54 (m, 1H), 1.41 - 1.32 (m, 1H).
Example 41
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine was obtained as a yellow film (59 mg, 39%) from 4-(2-azaspiro[3.4]octan-6-
yl)morpholine (Example 35, step 2, HC1 salt) and 4-methyl-6-(trifluoromethyl)pyridine-3- sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 420.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 6 ppm 9.03 (s, 1H), 8.14 (s, 1H), 3.78 - 3.75 (m, 2H), 3.75 - 3.69 (m, 2H), 3.52 (t, J= 4.6 Hz, 4H), 2.70 (s, 3H), 2.47 - 2.41 (m, 1H), 2.35 - 2.25 (m, 4H), 1.96 - 1.90 (m, 1H), 1.82 - 1.77 (m, 1H), 1.76 - 1.67 (m, 2H), 1.58 - 1.52 (m, 1H), 1.40 - 1.33 (m, 1H).
Example 42
4-(2-((6-Chloro-2-methylpyri din-3 -yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a light brown film(176 mg, 49%) from 4-(2-azaspiro[3.4]octan-6-yl)morpholine (Example 35, step 2, HC1 salt) and 6-chloro-2-methylpyridine-3-sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 386.1 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 6 ppm 8.18 (d, J= 8.5 Hz, 1H), 7.61 (d, = 7.9 Hz, 1H), 3.70 - 3.62 (m, 4H), 3.52 (t, J= 4.6 Hz, 4H), 2.73 (s, 3H), 2.47 - 2.41 (m, 1H), 2.35 - 2.26 (m, 4H), 1.94 (dd, J= 12.8, 7.3 Hz, 1H), 1.81 - 1.76 (m, 1H), 1.75 - 1.67 (m, 2H), 1.57 - 1.51 (m, 1H), 1.40 - 1.33 (m, 1H).
Example 43
4-(2-(Mesitylsulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine
A solution of tert-butyl 6-morpholin-4-yl-2-azaspiro[3.4]octane-2-carboxylate (Example 35, step 1, 918 mg, 3.1 mmol) in HFIP (9 mL) was cooled in an ice water bath, then TFA (840 pL, 11.0 mmol) was added dropwise. Upon complete addition, the reaction was allowed to warm to 23 °C and stirred for 7.5 h. The reaction was evaporated under reduced pressure to afford 4-(2-azaspiro[3.4]octan-6-yl)morpholine (as TFA salt) as a colorless film that was used without purification. LCMS m/z = 197.1 [M+H]+.
To a solution of 4-(2-azaspiro[3.4]octan-6-yl)morpholine (144 mg, 0.5 mmol, TFA salt) in anhydrous THF (1.5 mL) was added DIPEA (0.5 mL, 2.9 mmol) dropwise and DMAP (6 mg, 0.1 mmol) at < 5 °C. After 5 mins, 2,4,6-trimethylbenzenesulfonyl chloride (153 mg, 0.7 mmol) was added to the cold heterogeneous solution, the reaction was allowed to warm to 23 °C and stirred for 30 mins. The reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 10 mins, then the biphasic mixture was extracted with EtOAc (3x). The combined organics were washed with saturated aqueous NaHCO3 solution (2x) then dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with (5-55 % 3: 1 EtOAc:EtOH in heptane) to give 4-(2-(mesitylsulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine(33 mg, 18%). LCMS m/z = 379.2 [M+H]+; 'H NMR (500 MHz, DMSO-d6): δ ppm 7.07 (s, 2H), 3.63 - 3.56 (m, 3H), 3.55 - 3.50 (m, 5H), 2.53 (s, 6H), 2.47 - 2.41 (m, 1H), 2.41 - 2.28 (m, 4H), 2.27 (s, 3H), 1.97 (dd, J= 12.8, 6.7 Hz, 1H), 1.84 - 1.78 (m, 1H), 1.77 - 1.68 (m, 2H), 1.56 (dd, J= 12.8, 9.2 Hz, 1H), 1.42 - 1.33 (m, 1H).
Example 44
4-(2-((4-(Difluoromethoxy)phenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine
4-(2-((4-(Difluoromethoxy)phenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a TFA salt, as a colorless film (19 mg, 8%) from 4-(2-azaspiro[3.4]octan-6- yl)morpholine (TFA salt, Example 43, step 1 and 4-(difluorom ethoxy )benzenesulfonyl chloride, following a similar procedure to that described in Example 43, step 2 except the product was additionally purified by prep HPLC using a Waters XSelect CSH Cl 8, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 55% B (0.2% TFA final v/v % modifier). LCMS m/z = 403.2 [M+H]+.
HNMR (500 MHz, DMSO-d6) δ = 8.04 - 7.83 (m, 2H), 7.65 - 7.30 (m, 2H), 4.03 - 3.91 (m, 1H), 3.73 - 3.41 (m, 4H), 3.40 - 3.25 (m, 2H), 3.06 - 2.92 (m, 1H), 2.62 - 2.41 (m, 3H), 2.31 - 2.15 (m, 1H), 2.13 - 2.00 (m, 1H), 1.97 - 1.84 (m, 1H), 1.82 - 1.50 (m, 4H), 1.50 - 1.21 (m, 2H).
Example 45
4-(2-((2,4-Dimethylphenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a colorless film (73 mg, 41%), from 4-(2-azaspiro[3.4]octan-6-yl)morpholine (TFA salt, Example 43, step 1) and 2,4-dimethylbenzenesulfonyl chloride, following a similar procedure to that described in Example 43, step 2, except DMAP was not used as a catalyst. LCMS m/z = 365.1 [M+H]+. 1H NMR (500 MHz, DMSO-d6): 6 ppm 7.70 (br d, J= 7.9 Hz, 1H), 7.28 (br s, 1H), 7.24 (br d, J= 7.9 Hz, 1H), 3.60 - 3.50 (m, 8H), 2.52 (br s, 3H), 2.42 (br s, 1H), 2.35 (br s, 3H), 2.29 (br s, 4H), 1.92 - 1.85 (m, 1H), 1.79 - 1.68 (m, 2H), 1.64 (br dd, J= 11.3, 7.6 Hz, 1H), 1.50 (br t, J= 10.4 Hz, 1H), 1.35 (br d, J= 9.2 Hz, 1H).
Example 46
4-(2-((2,4-Difluorophenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a colorless film (34 mg, 18%) from 4-(2-azaspiro[3.4]octan-6-yl)morpholine (TFA salt, Example 43, step 1) and 2,4-difluorobenzenesulfonyl chloride, following a similar procedure to that described in Example 35, step 3. The product was further purified by prep-HPLC using a Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 55% B (0.2% NH4OH final v/v % modifier) with flow rate at 80 mL/min. LCMS m/z = 373.2 [M+H]+. XH NMR (500 MHz, DMSO-d6): 8 ppm 7.89 (dt, J= 8.4, 6.4 Hz, 1H), 7.71 - 7.64 (m, 1H), 7.38 (dt, J= 8.4, 2.1 Hz, 1H), 3.78 - 3.49 (m, 7H), 2.45 - 2.12 (m, 2H), 1.88 - 1.65 (m, 5H), 1.64 - 1.29 (m, 5H).
Example 47
4-(2-((4,6-Dimethylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained (22 mg, 19%) from 4-(2-azaspiro[3.4]octan-6-yl)morpholine (TFA salt, Example 43, step 1) and 4, 6-dimethylpyridine-3 -sulfonyl chloride, following a similar procedure to that described for Example 35, step 3, except the product was further purified by HPLC Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 45% B (0.2% NH4OH final v/v% modifier) with flow rate at 80 mL/min. LCMS m/z = 366.1 [M+H]+; 'H NMR (500 MHz, DMSO-d6): 6 ppm 8.60 (s, 1H), 7.28 (s, 1H), 3.64 - 3.43 (m, 4H), 2.43 - 2.40 (m, 3H), 2.40 - 2.38 (m, 3H), 2.17 (br s, 4H), 1.78 (br dd, J= 11.6, 7.9 Hz, 2H), 1.67 - 1.48 (m, 5H), 1.40 (br dd, J= 12.5, 8.9 Hz, 2H), 1.28 - 1.18 (m, 2H).
Example 48
4-(2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine was obtained as a colorless film (60 mg, 37%) from, 4-(2-azaspiro[3.4]octan-6-yl)morpholine (TFA salt, Example 43, step 1 and 6-methoxy-2-methylpyridine-3 -sulfonyl chloride, following a similar procedure to that described for Example 35, step 3. LCMS m/z = 382.5 [M+ H]+. 1H NMR (500 MHz, DMSO-d6): δ ppm 8.03 (d, J= 8.5 Hz, 1H), 6.85 (d, J= 8.5 Hz, 1H), 3.93 (s, 3H), 3.64 - 3.58 (m, 3H), 3.56 - 3.51 (m, 5H), 2.68 (s, 3H), 2.45 - 2.39 (m, 1H), 2.34 - 2.24 (m, 4H), 1.91 (dd, J= 12.8, 7.3 Hz, 1H), 1.80 - 1.65 (m, 3H), 1.52 (dd, J= 12.8, 9.2 Hz, 1H), 1.40 - 1.31 (m, 1H).
Example 49 (l?)-4-(2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan- 6-yl)morpholine
To a solution of tert-butyl (R )-6-amino-2-azaspiro[3.4]octane-2-carboxylate (950 mg, 4.2 mmol) and l-bromo-2-(2-bromoethoxy)ethane (1.48 g, 6.4 mmol) in MeCN (45 mL) was added K2CO3 (2.29 g, 16.6 mmol) in portions at 23 °C under N2 and the reaction was heated to 90 °C for 19 h. The reaction was cooled to rt then filtered and the filtrate concentrated under reduced pressure. The residue was diluted with DCM then purified by silica gel column
eluting with (10-65 % 3: 1 EtOAc: EtOH in heptane) to afford tert-butyl ( ’)-6-morpholino-2- azaspiro[3.4]octane-2-carboxylate as an oil (986 mg, 79%) that was used without purification. LCMS m/z = 297.1 [M+H]+.
A solution of tert-butyl (A)-6-morpholino-2-azaspiro[3.4]octane-2-carboxylate (986 mg, 3.3 mmol) in MeOH (4 mL) was cooled in an ice water bath, then 4M HC1 in dioxane (4 M, 2.5 mL) was added dropwise. The reaction was allowed to warm to 23 °C and stirred for 2 h, then evaporated under reduced pressure to give (R)-4-(2-azaspiro[3.4]octan-6-yl)morpholine as an HC1 salt, that was used without purification. LCMS m/z = 197.1 [M+H]+.
To a solution of 4-(2-azaspiro[3.4]octan-6-yl)morpholine (103 mg, 0.4 mmol) HC1 salt, in anhydrous DCM (2 mL) was added DIPEA (410 pL, 2.4 mmol) dropwise under cooling in an ice water bath. After 5 mins, 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride (111 mg, 0.5 mmol) was added and the reaction was allowed to warm to 23 °C and stirred for 30 mins. The reaction was quenched by slow addition of aqueous 1 M NaOH solution. The mixture was stirred at 23 °C for 20 minutes, then the biphasic mixture was extracted with DCM (3 x). The combined organic extracts were dried over magnesium sulfate, the mixture filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with (25-80% 3 : 1 EtOAc:EtOH in heptane.) The product was further purified by HPLC using a Waters XSelect CSH C18, 5 pm, 50 mm x 100 mm column with mobile phase H2O (A) and MeCN (B) and a gradient of 5 - 55% B (0.2% NH4OH final v/v % modifier) with flow rate at 60 mL/min to give 4-(2-((l-methyl-3 -(trifluoromethyl)- \H- pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine as a colorless film (57 mg,
30%). LCMS m/z = 409.2 [M+H]+. 'H NMR (500 MHz, MeOH-d4): 6 ppm 7.21 (s, 1H), 4.17 (s, 3H), 3.85 - 3.79 (m, 2H), 3.79 - 3.73 (m, 2H), 3.67 (t, J= 4.6 Hz, 4H), 2.60 - 2.53 (m, 1H), 2.51 - 2.42 (m, 4H), 2.04 (dd, J= 12.8, 7.3 Hz, 1H), 1.93 - 1.86 (m, 2H), 1.80 - 1.73 (m, 1H), 1.61 (dd, J= 12.8, 9.2 Hz, 1H), 1.50 - 1.43 (m, 1H).
Example 50
(l?)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile
(R )-3-Fluoro-5-((6-morpholino-2-azaspiro[3 ,4]octan-2-yl)sulfonyl)benzonitrile was obtained as a colorless film (29 mg, 18%) from (R )-4-(2-azaspiro[3.4]octan-6-yl)morpholine HC1 salt (Example 49, step 2), and 3-cyano-5-fluoro-benzenesulfonyl chloride, following a similar procedure to that described in Example 49, step 3. LCMS m/z = 380.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 8.33 (br d, J= 8.2 Hz, 1H), 8.16 (s, 1H), 8.08 - 8.04 (m, 1H), 3.70- 3.68 (m, 2H), 3.67 - 3.62 (m, 2H), 3.51 (br t, J= 4.4 Hz, 4H), 2.40 - 2.34 (m, 1H), 2.32 - 2.17 (m, 4H), 1.74 (dd, J= 7.3, 12.8 Hz, 1H), 1.69 - 1.59 (m, 2H), 1.54 - 1.47 (m, 1H), 1.40 (dd, J = 8.5, 12.8 Hz, 1H), 1.35 - 1.26 (m, 1H).
Example 51
(S')-4-(2-(( 1 -met hyl-3-(t rinuoromethyl )-1H -py razol-5-yl (sulfonyl )-2-azaspiro|3.41 octan-
1. Synthesis of tert-butyl (R)-6-( (methylsulfonyl)oxy)-2-azaspiro[ 3.4 ]octane-2- carboxylate
A solution of tert-butyl (A)-6-hydroxy-2-azaspiro[3.4]octane-2-carboxylate (1.1 g, 4.9 mmol) in anhydrous DCM (40 mL) was cooled in an ice water bath then TEA (1.4 mL, 10.0 mmol) and DMAP (32 mg, 0.3 mmol) were added under cooling in an ice water bath and the solution stirred for 10 mins. Mesyl chloride (1.26 g, 11 mmol) was added dropwise, and the reaction was allowed to warm to rt and stirred for 5 h. The reaction was concentrated under reduced pressure, the residue was diluted with DCM then filtered. The filtrate was concentrated under reduced pressure and the crude was purified by silica gel column eluting with (5-80% EtOAc in heptane) to afford tert-butyl (A)-6-((methylsulfonyl)oxy)-2- azaspiro[3.4]octane-2-carboxylate as an oil (1.36 g, 91%) that was used without further purification. 'H NMR (500 MHz, DCM-d2): δ ppm 5.10 (td, J= 6.0, 2.8 Hz, 1H), 3.88 (d, J = 8.5 Hz, 1H), 3.79 - 3.75 (m, 3H), 2.97 (s, 3H), 2.25 - 2.20 (m, 1H), 2.18 - 2.13 (m, 1H), 2.11 - 2.03 (m, 2H), 2.02 - 1.95 (m, 1H), 1.88 - 1.82 (m, 1H), 1.41 (s, 9H).
To a flask containing morpholine (0.3 mL, 3.4 mmol) and tert-butyl (R )-6- methylsulfonyloxy- 2-azaspiro[3.4]octane-2-carboxylate (1.36 g, 4.5 mmol) in anhydrous MeCN (22 mL) was added K2CO3 (1.21 g, 8.8 mmol) in portions at rt. Upon complete addition, the reaction was stirred at 95 °C for 28 h. The reaction was cooled to rt then stirred for a further 4 days. The reaction was concentrated under reduced pressure, the residue was diluted with DCM then filtered. The filtrate was concentrated under reduced pressure, then the residue was purified by silica gel column (10-65 % 3: 1 EtOAc: EtOH in heptane) to give tert-butyl (S)-6-morpholino-2-azaspiro[3.4]octane-2-carboxylate as an oil (463 mg, 46% yield). LCMS m/z = 297.1 [M+ H]+.
A vial containing tert-butyl (68)-6-morpholino-2-azaspiro[3.4]octane-2-carboxylate (463 mg, 1.6 mmol) in HFIPA (2 mL) was cooled in an ice water bath, then TFA (0.4 mL, 5.2 mmol) was added dropwise. Upon complete addition, the mixture was allowed to warm to 23 °C and
stirred for 19 h. The reaction was concentrated under reduced pressure, the residue was dissolved in a mixture of DCM and MeOH (~9:1) and NazCOs (1.8 g, 17 mmol) added and the heterogeneous mixture stirred at rt for 2 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to afford (5)-4-(2-azaspiro[3.4]octan-6-yl)morpholine as a light yellow film. LCMS m/z = 197.1 [M+H]+.
(5)-4-(2-((l-Methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine was obtained as a colorless film (12 mg, 6%) from (S)-4-(2- azaspiro[3 ,4]octan-6-yl)morpholine and 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride, following a similar procedure to that described in Example 49, step 3. LCMS m/z = 409.2 [M+H]+. 'H NMR (500 MHz, DCM-d2): δ ppm 7.02 (s, 1H), 4.14 (s, 3H), 3.82 - 3.79 (m, 1H), 3.77 - 3.70 (m, 3H), 3.65 - 3.60 (m, 4H), 2.51 - 2.46 (m, 1H), 2.44 - 2.34 (m, 4H), 1.99 (dd, J= 12.8, 7.3 Hz, 1H), 1.91 - 1.81 (m, 2H), 1.78 - 1.72 (m, 1H), 1.66 - 1.61 (m, 1H), 1.50 - 1.43 (m, 1H).
Example 52
(5)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile was obtained as a colorless film (14 mg, 11%) from (8)-4-(2-azaspiro[3.4]octan-6-yl)morpholine (Example 51, step 3) and 3-cyano-5-fluoro-benzenesulfonyl chloride, following a similar procedure described in Example 49, step 3, except the product was not additionally purified by HPLC. LCMS m/z = 380.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 6 ppm 8.33 (br d, J= 8.5 Hz, 1H), 8.16 (s, 1H), 8.05 (br d, J= 7.9 Hz, 1H), 3.71 - 3.68 (m, 2H), 3.67 - 3.62 (m, 2H), 3.51
(t, J= 4.4 Hz, 4H), 2.41 - 2.34 (m, 1H), 2.32 - 2.18 (m, 4H), 1.74 (dd, J= 13.0, 7.2 Hz, 1H), 1.69 - 1.59 (m, 2H), 1.54 - 1.48 (m, 1H), 1.40 (dd, J= 13.0, 8.7 Hz, 1H), 1.34 - 1.27 (m, 1H).
Example 53
To a solution of tert-butyl 7-oxo-5-oxa-2-azaspiro[3.4]octane-2-carboxylate (692 mg, 3.05 mmol) in anhydrous DCM (50 mL) was added morpholine (0.8 mL, 9.2 mmol) and TEA (480 pL, 3.4 mmol) dropwise at 23 °C. After 15 mins, AcOH (440 pL, 7.3 mmol) was added dropwise to the reaction mixture to pH~5-6. Upon complete addition, the reaction was stirred at 23 °C for 30 mins, then NaBH(OAc)3 (5.33 g, 25.2 mmol) was added in portions. The reaction was stirred at 23 °C for 19 h (Additional anhydrous DCM (50 mL) was added to the thick white paste to aid stirring) then was quenched by slow addition of aqueous saturated ammonium chloride solution. The mixture was stirred at 23 °C for 15 mins, then the biphasic mixture was extracted with DCM (3x). The combined organic extracts were washed with brine (2x) then dried over anhydrous magnesium sulfate. The mixture was filtered and evaporated under reduced pressure to give tert-butyl (7S)-7-morpholino-5-oxa-2- azaspiro[3.4]octane-2-carboxylate that was used without purification. LCMS m/z = 299.1 [M+H]+.
A solution of tert-butyl (75)-7-morpholino-5-oxa-2-azaspiro[3.4]octane-2-carboxylate (908 mg, 3.0 mmol) in HFIP (7 mL) was cooled in an ice water bath, then TFA (0.7 mL, 9.1 mmol) was added dropwise. The mixture was allowed to warm to 23 °C and stirred for 8 h. The reaction was evaporated under reduced pressure to give 7-morpholino-5-oxa-2- azaspiro[3.4]octane (TFA salt) as a light yellow residue (950 mg) that was used without purification. LCMS m/z = 199.1 [M+H]+.
To a solution of 7-morpholino-5-oxa-2-azaspiro[3.4]octane (143 mg, 0.5 mmol, TFA salt) in anhydrous THF (1.5 mL) was added DIPEA (460 pL, 2.6 mmol) dropwise and DMAP (6 mg, 0.1 mmol) at < 5 °C. After 5 mins, 2,4,6-trimethylbenzenesulfonyl chloride (147 mg, 0.7 mmol) was added to the cold heterogeneous solution, the reaction was allowed to warm to 23 °C and stirred for 30 mins. The reaction was quenched by slow addition of aqueous 1 M NaOH solution, the mixture was stirred at 23 °C for 10 mins, then the biphasic mixture was extracted with EtOAc (3x). The combined organics were washed with saturated aqueous NaHCO3 solution (2x) then dried over anhydrous sodium sulfate. The mixture was filtered and concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with (10-70 % 3: 1 EtOAc:EtOH in heptane) to give 2-(mesitylsulfonyl)-7- morpholino-5-oxa-2-azaspiro[3.4]octane as a colorless film (66 mg, 36%). LCMS m/z = 381.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 7.08 (s, 2H), 3.82 (dd, J= 8.5, 6.7 Hz, 1H), 3.77 (s, 2H), 3.71 - 3.64 (m, 2H), 3.58 - 3.51 (m, 5H), 2.90 - 2.83 (m, 1H), 2.53 (s, 6H), 2.36 (dt, J= 4.0, 2.4 Hz, 2H), 2.31 - 2.24 (m, 6H), 2.02 - 1.97 (m, 1H).
Example 54
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3.4]octane
1. Synthesis of tert-butyl 7-(4-methylpiperidin-l-yl)-5-oxa-2-azaspiro[3.4]octane-2- carboxylate
tert- Butyl 7-(4-methylpiperidin-l-yl)-5-oxa-2-azaspiro[3.4]octane-2-carboxylate was obtained (742 mg, 95%) from tert-butyl 7-oxo-5-oxa-2-azaspiro[3.4]octane-2-carboxylate and 4-methylpiperidine, following the procedure described in Example 35, step 1. LCMS m/z
7-(4-Methylpiperidin-l-yl)-5-oxa-2-azaspiro[3.4]octane was obtained as an HC1 salt, as an off white solid, from tert-butyl 7-(4-methylpiperidin-l-yl)-5-oxa-2-azaspiro[3.4]octane-2- carboxylate, following the procedure described in Example 35, step 2. LCMS m/z = 211.2 [M+H]+
3. Synthesis of 2-((4-(difluoromethoxy)phenyl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5- oxa-2-azaspiro[ 3.4 ] octane
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3.4]octane was obtained as a colorless film(50 mg, 56%) from 7-(4-methylpiperidin- l-yl)-5-oxa-2-azaspiro[3.4]octane (HC1 salt) and 4-(difluoromethoxy)benzenesulfonyl chloride following the procedure described in Example 35, step 3. LCMS m/z = 417.5 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 7.92 - 7.86 (m, 2H), 7.64 - 7.32 (m, 3H), 3.83 (d, J= 9.2 Hz, 1H), 3.78 - 3.70 (m, 2H), 3.63 (d, J= 8.5 Hz, 1H), 3.51 (d, J= 8.5 Hz, 1H), 3.40 (t, J= 7.9 Hz, 1H), 2.78 - 2.71 (m, 1H), 2.71 - 2.66 (m, 1H), 2.56 - 2.51 (m, 1H), 2.09 (dd, J= 12.8, 7.3 Hz, 1H), 1.87 - 1.75 (m, 3H), 1.51 (br t, J= 14.6 Hz, 2H), 1.32 - 1.22 (m, 1H), 1.09 - 0.98 (m, 2H), 0.84 (d, J= 6.7 Hz, 3H).
Example 55
2-((l,3-Dimethyl-1H -pyrazol-5-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3.4]octane was obtained as a colorless film (47 mg, 44%) from 7-(4- methylpiperidin-l-yl)-5-oxa-2-azaspiro[3.4]octane (HC1 salt) (Example 54, step 2) and (1,3- dimethyl-1H -pyrazol-5-yl)sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 369.2 [M+H]+. 'H NMR (500 MHz, MeOH-d4): 6 ppm 6.65 (s, 1H), 4.01 (s, 3H), 3.96 - 3.89 (m, 3H), 3.85 - 3.81 (m, 1H), 3.78 - 3.74 (m, 1H), 3.61 (t, J= 8.2 Hz, 1H), 2.98 - 2.87 (m, 2H), 2.73 - 2.66 (m, 1H), 2.40 - 2.34 (m, 1H), 2.28 - 2.25 (m, 3H), 2.08 - 1.94 (m, 3H), 1.70 - 1.62 (m, 2H), 1.45 - 1.36 (m, 1H), 1.26 - 1.16 (m, 2H), 0.93 (d, J= 6.7 Hz, 3H).
Example 56
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3.4]octane was obtained as a colorless film (11 mg, 9%) from 7-(4-methylpiperidin- l-yl)-5-oxa-2-azaspiro[3.4]octane (HC1 salt) (Example 54, step 2) and 6-methoxy-2- methylpyridine-3 -sulfonyl chloride, following the procedure described in Example 35, step 3. LCMS m/z = 396.2 [M+H]+. 'H NMR (500 MHz, MeOH-d4): 8 ppm 8.06 (d, J= 8.5 Hz, 1H), 6.74 (d, J= 9.2 Hz, 1H), 3.98 (s, 3H), 3.97 - 3.93 (m, 1H), 3.92 - 3.89 (m, 1H), 3.88 - 3.85 (m, 1H), 3.78 - 3.73 (m, 2H), 3.63 (t, J= 7.9 Hz, 1H), 3.00 - 2.88 (m, 2H), 2.74 - 2.72 (m, 3H), 2.72 - 2.67 (m, 1H), 2.43 (dd, J= 13.1, 7.6 Hz, 1H), 2.10 - 1.97 (m, 3H), 1.70 - 1.62 (m, 2H), 1.45 - 1.35 (m, 1H), 1.27 - 1.16 (m, 2H), 0.92 (d, J= 6.7 Hz, 3H).
Example 57 (R )-2-((l-methyl-3-(trifluoromethyl)-1H -pyrazol-5-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3.4]octane
1. Synthesis of tert-butyl (S)-7-((methylsulfonyl)oxy)-5-oxa-2-azaspiro[3.4]octane-2- carboxylate
tert- Butyl (5)-7-((methylsulfonyl)oxy)-5-oxa-2-azaspiro[3 ,4]octane-2-carboxylate was obtained as a white solid (1.28 g, 95%) from tert-butyl (S)-7-hydroxy-5-oxa-2-
azaspiro[3.4]octane-2-carboxylate, following the procedure described in Example 51, step 1.
LCMS m/z = 308.0 [M+H]+
2. Synthesis of tert-butyl (R)-7-morpholino-5-oxa-2-azaspiro[3.4]octane-2-carboxylate
tert- Butyl (A)-7-morpholino-5-oxa-2-azaspiro[3.4]octane-2-carboxylate was obtained as a white solid (124 mg, 11%) from tert-butyl (S)-7-((m ethyl sulfonyl)oxy)-5 -oxa-2- azaspiro[3.4]octane-2-carboxylate and morpholine, following the procedure described in Example 51, step 2. LCMS m/z = 299.1 [M+H]+
A solution of tert-butyl (A)-7-morpholino-5-oxa-2-azaspiro[3.4]octane-2-carboxylate (124 mg, 0.4 mmol) in MeOH (1 mL) was cooled in an ice water bath, then 4M HC1 in Dioxane (4 M, 0.32 mL) was added dropwise. The mixture was allowed to warm to 23 °C and stirred for 20 h. The reaction was filtered, rinsing with EtOAc to give (A)-7-morpholino-5-oxa-2- azaspiro[3.4]octane, as the hydrochloride salt, that was used without purification. LCMS m/z = 199.1 [M+H]+.
4. Synthesis of (R)-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-7- morpholino-5-oxa-2-azaspiro[ 3.4 ] octane
(A)-2-((l -Methyl-3 -(tri fluoromethyl)- 1H/-pyrazol-5-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3.4]octane was obtained as a colorless film, from (A)-7-morpholino-5-oxa-2- azaspiro[3.4]octane (hydrochloride salt) and 2-methyl-5-(trifluoromethyl)pyrazole-3-sulfonyl chloride, following the procedure described in Example 51, step 4). LCMS m/z = 411.1
[M+H]+ 1H NMR (500 MHz, DCM-d2): 6 ppm 7.04 (s, 1H), 4.14 (s, 3H), 3.98 (s, 2H), 3.92 - 3.88 (m, 3H), 3.69 - 3.65 (m, 1H), 3.63 (t, J= 4.9 Hz, 4H), 2.88 (quin, J= 7.0 Hz, 1H), 2.45 - 2.40 (m, 2H), 2.34 - 2.27 (m, 3H), 2.07 (dd, J= 12.8, 7.9 Hz, 1H).
Example 58
(l?)-2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3.4]octane
(A)-2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3.4]octane was obtained as a colorless film(32 mg, 41%) from (R)-7-morpholino-5- oxa-2-azaspiro[3.4]octane (HC1 salt) (Example 57, step 3) and 2-methyl-6-
(trifluorom ethyl )pyridine-3 -sulfonyl chloride following the procedure described in Example 49, step 3. LCMS m/z = 422.2 [M+ H]+. 'H NMR (400 MHz, DCM-d2): 8 ppm 8.37 (d, J= 8.0 Hz, 1H), 7.67 (d, J= 8.3 Hz, 1H), 4.06 (d, J= 8.3 Hz, 1H), 3.98 - 3.90 (m, 3H), 3.85 (d, J = 8.3 Hz, 1H), 3.68 (dd, J= 8.5, 7.0 Hz, 1H), 3.63 (t, J= 4.6 Hz, 4H), 2.93 - 2.86 (m, 4H), 2.46 - 2.39 (m, 2H), 2.36 - 2.29 (m, 3H), 2.07 (dd, J= 12.9, 7.9 Hz, 1H).
Example 59
3-((7-((4,4-Difluorocyclohexyl)(methyl)amino)-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)-
A solution of 3-((7-((4,4-difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile (Example 26, 90 mg, 0.2 mmol) and (CH2O)n (63 mg, 2.1 mmol) in MeOH (3 mL) was adjusted to pH = 6 using AcOH. NaBHsCN (65.85 mg, 1.05 mmol) was added and the reaction mixture was stirred at 20 °C for 14 h. The mixture was diluted with water (50 mL) and extracted with DCM (50 mL x 3). The combined organic
phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude was purified by prep-HPLC ((Column: Boston Prime C18 150 x 30mm x 5pm, Condition: water (NH3 H2O+NH4HCO3)-MeCN, 45% to 75%, Flow Rate (mL/min): 25)) to give 3 -((7- ((4,4-difluorocyclohexyl)(methyl)amino)-5-oxa-2-azaspiro[3.4]octan-2-yl)sulfonyl)-4- fluorobenzonitrile (40 mg, 43%) as a white solid. LCMS m/z = 444.2 [M+H]+. XH NMR (400 MHz, MeOH-d4): δ ppm 8.24 (dd, J= 6.4, 2.0 Hz, 1H), 8.15 - 8.10 (m, 1H), 7.61 (t, J= 9.6 Hz, 1H), 4.07 - 4.04 (m, 1H), 4.00 - 3.83 (m, 4H), 3.57 (t, J= 8.0 Hz, 1H), 3.41-3.34 (m, 1H), 2.59 (t, J= 11.6 Hz, 1H), 2.38-2.35 (m, 1H), 2.15 (s, 3H), 2.06 - 1.96 (m, 3H), 1.88 - 1.71 (m, 4H), 1.65 - 1.57 (m, 2H).
Examples 60 and 61
(R )-4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine and ( )-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine (Example 40) was further purified by SFC using a Chiralpak IG 30x 250 mm, 5 pm column using 20%
MeOH with 0.1 % DMEA in CO2; Flow rate: 100 mL/min; ABPR 120 bar; MBPR 40 psi, column temperature 40°C; to give:
Peak 1, (A)-4-(2-((2-methyl-6-(trifhioromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (ri)-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid, (13 mg, 24%). LCMS m/z = 420.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): 6 ppm 8.48 - 8.43 (m, 1H), 8.00 (s, 1H), 3.79 - 3.74 (m, 3H), 3.72 - 3.69 (m, 1H), 3.54 - 3.51 (m, 4H), 2.83 (s, 3H), 2.48 - 2.41 (m, 1H), 2.37 - 2.27 (m, 4H), 1.99 - 1.93 (m, 1H), 1.85 - 1.78 (m, 1H), 1.77 - 1.68 (m, 2H), 1.59 - 1.53 (m, 1H), 1.41 - 1.34 (m, 1H).
Peak 2, (ri)-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3 ,4]octan-6- yl)morpholine or (R )-4-(2-((2 -methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-2-
azaspiro[3.4]octan-6-yl)morpholine as an off-white solid (14 mg, 27%). LCMS m/z = 420.2 [M+H]+. 1H NMR (500 MHz, DMSO-d6): 6 ppm 8.45 (d, J= 7.9 Hz, 1H), 7.99 (d, J= 8.5 Hz, 1H), 3.79 - 3.73 (m, 3H), 3.72 - 3.69 (m, 1H), 3.52 (t, J= 4.6 Hz, 4H), 2.83 (s, 3H), 2.46
- 2.41 (m, 1H), 2.38 - 2.27 (m, 4H), 1.96 (dd, J= 12.8, 7.3 Hz, 1H), 1.84 - 1.78 (m, 1H), 1.76
- 1.68 (m, 2H), 1.59 - 1.53 (m, 1H), 1.41 - 1.33 (m, 1H).
Stereochemistry of the isomers was arbitrarily assigned.
Examples 62 and 63: (R )-4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine and (S)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine (Example 41, 76 mg, 0.2 mmol) was further purified by chiral SFC using Chiralpak IA 30x 250 mm, 5pm column using 30% MeOH in CO2. Flow rate: 100 mL/min; ABPR 120 bar; MBPR 40 psi, column temperature 40 °C to afford:
Peak 1, (A)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (5)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid (21 mg, 26%). LCMS m/z = 420.2 [M+H]+. 'H NMR (500 MHz, MeOH-d4): δ ppm 9.05 (s, 1H), 7.91 (s, 1H), 3.89 - 3.86 (m, 1H), 3.83 - 3.80 (m, 2H), 3.76 - 3.74 (m, 1H), 3.67 (t, J= 4.6 Hz, 4H), 2.75 (s, 3H), 2.61 - 2.54 (m, 1H), 2.51 - 2.43 (m, 4H), 2.12 (dd, J= 7.3, 12.8 Hz, 1H), 1.97 - 1.89 (m, 2H), 1.85 - 1.78 (m, 1H), 1.69 - 1.64 (m, 1H), 1.53 - 1.44 (m, 1H).
Peak 2, (8)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2-azaspiro[3 ,4]octan-6- yl)morpholine and (A>)-4-(2-((4-methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine as an off-white solid (22 mg, 28%). LCMS m/z = 420.2 [M+H]+ XHNMR (500 MHz, MeOH-d4): 6 ppm 9.05 (s, 1H), 7.91 (s, 1H), 3.88 - 3.86 (m, 1H), 3.83 - 3.80 (m, 2H), 3.77 - 3.74 (m, 1H), 3.67 (t, J= 4.6 Hz, 4H), 2.75 (s, 3H), 2.60 -
2.55 (m, 1H), 2.52 - 2.44 (m, 4H), 2.12 (dd, J= 12.8, 7.3 Hz, 1H), 1.96 - 1.88 (m, 2H), 1.85 - 1.79 (m, 1H), 1.66 (dd, J= 12.8, 9.2 Hz, 1H), 1.51 - 1.44 (m, 1H).
Stereochemistry of the isomers was arbitrarily assigned.
Examples 64 and 65:
(l?)-4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine and (5)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine
4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine (Example 42, 169 mg, 0.4 mmol) was further purified by SFC using Chiralpak IA 30x 250 mm, 5pm column using 30% MeOH with 0.1 % DMEA in CO2. Flow rate: 100 mL/min; ABPR 120 bar; MBPR 40 psi, column temperature 40°C to afford:
Peak 1, (A)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (5)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as an off-white solid (51 mg, 28%). LCMS m/z = 386.1 [M+H]+. 'H NMR (500 MHz, MeOH-d4): δ ppm 8.21 (d, J= 8.5 Hz, 1H), 7.48 (d, J= 8.5 Hz, 1H), 3.83 - 3.80 (m, 1H), 3.77 - 3.74 (m, 2H), 3.71 - 3.67 (m, 5H), 2.79 (s, 3H), 2.62 - 2.55 (m, 1H), 2.53 - 2.45 (m, 4H), 2.12 (dd, J= 12.8, 7.3 Hz, 1H), 1.95 - 1.88 (m, 2H), 1.84 - 1.78 (m, 1H), 1.66 (dd, J= 12.8, 9.2 Hz, 1H), 1.51 - 1.45 (m, 1H).
Peak 2, (8)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (A)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3 ,4]octan-6- yl)morpholine as an off-white solid (55 mg, 31%). LCMS m/z = 386.1 [M+H]+. 'H NMR (500 MHz, MeOH-d4): 6 ppm 8.21 (d, J= 7.9 Hz, 1H), 7.48 (d, J= 7.9 Hz, 1H), 3.83 - 3.80 (m, 1H), 3.77 - 3.75 (m, 2H), 3.71 - 3.67 (m, 5H), 2.79 (s, 3H), 2.60 - 2.54 (m, 1H), 2.52 - 2.45 (m, 4H), 2.12 (dd, J= 13.1, 7.0 Hz, 1H), 1.96 - 1.88 (m, 2H), 1.84 - 1.78 (m, 1H), 1.66 (dd, J= 13.1, 9.5 Hz, 1H), 1.51 - 1.44 (m, 1H).
Stereochemistry of the isomers was arbitrarily assigned.
Examples 66 and 67:
(R )-4-(2-(( 1,3-dimet hyl-1H-py razol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl (morpholine and (S)-4-(2-(( 1 ,3-dimethyl- 1H-py razol-5-yl )sulfonyl )-2-azaspiro[3.4 ]octan-6- yl)morpholine
4-(2-((l,3-Dimethyl-l#-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine (Example 36, 254 mg, 0.7 mmol) was further purified by SFC using a Chiralpak AD-H 30 x 250 mm, 5 pm column using 40% MeOH with 0.1 % DEA in CO2. Flow rate: 100 mL/min; ABPR 120 bar; MBPR 40 psi, column temperature 40 °C to afford the following compounds that were concentrated to dryness and then lyophilized:
Peak 1, (R )-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (8)-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as a tan oil (95 mg, 34%). LCMS m/z = 355.2 [M+H]+. 'H NMR (500 MHz, DMSO-d6): δ ppm 6.70 (s, 1H), 3.96 (s, 3H), 3.66 (s, 2H), 3.64 - 3.59 (m, 2H), 3.55 - 3.50 (m, 4H), 2.46 - 2.39 (m, 1H), 2.35 - 2.23 (m, 4H), 2.21 (s, 3H), 1.84 (dd, J= 12.8, 7.0 Hz, 1H), 1.75 -1.68 (m, 2H), 1.64 - 1.57 (m, 1H), 1.48 (dd, J= 13.0, 8.7 Hz, 1H), 1.39 - 1.29 (m, 1H).
Peak 2, (8)-4-(2-((l,3-dimethyl-1H -pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine or (R )-4-(2-((l,3-dimethyl-1H-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine as a tan oil (68 mg, 24%). LCMS m/z = 355.2 [M+H]+. 1 H NMR (500 MHz, DMSO-d6): 6 ppm 6.70 (s, 1H), 3.96 (s, 3H), 3.66 (s, 2H), 3.65 - 3.59 (m, 2H), 3.52 (br s, 4H), 2.47 - 2.39 (m, 1H), 2.39 - 2.23 (m, 4H), 2.21 (s, 3H), 1.84 (br dd, J= 12.8, 7.0 Hz, 1H), 1.75 - 1.68 (m, 2H), 1.65 - 1.56 (m, 1H), 1.52 - 1.45 (m, 1H), 1.40 - 1.30 (m, 1H).
Stereochemistry of the isomers was arbitrarily assigned.
Example 68
6-(2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)- l-oxa-6-azaspiro[3.3]heptane
6-(2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)-l- oxa-6-azaspiro[3.3]heptane was obtained (67 mg, 54%), from 2-((6-(l,l-difluoroethyl)-2- methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (100 mg, 302.71 pmol) and 1-oxa- 6-azaspiro[3.3]heptane (73.65 mg, 393.52 pmol, Oxalate), following the procedure described in Example 1, step 6. LCMS m/z = 414.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 8.27 (d, ./=8,0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H),4.5O (t, J=8.0 Hz 2H), 3.89 (s, 2H), 3.84 (s, 2H), 3.50-3.47 (m, 2H), 3.07-3.05 (m, 2H), 2.95-2.88 (m, 1H), 2.85 (s, 3H), 2.82 (t, J=7.6 Hz, 2H), 2.23-2.18 (m, 2H), 2.01 (t, J=18.8 Hz, 3H), 1.95-1.90 (m, 2H).
Example 69
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine was obtained (150 mg, 64%), was obtained from 2-((6-(l, 1- difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (200 mg, 605.4 pmol) and ox etan-3 -amine (66.4 mg, 908.1 pmol) following the procedure described in Example 1, step 6. LCMS m/z = 388.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 8.27 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 4.78 (t, J=6.8 Hz, 2H), 4.39 (t, J=6.4 Hz, 2H), 3.93-
3.88 (m, 3H), 3.85 (s, 2H), 3.19-3.12 (m, 1H), 2.86 (s, 3H), 2.44-2.39 (m, 2H), 2.01 (t, J=18.8 Hz, 3H), 1.91-1.86 (m, 2H).
Example 70
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-2- azaspiro[3.3]heptan-6-amine (160 mg, 62%), was obtained from 2-((6-(l,l-difluoroethyl)-2- methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (200 mg, 605.4 pmol) and 2- oxaspiro[3.3]heptan-6-amine (108.70 mg, 726.50pmol, HC1 salt) following the procedure described in Example 1, step 6. LCMS m/z = 428.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 8.27 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H), 4.68 (s, 2H), 4.57 (s, 2H), 3.92 (s, 2H), 3.83 (s, 2H), 3.14-2.97 (m, 2H), 2.86 (s, 3H), 2.51-2.39 (m, 4H), 2.01 (t, J=18.8 Hz, 3H), 1.88-1.81 (m, 4H).
Example 71 2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4- yl)methyl)-2-azaspiro[3.3]heptan-6-amine
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-((tetrahydro-2H-pyran-4- yl)methyl)-2-azaspiro[3.3]heptan-6-amine (43 mg, 33%) was obtained from 2-((6-(l , 1 - difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (100 mg, 302.7
pmol) and (tetrahydro-2H-pyran-4-yl)methanamine (38.35 mg, 332.98 pmol) following the procedure described in Example 1, step 6. LCMS m/z = 430.1 [M+H]+. 1HNMR (400 MHz, CDC13): δ ppm 8.28 (d, J=8.4 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H), 3.97-3.93 (m, 4H), 3.86 (s, 2H), 3.39-3.33 (m, 2H), 3.18-3.11 (m, 1H), 2.86 (s, 3H), 2.47-2.42 (m, 2H), 2.36 (d, J=6.0 Hz, 2H), 2.01 (t, J=18.8 Hz, 3H), 1.89-1.84 (m, 2H), 1.66-1.62 (m, 2H), 1.55-1.49 (m, 1H), 1.31-1.21 (m, 2H).
Example 72
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-methyl-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro [3.3] heptan-6-amine
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(tetrahy dro-2H-pyran- 4-yl)-2-azaspiro[3.3]heptan-6-amine (68 mg, 52%) was obtained from 2-((6-(l, 1- difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (100 mg, 302.7 pmol) and l-(tetrahydro-2H-pyran-4-yl)ethan-l -amine (104.59 mg, 908.13 pmol) following the procedure described in Example 1, step 6. LCMS m/z = 430.2 [M+H]+. 1HNMR (400 MHz, CDC13): δ ppm 8.28 (d, =8.0 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 4.03-3.99 (m, 2H), 3.95 (s, 2H), 3.83 (s, 2H), 3.37-3.31 (m, 2H), 3.04-3.00 (m, 1H), 2.86 (s, 3H), 2.62-2.57 (m, 1H), 2.34-2.29 (m, 2H), 2.10-2.07 (m, 3H), 2.01 (t, J=18.8 Hz, 3H), 1.66-1.60 (m, 3H), 1.58- 1.55(m, 3H).
Example 73
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-methyl-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine (55 mg, 53%) was obtained from 2-((6-(l,l-difluoroethyl)-2- methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (100 mg, 302.7 pmol) and (CH2O)n (70.3 mg, 2.0 mmol) following the procedure described in Example 59. LCMS m/z = 402.1 [M+H]+. 1HNMR (400 MHz, CDC13): δ ppm 8.27 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H), 4.64 (t, J=6.4 Hz, 2H), 4.56 (t, J=6.4 Hz, 2H), 3.93 (s, 2H), 3.82 (s, 2H), 3.63-3.56 (m, 1H), 2.86 (s, 3H), 2.69-2.59 (m, 1H), 2.26-2.21 (m, 2H), 2.07-1.96 (m, 8H).
Example 74
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-methyl-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine
2-((6-(l,l-difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(2-oxaspiro[3.3 ]heptan- 6-yl)-2-azaspiro[3.3]heptan-6-amine (158 mg, 67%) was obtained from 2-((6-(l, 1- difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-2- azaspiro[3.3]heptan-6-amine (100 mg, 233.9 pmol) and (CH2O)n (79.7 mg, 2.34 mmol) following the procedure described in Example 59. LCMS m/z = 442.2 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 8.27 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.0 Hz, 1H), 4.68 (s, 2H), 4.55 (s, 2H), 3.93 (s, 2H), 3.80 (s, 2H), 2.86 (s, 3H), 2.63-2.46 (m, 2H), 2.34-2.23 (m, 4H), 2.08-1.96 (m, 7H), 1.92 (s, 3H).
Example 75
2-((6-(l,l-difluoroethyl)-2-methylpyridin-3-yl)sulfonyl)-N-methyl-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-((tetrahy dro-2H-pyran- 4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine (71 mg, 53%) was obtained from 2-((6-(l, 1- difhioroethyl)-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (100 mg, 302.7 pmol) and N-methyl-l-(tetrahydro-2H-pyran-4-yl)methanamine (50.8 mg, 394 pmol) following the procedure described in Example 1, step 6. LCMS m/z = 444.2 [M+H]+.
1HNMR (400 MHz, CDC13): δ ppm 8.28 (d, J=8.0 Hz, 1H), 7.59 (d, J=8.4 Hz, 1H), 3.96-3.92 (m, 4H), 3.83 (s, 2H), 3.39-3.33 (m, 2H), 2.86 (s, 3H), 2.60-2.54 (m, 1H), 2.30-2.25 (m, 2H), 2.06-1.97 (m, 10H), 1.64-1.62 (m, 3H), 1.24-1.14 (m, 2H).
Example 76
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2- azaspiro[3.3]heptan-6-amine (15 mg, 17%) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (70 mg, 208.77 pmol) and tetrahydro-2H-pyran-4-amine (63 mg, 626 pmol) following the procedure described in Example 16, step 4. LCMS m/z = 421.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 9.18
(s, 1H), 4.03 (s, 2H), 3.97-3.93 (m, 4H), 3.40-3.29 (m, 3H), 2.91 (s, 3H), 2.66-2.62 (m, 1H), 2.53-2.48 (m, 2H), 1.95-1.90 (m, 2H), 1.74-1.71 (m, 2H), 1.41-1.31 (m, 2H).
Example 77
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine (115 mg, 54%) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (180 mg, 536.8 pmol) and oxetan-3 -amine (47 mg, 644 pmol) following the procedure described in Example 16, step 4. LCMS m/z = 393.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 9.17 (s, 1H), 4.78 (t, J = 7.0 Hz, 2H), 4.39 (t, J = 6.5 Hz, 2H), 4.01 (s, 2H), 3.96 (s, 2H), 3.94-3.86 (m, 1H), 3.22-3.14 (m, 1H), 2.90 (s, 3H), 2.47-2.40 (m, 2H), 1.95-1.88 (m, 2H).
Example 78
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6- yl)-2-azaspiro [3.3] heptan-6-amine
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-2- azaspiro[3.3]heptan-6-amine (100 mg, 47 %) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (160 mg, 477.1 pmol) and 2-oxaspiro[3.3]heptan-6-amine (92.8 mg, 620 pmol) following the procedure described in Example 16, step 4. LCMS m/z = 433.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm
9.17 (s, 1H), 4.68 (s, 2H), 4.58 (s, 2H), 4.01 (s, 2H), 3.94 (s, 2H), 3.17-3.10 (m, 1H), 3.07-
2.98 (m, 1H), 2.90 (s, 3H), 2.53-2.42 (m, 4H), 1.94-1.87 (m, 4H).
Example 79
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4- yl)methyl)-2-azaspiro[3.3]heptan-6-amine
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H-pyran-4- yl)methyl)-2-azaspiro[3.3]heptan-6-amine (13 mg, 17%) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (60 mg, 178.9 pmol) and (tetrahydro-2H-pyran-4-yl)methanamine (24.7 mg, 214.7 pmol) following the procedure described in Example 16, step 4. LCMS m/z = 435.1 [M+H]+. 'HNMR (400 MHz, CDC13): 8 ppm 9.18 (s, 1H), 4.03 (s, 2H), 3.98 (s, 2H), 3.96-3.93 (m, 2H), 3.39-3.33 (m, 2H), 3.26- 3.22 (m, 1H), 2.90 (s, 3H), 2.53-2.48 (m, 2H), 2.43 (d, J=6.4 Hz, 2H), 2.07-2.06 (m, 1H), 1.75-1.69 (m, 2H), 1.34-1.24 (m, 4H).
Example 80
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro [3.3] heptan-6-amine
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H-pyran- 4-yl)-2-azaspiro[3.3]heptan-6-amine (22 mg, 23%) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3.3]heptan-6-one (70 mg, 208.8 pmol) and N-methyltetrahydro-2H-pyran-4-amine (36.1 mg, 313.1 pmol) following the procedure
described in Example 16, step 4. LCMS m/z = 435.1 [M+H]+. 1HNMR (400 MHz, CDC13): δ ppm 9.18 (s, 1H), 4.04-3.99 (m, 4H), 3.93 (s, 2H), 3.37-3.31 (m, 2H), 3.07-2.99 (m, 1H), 2.91 (s, 3H), 2.63-2.57 (m, 1H), 2.36-2.31 (m, 2H), 2.08 (s, 3H), 1.66-1.51 (m, 6H).
Example 81
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine (35 mg, 67.6%) was obtained from 2-((4-methyl-2- (trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(oxetan-3-yl)-2-azaspiro[3.3]heptan-6-amine (50 mg, 127.4 pmol) and (CH2O)n (764 mg, 637 pmol) following the procedure described in Example 59. LCMS m/z = 407.1 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 9.17 (s, 1H), 4.64 (t, J = 6.5 Hz, 2H), 4.56 (t, J = 6.5 Hz, 2H), 4.02 (s, 2H), 3.92 (s, 2H), 3.63-3.57 (m, 1H), 2.90 (s, 3H), 2.68-2.62 (m, 1H), 2.28-2.22 (m, 2H), 2.10-2.05 (m, 2H), 2.04 (s, 3H).
Example 82
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine (20 mg. 24%) was obtained from 2- ((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2-oxaspiro[3.3]heptan-6-yl)-2- azaspiro[3.3]heptan-6-amine (80 mg, 185 pmol) and (CH2O)n (63 mg, 1.85 mmol) following
the procedure described in Example 59. LCMS m/z = 447.1 [M+H]+. 1HNMR (400 MHz, CDC13): δ ppm 9.17 (s, 1H), 4.69 (s, 2H), 4.56 (s, 2H), 4.03 (s, 2H), 3.92 (s, 2H), 2.90 (s, 3H), 2.63-2.49 (m, 2H), 2.33-2.29 (m, 4H), 2.11-2.01 (m, 4H), 1.94 (s, 3H). Example 83
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine (38 mg, 45.6%) was obtained from 2-((4- methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2-azaspiro[3 ,3]heptan-6-one (60 mg, 178.9 pmol) and N-methyl-l-(tetrahydro-2H-pyran-4-yl)methanamine (27.7 mg, 214.7 pmol) following the procedure described in Example 16, step 4. LCMS m/z = 449.2 [M+H]+. 1HNMR (400 MHz, CDC13): 8 ppm 9.18 (s, 1H), 4.01 (s, 2H), 3.99-3.93 (m, 4H), 3.40-3.34 (m, 2H), 2.91 (s, 3H), 2.64-2.56 (m, 1H), 2.33-2.28 (m, 2H), 2.06 (s, 3H), 2.02-1.95 (m, 4H), 1.69-1.67 (m, 1H), 1.67-1.64 (m, 2H), 1.24-1.14 (m, 2H).
ASSAYS
EBP Functional Assay
The EBP immunoaffinity (IA) LC-MS assay measures the potency of small molecule inhibitors of EBP by quantifying their concentration-dependent changes in the enzyme’s substrate and product using liquid chromatography atmospheric pressure chemical ionization multiple reaction monitoring mass spectrometry (LC-APCI MRM MS). HEK293T cells were utilized as the source of EBP enzyme. The enzyme was incubated with the small molecule inhibitors at variable concentrations for 30 min. Deuterated form of EBP substrate, zymosterol-d5 (Avanti Polar Lipids, Cat# 700068P-lmg), was then added and the plate was incubated at 37 °C for 4 h. Finally, the sterol isomers were extracted and injected to LC-APCI MRM MS. MRM transition used for the quantification for both zymosterol and dihydrolathosterol (substrate and product of EBP enzymatic reaction, respectively) is 372.3-203.2, CE 30 and DP 80 in positive ion mode. Percent conversion of the zymosterol-d5 to dehydrolathosterol-d5 was used to derive IC50 curves. Tasin-1 (l'-[(4-Methoxyphenyl)sulfonyl]-4-methyl-1,4’-bipiperidine, CAS 792927-06-1) was used as the reference small molecule inhibitor.
Zymosterol-d5 Dehydrolathosterol-d5
Percent conversion versus the compound concentration data were fit to the following 4- parameter logistic model to generate IC50 curves:
DATA FOR EXAMPLES
*N/Ameans>3 μM ; + means 3 μM to>0.5 μM ; ++ means 0.1 -0.5 μM ; +++ means <0.1 μM ;
NT = Not Tested
Claims
What is claimed is:
X is O, CH2, or a bond;
R1 and R2 are each independently selected from H, Ci-ealkyl, Ci-shaloalkyl, C3- scycloalkyl, Het, and -Z-Het, wherein the Ci-ealkyl, Cx-xcycloalkyl, and Het are each optionally substituted with one or more R4, provided at least one of R1 and R2 is not H; or R1 and R2 together with the N atom from which they are attached form a 4 to 7-membered monocyclic heterocycle or 6 to 10-membered bicyclic heterocycle, each of which is optionally substituted with one or more R4;
Z is Ci-4alkyl optionally substituted with one or more R4;
Het is a 4 to 6 membered monocyclic heterocyclyl, or a 6 to 8-membered bicyclic heterocyclyl, each of which is optionally substituted with R4; each R4 is independently selected from OR4a, halo, C1-3alkyl, Ci-shaloalkyl, and 4 to 7-membered monocyclic heterocycle;
R4a is selected from H, C1-3alkyl, and C1-3haloalkyl;
R3 is phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, or 6 to 10 membered bicyclic heterocycle, wherein the phenyl, 5 or 6-membered monocyclic heteroaryl, 9 or 10-membered bicyclic heteroaryl, and 6 to 10 membered bicyclic heterocycle are each optionally substituted with one or more substituent R5; each R5 is independently selected from C1-3alkyl, C1-3haloalkyl, OR5a, cyano, and halo;
R5a is selected from H, C1-3alkyl, and C3-6cycloalkyl, wherein the C1-3alkyl is optionally substituted with one or more halo;
provided that R1 and R2 together with the N atom from which they are attached do not form an unsubstituted pyrrolidine, unsubstituted piperidine, or 4-methyl piperazine.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is phenyl or 5 or 6-membered monocyclic heteroaryl, each of which are each optionally substituted with one to three substituent R5.
3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R3 is phenyl, pyridinyl, pyrimidinyl, or pyrazoyl, each of which are each optionally substituted with one to three substituent R5.
4. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R3 is represented by the following formula:
wherein each of the formula depicted above is optionally substituted with one to three R5.
5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the N atom from which they are attached form a saturated 4 to 6-membered monocyclic heterocycle or a saturated 7 to 10 membered bicyclic heterocycle, each of which is optionally substituted with one or two R4.
6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
wherein each of the formula depicted above is optionally substituted with one or two R4.
7. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or C1-3alkyl optionally substituted with one to three R4;
R2 is C1-3alkyl, C3-6cycloalkyl, Het, or -Z-Het, wherein the C1-3alkyl, C3- 6cycloalkyl; and
Het is a saturated 4 to 6 membered monocyclic heterocycle containing 1 to 2 heteroatoms selected from oxygen and nitrogen, at least one of which is oxygen, wherein the saturated 4 to 6 membered monocyclic heterocycle is optionally substituted with one to three R4. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein Het is selected from tetraphydropyran and oxetane, each of which is optionally substituted with one to two R4. The compound of any one of claims 1 to 8, wherein the compound is represented by Formula (II):
or a pharmaceutically acceptable salt thereof. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R3 is represented by the following formula:
The compound of claim 9 or 10, or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence, is independently selected from C1-3alkyl, C1- 3haloalkyl, and OR5a. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence is independently selected from -CH3, -CF3, -CF2CH3, -CH(CH3)2, and -OCHF2.
The compound of any one of claims 9 to 12, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
The compound of any one of claims 9 to 12, or a pharmaceutically acceptable salt thereof, wherein R1 is H or -CH3, and R2 is represented by the following formula
wherein each of the formula depicted above is optionally substituted with one or two R4. The compound of any one of claims 9 to 12, or a pharmaceutically acceptable salt thereof, wherein R1 is H and R2 is represented by the following formula
wherein each of the formula depicted above is optionally substituted with one or two R4. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R2
18. The compound of any one of claims 9 to 17, or a pharmaceutically acceptable salt thereof, wherein R4, for each occurrence, is independently selected from C1-3alkyl and 4 to 7-membered monocyclic heterocycle.
19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R4, for each occurrence, is independently selected from -CH3 and tetrahydropyran. 0. The compound of any one of claims 1 to 8, wherein the compound is represented by Formula (III) or (IV):
or a pharmaceutically acceptable salt thereof. 1. The compound of claim 20, wherein the compound is represented by Formula (IIIA),
23. The compound of any one of claims 20 to 22, or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence, is independently selected from halo, cyano, Ci-2alkyl, Ci-2haloalkyl and OR5a; and R5a is Ci.2alkyl or Ci.2haloalkyl.
24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R5, for each occurrence, is independently selected from F, Cl, cyano, -CH3, -CF3, -CHF2, -OCH3, and -OCHF2.
25. The compound of any one of claims 20 to 24, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 together with the nitrogen atom from which they are attached form groups represented by the following formula:
26. The compound of any one of claims 20 to 25, or a pharmaceutically acceptable salt thereof, wherein:
R1 is H or C1-3alkyl; and
R2 is C1-3alkyl, C3-6cycloalkyl, -Z-Het, or Het, each of which is optionally substituted with one to three R4.
27. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein R1 is H or -CH3 and R2 is C1-3alkyl optionally substituted with one R4, or is represented
depicted above is optionally substituted with one or two R4.
28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R1 is H or -CH3 and R2 is represented by the following formula:
29. The compound of any one of claims 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R4, for each occurrence, is independently selected from OR4a, halo, and C1-3alkyl, and wherein R4a is C1-3alkyl.
30. The compound of claim 29, or a pharmaceutically acceptable salt thereof, wherein R4, for each occurrence, is independently selected from halo, -CH3, and -OCH3.
31. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
6-(2-((6-( 1,1 -Difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
2-((6-( 1,1 -Difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(tetrahy dro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)morpholine;
6-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
2-((2-Methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-N-( l-(tetrahy dro-2H- pyran-4-yl)cyclopropyl)-2-azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-N-(oxetan-3-yl)-2- azaspiro[3.3]heptan-6-amine;
2-((2-Methyl-6-(trifluoromethyl)pyri din-3 -yl)sulfonyl)-N-((3 -methyl ox etan-3 - yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)morpholine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-(oxetan-3- ylmethyl)-2-azaspiro[3.3]heptan-6-amine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-((3- m ethyl ox etan-3 -yl)methyl)-2-azaspiro[3.3 ]heptan-6-amine;
2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-N-(oxetan-3-yl)- 2-azaspiro[3.3]heptan-6-amine;
6-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
6-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
6-(2-((4-Methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-2-oxa-6-azaspiro[3.3]heptane;
2-Methyl-N-(2-(tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-yl)-6- (trifluoromethyl)pyridine-3-sulfonamide;
4-(2-((3-Isopropyl-l-methyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.3]heptan- 6-yl)morpholine;
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-6-(4-methylpiperidin-l-yl)-2- azaspiro[3.3]heptane;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-N-(tetrahydro-2H-pyran-4-yl)- 5-oxa-2-azaspiro[3.4]octan-7-amine;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(2-oxa-6- azaspiro[3.3]heptan-6-yl)-5-oxa-2-azaspiro[3.4]octane;
2-((2-Methoxy-5-methylpyridin-3-yl)sulfonyl)-7-(3-methoxyazetidin-l-yl)-5- oxa-2-azaspiro[3 ,4]octane;
N-(4,4-Difluorocyclohexyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5- oxa-2-azaspiro[3.4]octan-7-amine;
N-(3,3-Difluorocyclobutyl)-2-((2-methoxy-5-methylpyridin-3-yl)sulfonyl)-5- oxa-2-azaspiro[3.4]octan-7-amine;
3-((7-((4,4-Difluorocyclohexyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile;
4-Fluoro-3 -((7-((tetrahydro-2H-pyran-4-yl)amino)-5 -oxa-2- azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
3-((7-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-5-fluorobenzonitrile;
4-(2-((3,5-Dimethylpyridin-2-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
6-(2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)-
2-oxa-6-azaspiro[3.3]heptane;
N-(4,4-Difluorocyclohexyl)-2-((6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-amine;
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-N-(2-methoxyethyl)-N-methyl- 2-azaspiro[3 ,4]octan-6-amine;
N-(2-Methoxyethyl)-N-methyl-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-
5-yl)sulfonyl)-2-azaspiro[3.4]octan-6-amine;
4-(2-((3-Methoxy-l-methyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((l,3-Dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((4-Chloro-l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan- 6-yl)morpholine;
4-(2-((4-(Difluoromethyl)-l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Methoxy-2-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-(Mesitylsulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-(Difluoromethoxy)phenyl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((2,4-Dimethylphenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((2,4-Difluorophenyl)sulfonyl)-2-azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4,6-Dimethylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((6-methoxy-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((l-Methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
(R)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile;
4-(2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((l-methyl-3 -(trifluoromethyl)- lH-pyrazol-5-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2-yl)sulfonyl)benzonitrile;
(S)-3-Fluoro-5-((6-morpholino-2-azaspiro[3.4]octan-2- yl)sulfonyl)benzonitrile;
2-(Mesitylsulfonyl)-7-morpholino-5-oxa-2-azaspiro[3.4]octane;
2-((4-(Difluoromethoxy)phenyl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa-2- azaspiro[3 ,4]octane;
2-((l,3-Dimethyl-lH-pyrazol-5-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5-oxa- 2-azaspiro[3 ,4]octane;
2-((6-Methoxy-2-methylpyridin-3-yl)sulfonyl)-7-(4-methylpiperidin-l-yl)-5- oxa-2-azaspiro[3 ,4]octane;
2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-7-morpholino-5- oxa-2-azaspiro[3 ,4]octane;
(R)-2-((l-methyl-3-(trifluoromethyl)-lH-pyrazol-5-yl)sulfonyl)-7- morpholino-5-oxa-2-azaspiro[3.4]octane;
2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5-oxa-2- azaspiro[3 ,4]octane;
(R)-2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-7-morpholino-5- oxa-2-azaspiro[3 ,4]octane;
3-((7-((4,4-Difluorocyclohexyl)(methyl)amino)-5-oxa-2-azaspiro[3.4]octan-2- yl)sulfonyl)-4-fluorobenzonitrile;
4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((2-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(R)-4-(2-((4-Methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
(S)-4-(2-((4-methyl-6-(trifluoromethyl)pyridin-3-yl)sulfonyl)-2- azaspiro[3.4]octan-6-yl)morpholine;
4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(R)-4-(2-((6-Chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(S)-4-(2-((6-chloro-2-methylpyridin-3-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(R)-4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
(S)-4-(2-((l,3-dimethyl-lH-pyrazol-5-yl)sulfonyl)-2-azaspiro[3.4]octan-6- yl)morpholine;
6-(2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-2- azaspiro[3.3]heptan-6-yl)-l-oxa-6-azaspiro[3.3]heptane;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N- (tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1,1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(oxetan- 3 -yl)-2-azaspiro[3.3 ]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-m ethyl -N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((6-( 1 , 1 -difluoroethyl)-2-methylpyri din-3 -yl)sulfonyl)-N-methyl-N- ((tetrahydro-2H-pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(tetrahydro-2H- pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl -2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(ox etan-3 -yl)-2- azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine;
2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-((tetrahydro-2H- pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N- (tetrahydro-2H-pyran-4-yl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N- (oxetan-3-yl)-2-azaspiro[3.3]heptan-6-amine;
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N-(2- oxaspiro[3.3]heptan-6-yl)-2-azaspiro[3.3]heptan-6-amine; and
N-methyl-2-((4-methyl-2-(trifluoromethyl)pyrimidin-5-yl)sulfonyl)-N- ((tetrahydro-2H-pyran-4-yl)methyl)-2-azaspiro[3.3]heptan-6-amine; or a or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. A method of treating a disease mediated by Emopamil-Binding Protein comprising administering to a subject an effective amount of a compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 32. A method of treating an autoimmune disease in a subject comprising administering to the subject an effective amount of a compound of any one of claims 1 to 31, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 32. The method of claim 34, wherein said autoimmune disease is multiple sclerosis. The method of claim 35, wherein said compound or pharmaceutical composition repairs or forms new myelin sheaths in said subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263391578P | 2022-07-22 | 2022-07-22 | |
US63/391,578 | 2022-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024020156A1 true WO2024020156A1 (en) | 2024-01-25 |
Family
ID=87747812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/028271 WO2024020156A1 (en) | 2022-07-22 | 2023-07-20 | Emopamil-binding protein inhibitors and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024020156A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015038644A2 (en) * | 2013-09-10 | 2015-03-19 | Debrabander Jef | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
EP3705121A1 (en) * | 2017-10-30 | 2020-09-09 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
WO2023074847A1 (en) * | 2021-10-29 | 2023-05-04 | 田辺三菱製薬株式会社 | Novel spiro compound |
WO2023097230A1 (en) * | 2021-11-23 | 2023-06-01 | Genentech, Inc. | Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination |
-
2023
- 2023-07-20 WO PCT/US2023/028271 patent/WO2024020156A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015038644A2 (en) * | 2013-09-10 | 2015-03-19 | Debrabander Jef | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
EP3705121A1 (en) * | 2017-10-30 | 2020-09-09 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
WO2023074847A1 (en) * | 2021-10-29 | 2023-05-04 | 田辺三菱製薬株式会社 | Novel spiro compound |
WO2023097230A1 (en) * | 2021-11-23 | 2023-06-01 | Genentech, Inc. | Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination |
Non-Patent Citations (7)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, pages: 1289 - 1329 |
CAS, no. 792927-06-1 |
HUBLER ET AL., NATURE, vol. 560, no. 7718, 2019, pages 372 - 376 |
LOUIS F. FIESERMARY FIESER: "Reagents for Organic Synthesis", vol. 1-19, 1967, WILEY |
SILVE ET AL., J BIOL CHEM., vol. 271, no. 37, 1996, pages 22434 - 22440 |
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
THEODOROPOULOUS ET AL., J. AM. CHEM. SOC., vol. 142, no. 13, 2020, pages 6128 - 6138 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10028942B2 (en) | 3-substituted pyrazoles and uses thereof | |
US9556187B2 (en) | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | |
KR20200120713A (en) | Pyrimidine-fused ring compound and its preparation method and use | |
EA038428B1 (en) | Novel compound as autotaxin inhibitor and pharmaceutical composition comprising the same | |
US11370796B2 (en) | Substituted pyrazoles as LRRK2 inhibitors | |
KR20160099705A (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
EP0307141B1 (en) | Oxazoles and thiazoles for the treatment of senile dementia | |
US20110046130A1 (en) | Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists | |
US20240025902A1 (en) | Bifunctional compounds for degradation of egfr and related methods of use | |
US11679108B2 (en) | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | |
WO2002040019A1 (en) | Benzimidazole derivatives | |
CN116997548A (en) | HTT modulators for the treatment of huntington's disease | |
WO2022165513A1 (en) | Cdk2 inhibitors and methods of using the same | |
EP4334323A1 (en) | Orexin receptor agonists and uses thereof | |
WO2024020156A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
US8912176B2 (en) | Azetidines as histamine H3 receptor antagonists | |
US10335402B2 (en) | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders | |
AU2020360928A1 (en) | Azepan derivative | |
WO2023141323A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
WO2024015503A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
US11970493B2 (en) | Autotaxin inhibitor compounds | |
WO2023154499A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
WO2023164063A1 (en) | Emopamil-binding protein inhibitors and uses thereof | |
TW202409039A (en) | Emopamil-binding protein inhibitors and uses thereof | |
US20220106311A1 (en) | Autotaxin inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23757730 Country of ref document: EP Kind code of ref document: A1 |